WO2022239842A1 - Skin external agent - Google Patents

Skin external agent Download PDF

Info

Publication number
WO2022239842A1
WO2022239842A1 PCT/JP2022/020110 JP2022020110W WO2022239842A1 WO 2022239842 A1 WO2022239842 A1 WO 2022239842A1 JP 2022020110 W JP2022020110 W JP 2022020110W WO 2022239842 A1 WO2022239842 A1 WO 2022239842A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
less
mass
external preparation
component
Prior art date
Application number
PCT/JP2022/020110
Other languages
French (fr)
Japanese (ja)
Inventor
大輝 高橋
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN202280020822.9A priority Critical patent/CN117042746A/en
Publication of WO2022239842A1 publication Critical patent/WO2022239842A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29Titanium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to an external preparation for skin.
  • Patent Document 1 International Publication No. 2009/017104 discloses that infrared rays are prevented from reaching tissues deeper than skin tissues, and infrared rays protect those tissues.
  • an agent for preventing near-infrared damage to living tissue containing an infrared transmission shielding agent consisting of titanium oxide powder and zinc oxide powder has been disclosed.
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2017-95361 discloses a near-infrared protective cosmetic composition composed of titanium oxide powder and zinc oxide powder, which achieves both excellent near-infrared protective effect and high transparency.
  • Patent Document 3 International Publication No. 2020/138431), Patent Document 4 (JP 2020-105175), Patent Document 5 (JP 2020-105176) and Patent Document 6 (JP 2020-105177) Publication discloses an external preparation for skin containing a plate-like metal oxide having a predetermined shape as an external preparation for skin having a more excellent infrared protection effect.
  • the present invention relates to the following.
  • Component (A) one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less, and a component (B): non-volatile oil, wherein the content of component (A) in the external skin preparation is 2% by mass or more and 50% by mass or less, and the viscosity at 25°C is 2,500 mPa ⁇ s or more.
  • External agent [2] A method for protecting the skin from infrared radiation, which comprises applying the external preparation for skin according to [1] to the skin.
  • FIG. 10 is an IR microscope observation photograph (score 5) in evaluation of coating film uniformity of the external preparation for skin of Example 9.
  • FIG. 4 is an IR microscope observation photograph (score 1) in evaluation of coating film uniformity of the external preparation for skin of Comparative Example 2.
  • FIG. 10 is an IR microscope observation photograph (score 5) in evaluation of coating film uniformity of the external preparation for skin of Example 9.
  • FIG. 4 is an IR microscope observation photograph (score 1) in evaluation of coating film uniformity of the external preparation for skin of Comparative Example 2.
  • FIG. 10 is an IR microscope observation photograph (score 5) in evaluation of coating film uniformity of the external preparation for skin of Example 9.
  • FIG. 4 is an IR microscope observation photograph (score 1) in evaluation of coating film uniformity of the external preparation for skin of Comparative Example 2.
  • the skin external preparation of the present invention is Component (A): one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less, and component (B) : non-volatile oil, wherein the content of component (A) in the external skin preparation is 2% by mass or more and 50% by mass or less, and the viscosity at 25°C is 2,500 mPa ⁇ s or more.
  • the external preparation for skin of the present invention having the above-described constitution is excellent in the protective effect against ultraviolet rays, infrared rays, etc., and produces less whitening when applied to the skin.
  • An object of the present invention is to provide an external preparation for skin which has excellent protective effect against ultraviolet rays, infrared rays, etc., and which causes less whitening when applied to the skin.
  • the present inventor found that an external preparation for skin containing a predetermined shape, a predetermined amount of metal oxide, and a non-volatile oil and having a viscosity of a predetermined value or more can solve the above problems.
  • an external preparation for skin that has excellent protective effects against ultraviolet rays, infrared rays, etc., and that leaves little whitening when applied to the skin.
  • the external preparation for skin When the external preparation for skin is applied to the skin, it can protect the skin from ultraviolet rays, infrared rays, and the like, and can also provide an effect of suppressing an increase in skin temperature and an effect of suppressing fatigue due to sunlight irradiation.
  • the external preparation for skin of the present invention provides the above effects. It is known that skin preparations containing metal oxides such as titanium oxide with a larger particle size are more effective in protecting against ultraviolet rays and infrared rays. However, simply using a metal oxide having a large particle size limits the improvement in the infrared protection effect. In addition, for example, when a spherical metal oxide having a large particle size is added to an external preparation for skin, visible light is scattered on the surface of the particles when applied to the skin, which tends to cause whitening. Therefore, it has been difficult to simultaneously improve the protective effect against ultraviolet rays, infrared rays, etc.
  • the external preparation for skin of the present invention has a protective effect against ultraviolet rays, infrared rays, etc., and suppresses whitening when applied to the skin. is also possible. Furthermore, in order to further improve the protective effect against ultraviolet rays, infrared rays, etc., in external preparations for skin containing metal oxides, the present inventors have found that the uniform applicability of the external preparations for skin, in particular, the ability to protect against ultraviolet rays, infrared rays, etc.
  • component (A) which has a high specific gravity, is unlikely to be retained in the coating film, so component (A) is likely to settle in the sulcus cutis. be done.
  • component (A) which has a large particle size, tends to settle in the sulcus cutis and cannot be distributed uniformly on the skin surface, and is considered to reduce the protective effect against ultraviolet rays, infrared rays, and the like.
  • the external preparation for skin of the present invention contains a non-volatile oil as component (B) in addition to component (A), and has a viscosity of a predetermined value or more, so that when applied to the skin, the skin groove of component (A) is reduced.
  • component (B) a non-volatile oil as component (B) in addition to component (A)
  • a viscosity of a predetermined value or more so that when applied to the skin, the skin groove of component (A) is reduced.
  • the sedimentation to the surface can be suppressed, and the uniform coating property can be improved, so that the protective effect against ultraviolet rays, infrared rays, etc. can be further enhanced.
  • ultraviolet light means electromagnetic waves with a wavelength of 200 to 360 nm
  • infrared light means electromagnetic waves with a wavelength of 780 nm to 1 mm.
  • the external preparation for skin of the present invention is particularly excellent in the near-infrared protective effect with a wavelength of 780 nm to 2500 nm. Due to this near-infrared protection effect, it is possible to obtain an effect of suppressing an increase in skin temperature due to sunlight irradiation and an effect of suppressing fatigue.
  • the infrared protection rate at a wavelength of 825 nm is used as an indicator of the infrared protection effect.
  • the skin preparation for external use of the present invention is applied at 25° C. from the viewpoint of improving uniform applicability, suppressing precipitation of component (A) in the skin grooves when applied to the skin, and improving the protective effect against ultraviolet rays, infrared rays, and the like.
  • the viscosity at the That's it is preferably 200,000 mPa ⁇ s or less, more preferably 150,000 mPa ⁇ s or less, even more preferably 100,000 mPa ⁇ s or less, and even more preferably 50,000 mPa ⁇ s or less.
  • the viscosity of the external preparation for skin of the present invention at 25° C. is 2,500 mPa ⁇ s or more, preferably 2,500 mPa ⁇ s or more and 200,000 mPa ⁇ s or less, more preferably 3,000 mPa ⁇ s or more and 200 mPa ⁇ s or more.
  • the viscosity of the external preparation for skin of the present invention at 25° C. is preferably 2,500 mPa ⁇ s or more and 150,000 mPa ⁇ s or less, more preferably 2,500 mPa ⁇ s or more and 100,000 mPa ⁇ s or less.
  • the viscosity of the external preparation for skin at 25°C is a value measured at 25°C using a Brookfield viscometer, and can be specifically measured by the method described in Examples.
  • Means for adjusting the viscosity of the external preparation for skin of the present invention within the above range include selecting the type and content of component (A) used in the external preparation for skin, selecting the type and content of component (B), and increasing the viscosity described later. Selection of the use and content of viscosity agents, emulsifiers, dispersants, aqueous media, etc., and selection of dispersion methods for component (A) are included.
  • the dosage form of the external preparation for skin of the present invention is not particularly limited as long as the viscosity is within the above range, and from the viewpoint of ease of application to the skin, it is preferably liquid, gel or cream. As long as the viscosity is within the above range, the dosage form of the external skin preparation of the present invention is preferably a solid form such as a stick preparation from the viewpoint of infrared protection.
  • the external preparation for skin may be a non-aqueous composition or an emulsified composition, and the emulsified composition may be either an oil-in-water emulsified composition or a water-in-oil emulsified composition.
  • the external preparation for skin of the present invention is preferably an emulsified composition from the viewpoint of excellent feeling in use, and is preferably a water-in-oil type emulsified composition from the viewpoint of excellent protective effect against ultraviolet rays, infrared rays, etc. and excellent feeling in use. preferable.
  • the external preparation for skin of the present invention may be a skin preparation for protecting against ultraviolet rays or infrared rays, or a skin cosmetic such as lotion, cream, milky lotion, serum, suntan, makeup base cosmetic, and the like.
  • the skin external preparation of the present invention contains, as component (A), one or more selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less. Contains metal oxides.
  • component (A) the topical preparation for skin of the present invention has an excellent protective effect against ultraviolet rays, infrared rays, etc., provides a skin temperature rise suppressing effect and fatigue suppressing effect, and prevents whitening when applied to the skin. It has the effect of being able to suppress it.
  • Component (A1) spherical metal oxide having an average particle size of 350 nm or more and 2,500 nm or less
  • Component (A1) used in the present invention is a spherical metal oxide having an average particle size of 350 nm or more and 2,500 nm or less.
  • the term "spherical” as used herein includes a spherical shape and a substantially spherical shape.
  • the shape of either the primary particles or the secondary particles of the metal oxide may be spherical.
  • the average particle size of the component (A1) means the average particle size of the secondary particles.
  • the average particle diameter of component (A1) is 350 nm or more, preferably 400 nm or more, more preferably 700 nm or more, and still more preferably 800 nm or more, from the viewpoint of protection against ultraviolet rays, infrared rays, and the like.
  • it is 2,500 nm or less, preferably 2,000 nm or less, more preferably 1,800 nm or less. It is more preferably 1,500 nm or less, still more preferably 1,200 nm or less.
  • the average particle diameter of component (A1) is 350 nm or more and 2,500 nm or less, preferably 400 nm or more and 2,000 nm or less, more preferably 700 nm or more and 2,000 nm or less, still more preferably 700 nm or more and 1,800 nm or less, More preferably 700 nm or more and 1,500 nm or less, still more preferably 800 nm or more and 1,200 nm or less.
  • the average particle diameter of component (A1) is the median diameter (d 50 ), which can be determined, for example, by laser diffraction/light scattering particle size distribution measurement. In the measurement, a solvent in which the component (A1) is easily dispersed can be used as appropriate.
  • purified water is used for metal oxides that are not surface-treated, and metal oxides that are surface-treated with silicone or the like are used.
  • Silicone oils eg, methylpolysiloxane, cyclopentasiloxane, etc. can be used.
  • Component (A2) used in the present invention is a plate-like metal oxide.
  • Component (A2) is plate-shaped and preferably has a thickness and an aspect ratio within the ranges described below.
  • the reflectance of light observed on the upper surface side of the skin is reduced to light with a wavelength in the infrared region due to the light interference effect. is higher for light in the visible region, and lower for light with wavelengths in the visible region. As a result, a higher infrared protection effect can be obtained, and whitening when applied to the skin can be easily suppressed.
  • the thickness of the component (A2) is preferably 30 nm or more, more preferably 50 nm or more, still more preferably 60 nm or more, still more preferably 75 nm or more, still more preferably 90 nm or more, and still more preferably 90 nm or more, from the viewpoint of improving the infrared protection effect. It is preferably 100 nm or more.
  • the thickness of the component (A2) is preferably 360 nm or less, more preferably 330 nm or less, still more preferably 310 nm or less.
  • the thickness of component (A2) is preferably 30 nm or more and 360 nm or less, more preferably 50 nm or more and 330 nm or less, still more preferably 60 nm or more and 310 nm or less, still more preferably 75 nm or more and 280 nm or less, still more preferably 90 nm or more and 270 nm or less.
  • the thickness of component (A2) means the length of the shortest axis in the plate-like metal oxide particles.
  • the thickness of component (A2) can be obtained from an image observed by a scanning electron microscope (SEM). Specifically, the component (A2) was observed with an SEM at an observation magnification of 10,000 times, the thickness of 50 particles in the observed image was measured, and the average thickness per number was calculated. It is obtained by calculating
  • the aspect ratio of the component (A2) is preferably 3 or more, more preferably 5 or more, still more preferably 10 or more, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin. Still more preferably 30 or more, still more preferably 50 or more, still more preferably 55 or more, preferably 300 or less, more preferably 230 or less, still more preferably 200 or less, still more preferably 140 or less, and more More preferably 125 or less, still more preferably 120 or less.
  • the aspect ratio of component (A2) is preferably 3 or more and 300 or less, more preferably 3 or more and 230 or less, still more preferably 10 or more and 230 or less, still more preferably 30 or more and 230 or less, still more preferably 50 or more and 200 Below, more preferably 55 or more and 140 or less, still more preferably 55 or more and 125 or less, and still more preferably 55 or more and 120 or less.
  • the aspect ratio of component (A2) was determined by SEM observation under the same conditions as above, and the length of the shortest axis (thickness) and the length of the longest axis (major axis) in 50 particles in the observed image. is measured to calculate the aspect ratio (major diameter/thickness) of each particle, and the average value is obtained.
  • the aspect ratio of component (A2) can be measured by the method described in Examples.
  • Component (A2) preferably has a thickness of 30 nm or more and 360 nm or less and an aspect ratio of 3 or more and 300 or less from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin.
  • the thickness is 50 nm or more and 330 nm or less
  • the aspect ratio is 3 or more and 230 or less
  • the thickness is 60 nm or more and 310 nm or less
  • the aspect ratio is 10 or more and 230 or less, and still more preferably the thickness 75 nm or more and 280 nm or less
  • an aspect ratio of 30 or more and 230 nm or less more preferably a thickness of 90 nm or more and 270 nm or less, and an aspect ratio of 50 or more and 200 or less, and still more preferably a thickness of 100 nm or more and 230 nm or less.
  • an aspect ratio of 55 to 140 more preferably a thickness of 100 nm to 200 nm, and an aspect ratio of 55 to 125, still more preferably a thickness of 100 nm to 180 nm, and an aspect ratio is 55 or more and 120 or less.
  • the external preparation for skin may contain either component (A1) or component (A2) as component (A), or may contain both component (A1) and component (A2). .
  • the mass ratio is not particularly limited, from the viewpoint of improving the infrared protection effect and from the viewpoint of suppressing whitening when applied to the skin. Therefore, the mass ratio (A1)/(A2) is preferably 10/90 to 90/10, more preferably 20/80 to 80/20, still more preferably 30/70 to 70/30.
  • the external preparation for skin may contain two or more components (A1) as component (A), and may contain two or more components (A2).
  • metal oxides in components (A1) and (A2) include titanium oxide, zinc oxide, zirconium oxide, iron oxide, aluminum oxide, and cerium oxide.
  • titanium oxide one or more selected from the group consisting of titanium oxide and zinc oxide is preferred, and titanium oxide is more preferred, from the viewpoint of the protective effect against ultraviolet rays, infrared rays, etc., particularly from the viewpoint of improving the infrared protective effect.
  • the crystal structure of titanium oxide may be any of rutile type, anatase type and amorphous type, but the rutile type is preferable from the viewpoint of protection against ultraviolet rays, infrared rays and the like.
  • Component (A1) and component (A2) may be metal oxides that have not been surface-treated, and in order to enhance dispersibility in external skin preparations, surface treatment such as hydrophobic treatment is performed by a known method as necessary. It may be a metal oxide that has been used.
  • the component (A1) and the component (A2) are distinguished from particles other than metal oxide whose surface is treated with a metal oxide.
  • Examples of surface treatment agents used for surface treatment of metal oxides include silicones; alkylalkoxysilanes; fluorine-containing compounds such as perfluoroalkyl phosphates and perfluoroalcohols; amino acids such as N-acylglutamic acid; Soap; fatty acids such as stearic acid; alkyl phosphates; Among these, at least one selected from the group consisting of silicones and alkylalkoxysilanes is preferred.
  • Silicone as a surface treatment agent is not particularly limited, and examples include methylpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane [hydrogen dimethicone], methylcyclopolysiloxane, octamethylcyclotetrasiloxane, decamethyl Cyclopentasiloxane, dodecamethylcyclohexasiloxane, octamethyltrisiloxane, tetradecamethylhexasiloxane, dimethylsiloxane-methyl (polyoxyethylene) siloxane-methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane-methyl (polyoxy Ethylene)siloxane copolymer, dimethylsiloxane/methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane/
  • alkylalkoxysilane as the surface treatment agent, those having a branched or linear alkyl group of 6 to 20 carbon atoms are preferred, and octyltriethoxysilane and octyltrimethoxysilane are particularly exemplified.
  • methylpolysiloxane From the viewpoint of enhancing the dispersibility of the component (A) in the external preparation for skin and further improving the protective effect against ultraviolet rays, infrared rays, etc., methylpolysiloxane, dimethylpolysiloxane, At least one selected from the group consisting of siloxane, methylhydrogenpolysiloxane, (alkyl acrylate/dimethicone) copolymer, and octyltriethoxysilane is preferred.
  • component (A1) or component (A2) is a surface-treated metal oxide
  • the amount of coating with the surface treatment agent is adjusted from the viewpoint of increasing the dispersibility in the skin preparation for external use. ), preferably 1% by mass or more and 9% by mass or less, more preferably 2% by mass or more and 8% by mass or less.
  • Component (A) preferably contains component (A2) from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin.
  • component (A2) when the metal oxide constituting the component (A2) is a material with a high refractive index, a higher optical interference effect can be obtained. Therefore, component (A) more preferably contains at least one selected from the group consisting of plate-like titanium oxide and plate-like zinc oxide as component (A2), and more preferably contains plate-like titanium oxide.
  • the content of the component (A2) in the component (A) is, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin, It is preferably 50% by mass or more, more preferably 60% by mass or more, still more preferably 70% by mass or more, still more preferably 80% by mass or more, still more preferably 90% by mass or more and 100% by mass or less.
  • the content of component (A) in the external preparation for skin is 2% by mass or more, preferably 3% by mass or more, more preferably 5% by mass or more, from the viewpoint of improving the protective effect against ultraviolet rays, infrared rays, and the like.
  • the content is 50% by mass or less.
  • the content of component (A) in the external preparation for skin is more preferably within the following range.
  • the content of the spherical titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 30% by mass or less, still more preferably It is 5 mass % or more and 25 mass % or less.
  • the content of the spherical titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 40% by mass or less. It is preferably 5% by mass or more and 30% by mass or less.
  • the content of the plate-like titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 30% by mass or less.
  • component (A) is spherical zinc oxide or plate-like zinc oxide having an average particle size of 350 nm or more and 2,500 nm or less
  • the content of said spherical zinc oxide or plate-like zinc oxide in the external preparation for skin is more preferably 7 mass % or more and 50 mass % or less, more preferably 10 mass % or more and 50 mass % or less.
  • the content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more, more preferably 5% by mass or more, still more preferably 5% by mass or more, from the viewpoint of improving the protective effect against ultraviolet rays, infrared rays, and the like. It is 10% by mass or more. From the viewpoint of suppressing whitening when applied to the skin, the content is preferably 50% by mass or less, more preferably 40% by mass or less, even more preferably 30% by mass or less, and even more preferably 20% by mass or less.
  • the content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more and 50% by mass or less, more preferably 5% by mass or more and 40% by mass or less, and still more preferably 10% by mass or more. It is 30% by mass or less, more preferably 10% by mass or more and 20% by mass or less.
  • non-volatile component in the external skin preparation means a component obtained by excluding water, an aqueous medium described later, and a volatile oil (an oil other than component (B)) from the total amount of the external skin preparation.
  • the viscosity (mPa s) of the topical skin preparation relative to the content (% by mass) of component (A) in the topical skin preparation is adjusted according to the content of component (A) to improve uniform applicability.
  • the [viscosity of the external preparation for skin (mPa s) / content of component (A) in the external preparation for skin (% by mass)] is preferably 100.
  • the [viscosity of the external skin preparation (mPa ⁇ s)/content of component (A) in the external skin preparation (% by mass)] is preferably 100 or more and 25,000 or less, more preferably 250 or more and 20,000. 300 or more and 15,000 or less, still more preferably 350 or more and 10,000 or less, still more preferably 350 or more and 5,000 or less, still more preferably 350 or more and 3,000 or less.
  • a commercially available metal oxide can also be used as component (A).
  • commercially available spherical titanium oxide used as the component (A1) includes “ST-750EC” manufactured by Titan Kogyo Co., Ltd., “R-38L” manufactured by Sakai Chemical Industry Co., Ltd., and the like.
  • Zinc includes “LP-ZINC-2KS” manufactured by Sakai Chemical Industry Co., Ltd., and the like.
  • commercially available plate-like titanium oxide used as component (A2) includes "Featheleve PT-9001K", “Featheleve PT-7001K”, “Featheleve PT-7401K”, “Featheleve PT-7801K” and “Featheleve PT” manufactured by CQV. -7901K", surface-coated products thereof, and the like
  • commercially available plate-like zinc oxide includes "XZ-1000F-LP” manufactured by Sakai Chemical Industry Co., Ltd., and the like.
  • the external preparation for skin of the present invention contains a non-volatile oil as component (B) from the viewpoints of easily adjusting the viscosity to a desired level and improving the protective effect against ultraviolet rays, infrared rays, etc. by improving uniform application properties.
  • a non-volatile oil refers to an oil having an evaporation rate of less than 20% at 25° C. for 6 hours, as measured by the following method (1). Method (1): Place a filter paper with a diameter of 90 mm in a glass petri dish with a diameter of 120 mm. After 6 hours, the residue of the sample is measured and the amount of evaporation is calculated.
  • component (B) is preferably liquid at 25° C. under 1 atm. More specifically, component (B) has a viscosity at 25° C. of preferably 500 mPa ⁇ s or less, more preferably 300 mPa ⁇ s or less, even more preferably 100 mPa ⁇ s or less, and still more preferably It is 50 mPa ⁇ s or less, preferably 5 mPa ⁇ s or more.
  • the viscosity was measured using a Brookfield viscometer "TVB-10" (manufactured by Toki Sangyo Co., Ltd.). 1. It can be measured under the conditions of 25° C., 60 rpm, and 1 minute.
  • component (B) include non-volatile oils that are liquid at 25°C, such as one or more selected from the group consisting of ester oils, silicone oils, hydrocarbon oils, higher fatty acids, and higher alcohols. be done.
  • non-volatile liquid ester oils examples include monoesters of fatty acids having 8 to 18 carbon atoms and branched alcohols having 2 to 22 carbon atoms, and triesters of branched fatty acids having 6 to 18 carbon atoms and glycerin.
  • a diester of a dicarboxylic acid having 2 to 18 carbon atoms and a branched alcohol having 2 to 18 carbon atoms a diester of a fatty acid having 6 to 18 carbon atoms and a dialcohol having 2 to 10 carbon atoms, and an alkyl benzoate
  • Monoesters of fatty acids having 8 to 18 carbon atoms and branched alcohols having 2 to 22 carbon atoms include isononyl isononanoate, isotridecyl isononanoate, isopropyl myristate, isocetyl myristate, octyldodecyl myristate, isopropyl palmitate, Examples include ethylhexyl palmitate and 2-hexyldecyl palmitate.
  • Examples of triesters of fatty acids having 6 to 18 carbon atoms and glycerin include glyceryl tri-2-ethylhexanoate and glyceryl tri(caprylate/caprate).
  • Examples of diesters of dicarboxylic acids having 2 to 18 carbon atoms and branched alcohols having 2 to 18 carbon atoms include di-2-ethylhexyl sebacate, diisopropyl sebacate and diisostearyl malate.
  • Examples of diesters of fatty acids having 6 to 18 carbon atoms and dialcohols having 2 to 10 carbon atoms include diethylene glycol dicaprate, neopentyl glycol dicaprate, and neopentyl glycol di-2-ethylhexanoate.
  • Examples of the alkyl benzoate include alkyl benzoate (C12 to C15) (eg Finsolv TN; manufactured by Innospec Active Chemicals LLC).
  • ester oils used as component (B) from the viewpoint of ease of viscosity adjustment, the viewpoint of improving the solubility of thickeners and the like described later, and the viewpoint of suppressing stickiness when applied to the skin, C 12 Monoesters of fatty acids having 18 or more and branched alcohols having 2 to 22 carbon atoms, triesters of branched fatty acids having 6 to 18 carbon atoms and glycerin, dicarboxylic acids having 2 to 18 carbon atoms and 2 or more carbon atoms One or more selected from the group consisting of diesters with branched alcohols of 18 or less, diesters of fatty acids with 6 to 18 carbon atoms and branched dialcohols with 2 to 10 carbon atoms, and alkyl benzoates (C12 to C15) isopropyl myristate, isocetyl myristate, octyldodecyl myristate, isopropyl palmitate, ethylhexyl
  • methylpolysiloxane is preferable, and methylpolysiloxane having a viscosity of 20 mPa ⁇ s or less at 25°C is more preferable.
  • Non-volatile liquid hydrocarbon oils include liquid paraffin, light liquid isoparaffins such as hydrogenated polyisobutene, heavy liquid isoparaffins, liquid ozokerite, squalane, pristane, squalene, and isohexadecane.
  • Non-volatile liquid higher fatty acids include fatty acids having 12 to 22 carbon atoms, and specific examples include oleic acid, isostearic acid, linoleic acid, and linolenic acid.
  • Nonvolatile liquid higher alcohols include, for example, alcohols having 12 to 28 carbon atoms, and specific examples include oleyl alcohol, 2-decyltetradecinol, dodecanol, isostearyl alcohol, octyldodecanol, and the like. mentioned.
  • Component (B) is a non-volatile oil that is liquid at 25 ° C., from the viewpoint of ease of viscosity adjustment, from the viewpoint of improving the solubility of thickeners described later, and from the viewpoint of suppressing stickiness when applied to the skin. From the viewpoint, it is preferably one or more selected from the group consisting of ester oil, silicone oil and hydrocarbon oil, more preferably one or more selected from the group consisting of ester oil and silicone oil, and still more preferably ester oils and silicone oils.
  • the content of the component (B) in the external preparation for skin of the present invention is preferably 1% by mass or more from the viewpoint of easy adjustment to a desired viscosity and enhancement of the protective effect against ultraviolet rays, infrared rays, etc. by enhancing uniform application properties. , more preferably 5% by mass or more.
  • it is preferably 90% by mass or less, more preferably 80% by mass or less, even more preferably 70% by mass or less, and even more preferably 65% by mass or less.
  • the content of component (B) in the external preparation for skin is more preferably 15% by mass or more from the viewpoint of water-in-oil type. , Still more preferably 20% by mass or more, still more preferably 25% by mass or more, still more preferably 30% by mass or more, and even more preferably 35% by mass or more.
  • the content of component (B) in the external preparation for skin is more preferably 30% by mass or less from the viewpoint of making it oil-in-water. More preferably 20 mass % or less, still more preferably 10 mass % or less.
  • the mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] increases the uniformity of application, thereby protecting against ultraviolet rays, infrared rays, etc.
  • it is preferably 0.05 or more, more preferably 0.1 or more, still more preferably 0.2 or more, even more preferably 0.5 or more, and even more preferably 1 above, more preferably 2 or more, still more preferably 3 or more, still more preferably 3.6 or more, and from the viewpoint of suppressing stickiness when applied to the skin, preferably 60 or less, more preferably 50 or less, More preferably 30 or less, still more preferably 20 or less, still more preferably 10 or less, and even more preferably 8 or less.
  • the mass ratio [(B)/(A)] is preferably 0.05 or more and 60 or less, more preferably 0.1 or more and 50 or less, still more preferably 0.2 or more and 30 or less, and even more preferably 0.2 or more. 5 or more and 20 or less, more preferably 1 or more and 10 or less, still more preferably 2 or more and 10 or less, still more preferably 3 or more and 10 or less, and even more preferably 3.6 or more and 8 or less.
  • the total content of the component (A) and the component (B) in the external preparation for skin is preferably 2. % by mass or more, more preferably 10% by mass or more, still more preferably 20% by mass or more, even more preferably 30% by mass or more, even more preferably 40% by mass or more, still more preferably 45% by mass or more, and even more preferably is 47% by mass or more, more preferably 50% by mass or more, and 100% by mass or less.
  • the external preparation for skin of the present invention preferably further contains a thickening agent from the viewpoints of facilitating viscosity adjustment, improving uniform applicability, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like.
  • the "thickener” means an additive that acts to thicken the external preparation for skin.
  • thickeners include oil thickeners, water-soluble thickeners, and the like, which can be appropriately selected according to the dosage form of the external preparation for skin.
  • an oil thickener oil gelling agent
  • oil thickeners include those used in ordinary external skin preparations, such as solid waxes, organically modified clay minerals, fumed silica, colloidal silica, dextrin fatty acid esters, metallic soaps, sucrose fatty acid esters, amino acids. system gelling agents and the like.
  • solid waxes, organically modified clay minerals, dextrin fatty acid esters, and amino acid-based waxes are preferred from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. It is one or more selected from the group consisting of gelling agents, and more preferably one or more selected from the group consisting of solid waxes, organically modified clay minerals, and dextrin fatty acid esters.
  • Solid waxes include waxes having a melting point of 61° C. or higher. Waxes with a melting point of 61°C or higher exhibit solid properties at 25°C.
  • the melting point is measured according to the Standards for Quasi-drug Ingredients, Method 1, Method 2, or Method 3 of general test methods. As for which method to use, if there is a measurement method described in the standards for quasi-drug raw materials for each component, follow that method. If there is no description, select the measurement method in consideration of the melting point. Specifically, Method 1 is used when the melting point is much higher than 80°C, Method 2 is used for solid fats with a lower melting point, and Method 3 is used for what is called paste oil in catalogs. However, any method may be used as long as it can be measured.
  • Waxes having a melting point of 61° C. or higher are not particularly limited as long as they are used in ordinary external skin preparations.
  • Examples include mineral waxes such as ozokerite and ceresin; petroleum waxes such as paraffin and microcrystalline wax; Synthetic hydrocarbons such as tropsch wax, polyethylene wax, synthetic hydrocarbon wax; vegetable waxes such as carnauba wax, candelilla wax, rice wax, sunflower wax; animal waxes such as beeswax and whale wax; silicone wax, synthetic beeswax, etc. synthetic wax; and the like.
  • one or more selected from the group consisting of petroleum waxes and silicone waxes is preferable from the viewpoint of facilitating viscosity adjustment, improving uniform coating properties, and improving the protective effect against ultraviolet rays, infrared rays, and the like.
  • These waxes preferably have a melting point of 65° C. or higher and 140° C. or lower, 70° C. or higher, and 70° C. or higher, from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. 110° C. or less is more preferable.
  • the organically modified clay mineral is not particularly limited as long as it is used in usual external preparations for skin.
  • Cation-modified clay minerals obtained by treatment with salt-type cationic surfactants can be mentioned. Specifically, one or more selected from the group consisting of benzyldimethylstearylammonium chloride and dimethyldistearylammonium chloride is preferable, and dimethyldistearylammonium chloride is more preferable.
  • Commercially available organic modified clay minerals include "Bentone 38", “Bentone 38VCG” and "Bentone 27" manufactured by Elementis Japan.
  • the organically modified clay mineral can also be used as a premixed gel diluted with a solvent from the viewpoint of improving workability and thickening effect.
  • a premixed gel in which an organically modified clay mineral is previously dispersed in a solvent is preferred.
  • the solvent is not limited as long as it can be gelled by an organically modified clay mineral, and octyldodecanol, mineral oil, and the like are preferable from the viewpoint of improving the thickening effect.
  • the content of the organically modified clay mineral in the premix gel is preferably 5% by mass or more, more preferably 8% by mass, from the viewpoint of improving workability and thickening effect, and suppressing oil separation of the premix gel itself. % by mass or more, more preferably 10% by mass or more, preferably 25% by mass or less, more preferably 20% by mass or less, and even more preferably 18% by mass or less.
  • Commercially available premixed gels include "Bentongel EUGV", “Bentongel MIOV”, “Bentongel VS-5 PCV”, “Bentongel PTM V", and "Bentongel GTCC V" manufactured by Elementis Japan.
  • the dextrin fatty acid ester is not particularly limited as long as it is used in ordinary skin preparations for external use.
  • An ester of a fatty acid having 8 to 24 carbon atoms and dextrin is preferable, and an ester of a fatty acid having 14 to 20 carbon atoms and dextrin is more preferable.
  • the dextrin preferably has an average degree of polymerization of 3 or more and 150 or less.
  • dextrin palmitate dextrin stearate, dextrin palmitate/stearate, dextrin oleate, dextrin isopalmitate, dextrin isostearate, dextrin myristate, dextrin palmitate/2-ethylhexanoate, and the like.
  • dextrin palmitate, dextrin myristate, and dextrin palmitate/2-ethylhexanoate are used from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like.
  • Preferred are those containing at least dextrin palmitate.
  • dextrin fatty acid esters include dextrin palmitate manufactured by Chiba Flour Mills Co., Ltd. (“Leopal KL2”, “Leopal KS2”, “Leopal TL2”), dextrin palmitate/2-ethylhexanoate “Leopal TT2”, Dextrin myristate “Rheopearl MKL2” and the like can be mentioned.
  • amino acid-based gelling agent any amino acid-based gelling agent can be used without particular limitation as long as it is used in usual external preparations for skin. Specifically, dibutyl lauroyl glutamide and dibutylethylhexanoyl glutamide are preferred.
  • Commercially available amino acid-based gelling agents include dibutyl lauroyl glutamide "GP-1” and dibutyl ethylhexanoyl glutamide "EB-21” manufactured by Ajinomoto Co., Inc., and the like.
  • the amino acid-based gelling agent can also be used as a premixed gel diluted and dissolved with a solvent from the viewpoint of improving workability and thickening effect.
  • a premixed gel obtained by previously dissolving an amino acid-based gelling agent in a solvent is preferred.
  • the solvent is not limited as long as it can be gelled by an amino acid-based gelling agent, but octyldodecanol, isostearic acid, and the like are preferable from the viewpoint of improving the thickening effect.
  • the content of the amino acid-based gelling agent in the premix gel is preferably 10% by mass or more, more preferably 10% by mass or more, from the viewpoint of improving workability and thickening effect, and suppressing oil separation of the premix gel itself. It is 15% by mass or more, more preferably 20% by mass or more, preferably 45% by mass or less, more preferably 40% by mass or less, and even more preferably 36% by mass or less.
  • Commercially available premix gels include "AJK-OD2046" (containing 20% by mass of an amino acid-based gelling agent) and "AJK-IS3613" (containing 36% by mass of an amino acid-based gelling agent) manufactured by Kokyu Alcohol Kogyo Co., Ltd. etc.
  • One or two or more thickeners can be used.
  • the content of the thickening agent in the external preparation for skin is adjusted from the viewpoint of adjusting the viscosity, improving the uniform application property, and improving the protective effect against ultraviolet rays, infrared rays, etc.
  • the content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more and 50% by mass or less, more preferably 0.5% by mass or more and 30% by mass or less, and still more preferably 1% by mass or more and 25% by mass. % by mass or less, more preferably 2% by mass or more and 20% by mass or less, and even more preferably 3% by mass or more and 15% by mass or less.
  • the external preparation for skin of the present invention may further contain an emulsifier from the viewpoint of enhancing the dispersibility of component (A) and from the viewpoint of preparing an emulsified composition.
  • the "emulsifier” means an additive other than the thickener, which has emulsifying properties.
  • the emulsifier used in the present invention may be either a low-molecular-weight emulsifier or a high-molecular-weight emulsifier, but a high-molecular-weight emulsifier is preferable from the viewpoint of enhancing the dispersibility of component (A) and facilitating viscosity adjustment.
  • a polymer emulsifier having a hydrophilic site and a hydrophobic site is preferable, and examples thereof include alkyl-modified polyacrylic acid-based polymer, alkyl-modified polysaccharide-based polymer, and oxazoline-modified silicone.
  • alkyl-modified polyacrylic acid-based polymers examples include (meth)acrylic acid/alkyl (meth)acrylate copolymers, alkyl acrylate/alkyl methacrylate/polyoxyethylene stearyl ether methacrylate copolymers, and the like. .
  • alkyl-modified polysaccharide polymers include hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, stearoxyhydroxypropylmethylcellulose, laureth-13PG hydroxyethylcellulose, stearoxy PG hydroxyethylcellulose sulfonate, and the like. be done.
  • oxazoline-modified silicone examples include polymers having a hydrophilic segment having N-acylalkyleneimine as a repeating unit and an organopolysiloxane segment as structural units.
  • N-propionylpolyethyleneimine/methylpolysiloxane copolymer POLYSILICONE-9
  • POLYSILICONE-9 N-propionylpolyethyleneimine/methylpolysiloxane copolymer
  • oxazoline-modified silicone is preferable from the viewpoint of enhancing the dispersibility of component (A) and the viewpoint of ease of viscosity adjustment.
  • the content of the emulsifier in the topical skin preparation is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, from the viewpoint of emulsifying performance. Also, it is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, even more preferably 3% by mass or less, and even more preferably 1% by mass or less.
  • the content of the emulsifier in the external preparation for skin is preferably 0.1% by mass or more and 15% by mass or less, more preferably 0.1% by mass or more and 10% by mass or less, and still more preferably 0.1% by mass or more and 5 % by mass or less, more preferably 0.1% by mass or more and 3% by mass or less, and even more preferably 0.2% by mass or more and 1% by mass or less.
  • the external preparation for skin of the present invention may further contain a dispersant from the viewpoint of enhancing the dispersibility of component (A).
  • a dispersant means an additive that mainly contributes to improving the dispersibility of component (A).
  • a nonionic surfactant is preferable from the viewpoint of enhancing the dispersibility of the component (A).
  • the nonionic surfactant is not particularly limited as long as it is used in usual external preparations for skin, and silicone surfactants, fluorine-containing surfactants and the like can also be used.
  • nonionic surfactants used as dispersants include alkanolamides, amine oxides, polyoxyethylene alkyl ethers, polyoxyethylene hydrogenated castor oils, polyoxyethylene fatty acid amides, polyoxyethylene alkylamines, alkyl saccharides, ⁇ -monoalkyl glyceryl ether, polyether-modified silicone, etc., and one or more of these can be used.
  • the dispersant preferably contains a nonionic silicone-based surfactant, and more preferably contains a polyether-modified silicone.
  • examples of commercially available polyether-modified silicones used as dispersants include "KF-6012" (poly(oxyethylene/oxypropylene) methylpolysiloxane copolymer) manufactured by Shin-Etsu Chemical Co., Ltd., Shin-Etsu Chemical Co., Ltd. Co., Ltd. "KF-6015”, “KF-6017”, “KF-6028”, “KF-6038", Dow Toray Co., Ltd. "SH3775M” (above, polyoxyethylene methyl polysiloxane copolymer), "SH3772C” manufactured by Dow Toray Industries, Inc., and the like.
  • a polyoxyethylene alkyl ether type nonionic surfactant is more preferable.
  • Commercially available polyoxyethylene alkyl ether type nonionic surfactants include, for example, "EMULGEN 121-G” (polyoxyethylene (21) lauryl ether) manufactured by Kao Corporation, and “EMULGEN 1620G” manufactured by Kao Corporation. (polyoxyethylene (20) 2-hexyldecyl ether), Kao Corporation “EMULGEN 2020G” (polyoxyethylene (20) octyldodecyl ether), and the like.
  • the content of the dispersant in the external preparation for skin is preferably 0.1% by mass or more, more preferably 0.1% by mass or more, from the viewpoint of enhancing the dispersibility of component (A). It is 0.3% by mass or more, more preferably 0.5% by mass or more, and preferably 15% by mass or less, more preferably 10% by mass or less, and even more preferably 5% by mass or less.
  • the content of the dispersant in the external preparation for skin is preferably 0.1% by mass or more and 15% by mass or less, more preferably 0.3% by mass or more and 10% by mass or less, and still more preferably 0.5% by mass or more. It is 5% by mass or less.
  • the external preparation for skin of the present invention preferably further contains water from the viewpoint of giving a refreshing feel to the skin.
  • the content of water in the topical skin preparation can be appropriately selected depending on the dosage form. % by mass or more, more preferably 10% by mass or more, preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 25% by mass or less.
  • the external preparation for skin of the present invention may further contain an aqueous medium other than water from the viewpoint of dispersing the component (A) and dispersing or dissolving other ingredients to further improve uniform application properties.
  • the aqueous medium include monohydric alcohols having 4 or less carbon atoms such as ethanol, isopropyl alcohol, and butyl alcohol; Low-molecular-weight diols and triols of 6 or less are included. Among these, one or more selected from the group consisting of monohydric alcohols having 4 or less carbon atoms are preferable, and ethanol is more preferable.
  • the content of the aqueous medium in the topical skin preparation can be appropriately selected depending on the dosage form. From the viewpoint of further improving uniform coating properties by increasing the is 20% by mass or less, more preferably 10% by mass or less.
  • the content of the aqueous medium in the external preparation for skin is preferably 0.1% by mass or more and 50% by mass or less, more preferably 0.1% by mass or more and 30% by mass or less, and still more preferably 0.1% by mass or more. 20 mass % or less, more preferably 0.5 mass % or more and 10 mass % or less.
  • the total content of water and aqueous medium in the skin external preparation is preferably 2% by mass or more, more preferably 5% by mass or more, and still more preferably 10% by mass, from the viewpoint of further improving the refreshing feeling of use. above, preferably 70% by mass or less, more preferably 60% by mass or less, even more preferably 40% by mass or less, and even more preferably 35% by mass or less.
  • the external preparation for skin of the present invention may contain other ingredients, such as ultraviolet absorbers, ultraviolet scattering agents, volatile oils, antiperspirants, fragrances, moisturizers, bactericides, and pH adjusters, if necessary, in addition to the above ingredients. , antioxidants, preservatives and the like can also be contained.
  • the external preparation for skin of the present invention may further contain an ultraviolet absorber from the viewpoint of improving the ultraviolet protection effect.
  • the UV absorber is preferably an organic UV absorber other than the component (B), and an oil-soluble organic UV absorber or a water-soluble organic UV absorber can be used.
  • the UV absorber is preferably an oil-soluble organic UV absorber.
  • oil-soluble means water-insoluble, and specifically, it means that the solubility in water at 25°C is 1 w/w% or less.
  • the UV absorber does not contain an inorganic UV absorber such as a UV absorber obtained by coating the surface of an inorganic filler with a UV absorbing material.
  • salicylic acid-based ultraviolet absorbers such as homomenthyl salicylate and octyl salicylate; 2-Ethylhexyl paramethoxycinnamate (for example, "Ubinal MC80" manufactured by BASF), glyceryl mono-2-ethylhexanoate di-paramethoxycinnamate, methyl 2,5-diisopropylcinnamate, methylbis trimethoxycinnamate (Trimethylsiloxy)silyl isopentyl, cinnamic acid-based UV absorbers such as a mixture of isopropyl para-methoxycinnamate and diisopropyl cinnamate; Benzoylmethane-based
  • PARASOL 340 dimethoxybenzylidene dioxoimidazolidine 2-ethylhexylpropionate (e.g., Ajinomoto Co., Ltd. "Soft Shade DH”), 1-(3,4-dimethoxyphenyl) )-4,4-dimethyl-1,3-pentanedione, cinoxate, methyl-O-aminobenzoate, 3-(4-methylbenzylidene)camphor, octyltriazone, diethylaminohydroxybenzoyl hexylbenzoate (2-(4- diethylamino-2-hydroxybenzoyl)benzoic acid hexyl ester, such as "Ubinal Aplus” manufactured by BASF), bisethylhexyloxyphenol methoxyphenyltriazine (2,4-bis ⁇ [4-(2-ethylhexyloxy)-2-hydroxy] Phenyl ⁇ -6-(
  • a salicylic acid UV absorber As the water-soluble organic UV absorber, a salicylic acid UV absorber, a cinnamic acid UV absorber, a benzoylmethane UV absorber, and other organic UV absorbers having a solubility in water of 1 w/w% are selected. More than one can be used, and examples thereof include salicylic acid triethanolamine salt, p-methoxyhydrocinnamic acid diethanolamine salt, and the like.
  • the UV absorber includes 2-ethylhexyl paramethoxycinnamate, 4-tert-butyl-4′-methoxydibenzoylmethane, octocrylene, dimethoxybenzylidene dioxoimidazolidine propionic acid.
  • a combination is more preferable. More preferably, it is one or more selected from the group consisting of 2-ethylhexyl paramethoxycinnamate, hexyl diethylaminohydroxybenzoylbenzoate, and bisethylhexyloxyphenol methoxyphenyltriazine, and a combination of two or more thereof is more preferable. More preferred.
  • the content thereof is preferably 0.2% by mass or more, more preferably 1.5% by weight, in the external preparation for skin from the viewpoint of improving the ultraviolet protection effect. Above, more preferably 5% by mass or more, still more preferably 7% by mass or more. From the viewpoint of improving the feeling of use of the external preparation for skin, the content is preferably 30% by mass or less, more preferably 25% by mass or less, even more preferably 20% by mass or less, and even more preferably 15% by mass or less.
  • the specific range of the content of the ultraviolet absorber in the external preparation for skin is preferably 0.2% by mass or more and 30% by mass or less, more preferably 1.5% by mass or more and 25% by mass or less, and even more preferably. is 5% by mass or more and 20% by mass or less, and more preferably 7% by mass or more and 15% by mass or less.
  • the external preparation for skin of the present invention may further contain an ultraviolet scattering agent from the viewpoint of improving the ultraviolet protection effect.
  • an ultraviolet scattering agent inorganic particles are preferable because they are highly effective in scattering ultraviolet rays.
  • metal oxide particles other than the plate-shaped metal oxide (A2) are more preferable.
  • the metal oxide include titanium oxide, zinc oxide, iron oxide, zirconium oxide, and aluminum oxide other than component (A), and are selected from the group consisting of titanium oxide and zinc oxide other than component (A). Species or more are more preferred.
  • the inorganic particles used in the UV scattering agent are preferably hydrophobized by surface treatment.
  • surface treatment methods for hydrophobization include silicone treatment with methylhydrogenpolysiloxane (hydrogendimethicone), methylpolysiloxane (dimethicone), methylhydrogenpolysiloxane/dimethylpolysiloxane copolymer, etc.; perfluoroalkyl Fluorine treatment with phosphate ester, perfluoroalcohol, etc.; amino acid treatment with N-acylglutamic acid, etc.; hexyltrimethoxysilane, octyltrimethoxysilane, decyltrimethoxysilane, octadecyltrimethoxysilane, octyltriethoxysilane, trifluoropropyltri Silane compound treatment with methoxysilane,
  • the particle shape of the UV-scattering agent may be spherical with an average particle size of less than 350 nm, rod-like, spindle-like, needle-like, or amorphous, but is not particularly limited as long as it has an UV-scattering effect.
  • the average particle size of the UV scattering agent is usually 1 nm or more, preferably 5 nm or more, more preferably 8 nm or more, and still more preferably 10 nm or more from the viewpoint of improving the UV protection effect.
  • it is preferably less than 350 nm, more preferably 300 nm or less, even more preferably 100 nm or less, and even more preferably 60 nm or less.
  • the average particle size can be measured by the same method as for the average particle size of component (A1).
  • UV scattering agents can also be used.
  • examples of commercially available titanium oxide particles used as UV scattering agents include “MT-100TV” (aluminum hydroxide, stearic acid treatment) and “MTY-110M3S” (aluminum hydroxide, silica, hydro Gendimethicone treatment) and the like.
  • Examples of commercially available zinc oxide particles used as UV scattering agents include “FINEX-50-LPTM” (dimethicone treatment), “FINEX-25” (no surface treatment), “FINEX- 25LP” (dimethicone treatment), “MZ-300” manufactured by Tayca Corporation (no surface treatment), “MZ-504R3M” (hydrogen dimethicone treatment), “MZY-303S” (hydrodimethicone treatment), “MZ-306X” "(triethoxysilylethylpolydimethylsiloxyethylhexyl dimethicone treatment),"MZ-200"(no surface treatment),”MZY-203S”(hydrogen dimethicone treatment),”MZ-150"(no surface treatment),”MZY- 153S” (hydrogen dimethicone treatment), “MZ-505S”, “MZY-505S” and the like.
  • the ultraviolet scattering agent can be used alone or in combination of two or more.
  • the content thereof is preferably 1% by mass or more, more preferably 3% by mass or more, and still more preferably 5% by mass or more, from the viewpoint of improving the ultraviolet protection effect. is.
  • the content is preferably 20% by mass or less, more preferably 18% by mass or less, and even more preferably 15% by mass or less.
  • the external skin preparation of the present invention can be used as a skin external preparation for protecting against ultraviolet rays or infrared rays, for suppressing skin temperature rise, or for suppressing fatigue.
  • the external preparation for skin of the present invention to the skin, it is possible to effectively protect the skin even when the skin is irradiated with ultraviolet light, infrared light, or light containing wavelengths in the ultraviolet to infrared region such as sunlight.
  • ultraviolet light infrared light
  • light containing wavelengths in the ultraviolet to infrared region such as sunlight.
  • an animal such as a human performs endurance exercise in a sunlight irradiation environment, fatigue is likely to occur if the amount of sunlight irradiation is large. It is possible to suppress fatigue caused by
  • the anti-fatigue effect of using an external preparation for skin can be evaluated, for example, by the following method.
  • the external preparation for skin is applied to the exposed areas (face, chest, back, arms, backs of hands, feet) of the test subject at a concentration of 2 mg/cm 2 and allowed to dry for 15 minutes.
  • artificial solar light sources are placed in front, back, left and right of the subject, and while irradiating simulated sunlight toward the upper body of the subject, an ergometer (for example, "Standard Ergometer 828E" manufactured by Monarch) is used to maintain a constant heart rate.
  • an ergometer for example, "Standard Ergometer 828E” manufactured by Monarch
  • Subjects self-evaluate heat sensation and fatigue sensation during exercise to evaluate the effect of topical skin preparations on exercise performance.
  • the method for producing the external preparation for skin of the present invention is not particularly limited, and a known method can be appropriately used depending on the dosage form of the external preparation for skin. For example, there is a method of blending components (A), (B) and all other components and uniformly mixing them with a disper or the like. Alternatively, a method of blending all components other than water and an aqueous medium and uniformly mixing them with a disper or the like, then adding water and an aqueous medium and further stirring and mixing with a homogenizer or the like can also be used.
  • the external preparation for skin is a water-in-oil emulsified composition or an oil-in-water emulsified composition
  • a method of preparing an aqueous phase and an oil phase and then mixing the two can also be used.
  • the present invention also provides a method for protecting the skin from infrared rays, comprising the step of applying the external preparation for skin of the present invention to the skin.
  • the infrared protection method of the present invention is not particularly limited as long as it includes the step of applying the external preparation for skin of the present invention to the skin. Examples of the method of applying the skin external preparation to the skin include coating, spraying, and the like.
  • the infrared protection rate at a wavelength of 825 nm is preferably 35% or higher, more preferably 45% or higher, and even more preferably 55% or higher. Moreover, when the infrared protection rate at a wavelength of 825 nm is 65% or more, the feeling of heat shielding on the skin becomes particularly good.
  • the infrared protection rate (%) can be specifically measured by the method described in Examples.
  • the present invention further discloses the following external preparations for skin.
  • the metal oxide in component (A1) and component (A2) is preferably one or more selected from the group consisting of titanium oxide, zinc oxide, zirconium oxide, iron oxide, aluminum oxide, and cerium oxide, ⁇ 1 >.
  • Viscosity at 25°C is preferably 2,500 mPa s or more and 150,000 mPa s or less, more preferably 2,500 mPa s or more and 100,000 mPa s or less, still more preferably 2,500 mPa s or more and 50,000 mPa s.
  • the skin according to ⁇ 1> or ⁇ 2> External agent preferably 2,500 mPa s or more and 30,000 mPa s or less, still more preferably 2,500 mPa s or more and 20,000 mPa s or less, the skin according to ⁇ 1> or ⁇ 2> External agent.
  • the viscosity (mPa s) of the external skin preparation relative to the content (% by mass) of the component (A) in the external skin preparation is preferably 100 or more, more preferably 250 or more, still more preferably 300 or more, and more more preferably 350 or more, preferably 25,000 or less, more preferably 20,000 or less, even more preferably 15,000 or less, even more preferably 10,000 or less, still more preferably 5,000 or less , and more preferably 3,000 or less, the external preparation for skin according to any one of ⁇ 1> to ⁇ 3>.
  • the viscosity (mPa s) of the external skin preparation relative to the content (% by mass) of the component (A) in the external skin preparation is preferably 100 or more and 25,000 or less, more preferably 250 or more and 20,000 or less. , More preferably 300 or more and 15,000 or less, still more preferably 350 or more and 10,000 or less, still more preferably 350 or more and 5,000 or less, still more preferably 350 or more and 3,000 or less, ⁇ 1> ⁇
  • the skin external preparation according to any one of ⁇ 4>.
  • the content of the component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more, more preferably 5% by mass or more, still more preferably 10% by mass or more, and preferably 50% by mass. % or less, more preferably 40% by mass or less, still more preferably 30% by mass or less, still more preferably 20% by mass or less, the external preparation for skin according to any one of ⁇ 1> to ⁇ 5>.
  • the content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more and 50% by mass or less, more preferably 5% by mass or more and 40% by mass or less, and still more preferably 10% by mass or more and 30% by mass.
  • Component (A1) preferably has an average particle size of 400 nm or more and 2,000 nm or less, more preferably 700 nm or more and 2,000 nm or less, still more preferably 700 nm or more and 1,800 nm or less, still more preferably 700 nm or more and 1,500 nm or less,
  • the external preparation for skin according to any one of ⁇ 1> to ⁇ 7>, which is more preferably 800 nm or more and 1,200 nm or less.
  • the component (A) preferably contains a spherical metal oxide having an average particle size of 700 nm or more and 2,500 nm or less as the component (A1), and preferably has a viscosity of 2,500 mPa s or more and 20,000 mPa s or less at 25°C.
  • the skin external preparation according to any one of ⁇ 1> to ⁇ 8>.
  • ⁇ 10> The skin external application according to any one of ⁇ 1> to ⁇ 9>, wherein the component (A) contains, as component (A2), preferably one or more selected from the group consisting of plate-like titanium oxide and plate-like zinc oxide. agent.
  • the thickness of the component (A2) is preferably 30 nm or more, more preferably 50 nm or more, still more preferably 60 nm or more, still more preferably 75 nm or more, still more preferably 90 nm or more, still more preferably 100 nm or more, Also, preferably 360 nm or less, more preferably 330 nm or less, still more preferably 310 nm or less, still more preferably 280 nm or less, even more preferably 270 nm or less, even more preferably 230 nm or less, still more preferably 200 nm or less, still more preferably 200 nm or less.
  • the thickness of component (A2) is preferably 30 nm or more and 360 nm or less, more preferably 50 nm or more and 330 nm or less, still more preferably 60 nm or more and 310 nm or less, still more preferably 75 nm or more and 280 nm or less, still more preferably 90 nm or more and 270 nm or less,
  • the external preparation for skin according to any one of ⁇ 1> to ⁇ 11> which is more preferably 100 nm or more and 230 nm or less, still more preferably 100 nm or more and 200 nm or less, still more preferably 100 nm or more and 180 nm or less.
  • the aspect ratio of the component (A2) is preferably 3 or more, more preferably 5 or more, still more preferably 10 or more, still more preferably 30 or more, still more preferably 50 or more, still more preferably 55 or more, Also, preferably 300 or less, more preferably 230 or less, still more preferably 200 or less, still more preferably 140 or less, still more preferably 125 or less, still more preferably 120 or less, ⁇ 1> to ⁇ 12>
  • the skin external preparation according to any one of the above.
  • the aspect ratio of the component (A2) is preferably 3 or more and 300 or less, more preferably 3 or more and 230 or less, still more preferably 10 or more and 230 or less, still more preferably 30 or more and 230 or less, still more preferably 50 or more and 200 or less. , More preferably 55 or more and 140 or less, still more preferably 55 or more and 125 or less, still more preferably 55 or more and 120 or less, ⁇ 1> to ⁇ 13>.
  • the content of component (A2) in component (A) is preferably 50% by mass or more, more preferably 60% by mass or more, still more preferably 70% by mass or more, still more preferably 80% by mass or more, and even more preferably is 90% by mass or more and 100% by mass or less, the skin external preparation according to any one of ⁇ 1> to ⁇ 14>.
  • the content of spherical titanium oxide having an average particle size of 350 nm or more and less than 800 nm in the skin external preparation is preferably 5% by mass or more and 30% by mass or less, more preferably 5% by mass or more and 25% by mass or less.
  • the content of spherical titanium oxide having an average particle size of 800 nm or more and 2,500 nm or less in the external preparation for skin is preferably 5% by mass or more and 40% by mass or less, more preferably 5% by mass or more and 30% by mass or less, ⁇ 1
  • the content of spherical zinc oxide or plate-shaped zinc oxide having an average particle size of 350 nm or more and 2,500 nm or less in the skin external preparation is preferably 7% by mass or more and 50% by mass or less, more preferably 10% by mass or more and 50% by mass.
  • the skin external preparation according to any one of ⁇ 1> to ⁇ 18> below.
  • the viscosity of component (B) at 25° C. is preferably 500 mPa ⁇ s or less, more preferably 300 mPa ⁇ s or less, still more preferably 100 mPa ⁇ s or less, still more preferably 50 mPa ⁇ s or less, and preferably 5 mPa.
  • the external preparation for skin according to any one of ⁇ 1> to ⁇ 19>, which is s or more.
  • the component (B) is preferably liquid at 25° C., more preferably one or more selected from the group consisting of ester oils, silicone oils, hydrocarbon oils, higher fatty acids, and higher alcohols, ⁇ 1>
  • the content of component (B) in the external preparation for skin is preferably 1% by mass or more, more preferably 5% by mass or more, and is preferably 90% by mass or less, more preferably 80% by mass or less, and still more preferably. is 70% by mass or less, more preferably 65% by mass or less.
  • the topical skin preparation is a water-in-oil emulsion composition, and the content of component (B) in the topical skin preparation is preferably 15% by mass or more, more preferably 20% by mass or more, and still more preferably 25% by mass or more. , More preferably 30% by mass or more, still more preferably 35% by mass or more, ⁇ 1> to ⁇ 22>.
  • the topical skin preparation is an oil-in-water emulsified composition, and the content of component (B) in the topical skin preparation is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less.
  • the skin external preparation according to any one of ⁇ 1> to ⁇ 23>.
  • the mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] is preferably 0.05 or more, more preferably 0.1 or more, and still more preferably 0.2 more preferably 0.5 or more, still more preferably 1 or more, still more preferably 2 or more, still more preferably 3 or more, still more preferably 3.6 or more, and preferably 60 or less,
  • the mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] is preferably 0.05 or more and 60 or less, more preferably 0.1 or more and 50 or less, and still more preferably is 0.2 or more and 30 or less, more preferably 0.5 or more and 20 or less, still more preferably 1 or more and 10 or less, still more preferably 2 or more and 10 or less, still more preferably 3 or more and 10 or less, still more preferably
  • the skin external preparation according to any one of ⁇ 1> to ⁇ 25>, which is 3.6 or more and 8 or less.
  • the total content of component (A) and component (B) in the external skin preparation is preferably 2% by mass or more, more preferably 10% by mass or more, still more preferably 20% by mass or more, and even more preferably 30% by mass. More preferably 40% by mass or more, still more preferably 45% by mass or more, still more preferably 47% by mass or more, still more preferably 50% by mass or more, and 100% by mass or less ⁇ 1> to ⁇ 26>, the external preparation for skin.
  • the content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more, more preferably 1% by mass or more, still more preferably 2% by mass or more, and even more preferably 3% by mass or more.
  • the skin external preparation according to any one of ⁇ 30>.
  • the content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more and 50% by mass or less, more preferably 0.5% by mass or more and 30% by mass or less, and still more preferably 1% by mass or more and 25% by mass. % or less, more preferably 2 to 20 mass %, still more preferably 3 to 15 mass %, the external preparation for skin according to any one of ⁇ 28> to ⁇ 31>.
  • the external skin preparation preferably further contains water, and the content of water in the external skin preparation is preferably 1% by mass or more, more preferably 5% by mass or more, still more preferably 8% by mass or more, and even more preferably. is 10% by mass or more, preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 25% by mass or less.
  • the external preparation for skin according to any one of ⁇ 1> to ⁇ 33> which is preferably liquid, gel, cream or solid.
  • ⁇ 35> The external preparation for skin according to any one of ⁇ 1> to ⁇ 34>, which is for protection against ultraviolet rays or infrared rays, suppression of skin temperature rise, or suppression of fatigue.
  • ⁇ 36> A method for protecting the skin from infrared rays, comprising the step of applying the external preparation for skin according to any one of ⁇ 1> to ⁇ 35> to the skin, preferably by coating or spraying.
  • ⁇ Viscosity> The viscosity at 25° C. of each example of the external preparation for skin was measured using a Brookfield viscometer ("TOKI SANGYO VISCOMETER TVB-10M" manufactured by Toki Sangyo Co., Ltd.) at a rotor speed of 6.0 rpm and a rotation time of 60 seconds. Under these conditions, measurements were made on the next day after preparation of the external preparation for skin. The rotor is No. 1 depending on the viscosity. 2-No. 4 was used. [No. 2: Viscosity 500-5000 mPa ⁇ s, No. 3: Viscosity more than 5000 mPa ⁇ s and 20000 mPa ⁇ s or less, No. 4: Viscosity over 20000 mPa s]
  • PMMA polymethyl methacrylate
  • the near-infrared protective effect was evaluated in 5 stages according to the following criteria.
  • the transmittance distribution of the corniculus part (the convex part of the PMMA plate) and the transcutaneous part (the concave part of the PMMA plate) was confirmed, and the uniformity was evaluated as "only the sulcus cutis is protected.”
  • the evaluation was made on a 5-point scale, with 1 point for the case where the skin bumps were almost completely protected, and 5 points for the case where both the skin bumps and the skin folds were evenly protected.
  • HAL-320W manufactured by Asahi Spectrosco Co., Ltd.
  • Examples 1 to 23 Comparative Examples 1 to 6 (manufacture and evaluation of external preparations for skin) Of the components shown in Tables 1 to 4, all components except water were blended and uniformly mixed with a disper. Then, water was added to the resulting mixed solution and mixed uniformly using a homogenizer to produce a water-in-oil type external preparation for skin having the composition shown in Tables 1 to 4. The resulting external preparation for skin was evaluated by the method described above. The results are shown in Tables 1-4.
  • surface is the amount of active ingredients (mass %) of each component except "BENTONE GEL PTM V.”
  • the blending amount of "BENTONE GEL PTM V" is mass % in the actual state.
  • a metal oxide that does not correspond to component (A) is indicated as "component (A1')".
  • Examples 24 to 27 (manufacture of external preparation for skin) For Examples 24 and 25, among the components shown in Table 5, all components except water were blended and uniformly mixed with a disper. Next, water was added to the resulting mixed solution and mixed uniformly using a homogenizer to produce a water-in-oil type solid skin preparation for external use having the composition shown in Table 5. For Examples 26 and 27, all the components shown in Table 5 were blended and uniformly mixed with a disper to produce a solid external preparation for skin. In addition, the compounding quantity described in the table
  • the external preparation for skin of this example has a high infrared protection effect and a high coating uniformity, and causes little whitening when applied to the skin. In addition, it is also excellent in skin temperature rise suppressing effect.
  • FIG. 1 shows an IR microscope observation photograph (score 5) in the coating film uniformity evaluation of the external skin preparation of Example 9, and FIG. An observation photograph (score 1) by an IR microscope is shown.
  • white portions indicate locations where component (A) is present, and black portions indicate locations where component (A) is not present.
  • Fig. 1 When the topical skin preparation of Example 9 was applied, a large amount of component (A) was present not only in the sulcus cutis but also in the carpus (Fig. 1), whereas the topical skin preparation of Comparative Example 2 was applied. In this case, most of the component (A) fell into the sulci, indicating that the uniformity of the coating film was low (Fig. 2).
  • an external preparation for skin that has excellent protective effects against ultraviolet rays, infrared rays, etc., and that leaves little whitening when applied to the skin.
  • the external preparation for skin When the external preparation for skin is applied to the skin, it can protect the skin from ultraviolet rays, infrared rays, and the like, and can also provide an effect of suppressing an increase in skin temperature and an effect of suppressing fatigue due to sunlight irradiation.

Abstract

This skin external agent contains: a component (A) which is at least one metal oxide selected from the group consisting of a spherical metal oxide (A1) having an average particle diameter of 350-2,500 nm and a plate-shaped metal oxide (A2); and a component (B) which is a nonvolatile oil, wherein the content of the component (A) in said skin external agent is 2-50 mass%, and the viscosity at 25ºC is at least 2,500 mPa∙s.

Description

皮膚外用剤Skin topical agent
 本発明は、皮膚外用剤に関する。 The present invention relates to an external preparation for skin.
 太陽光に対する皮膚防御の観点から、日焼け止め化粧料などの紫外線防御化粧料が知られている。一方で、近年は健康意識の高まりにより、赤外線に対する防御機能を有する皮膚外用剤が求められている。
 赤外線防御機能を有する皮膚外用剤に関して、例えば特許文献1(国際公開第2009/017104号)には、赤外線が皮膚の組織よりも深部の組織に到達することを阻害し、赤外線によるそれらの組織の損傷を防止する防止剤に関する技術として、酸化チタン粉末と酸化亜鉛粉末とからなる赤外線透過遮蔽剤を含有する生体組織の近赤外線損傷の防止剤が開示されている。特許文献2(特開2017-95361号公報)には、優れた近赤外防御効果と高い透明性を両立した、酸化チタン粉末と酸化亜鉛粉末とからなる近赤外線防御化粧料組成物が開示されている。
 また特許文献3(国際公開第2020/138431号)、特許文献4(特開2020-105175号公報)、特許文献5(特開2020-105176号公報)及び特許文献6(特開2020-105177号公報)には、より赤外線防御効果に優れる皮膚外用剤として、所定の形状の板状金属酸化物を含有する皮膚外用剤が開示されている。
From the viewpoint of skin protection against sunlight, UV protection cosmetics such as sunscreen cosmetics are known. On the other hand, in recent years, due to the heightened awareness of health, there is a demand for an external preparation for skin that has a protective function against infrared rays.
Regarding skin preparations for external use having an infrared protection function, for example, Patent Document 1 (International Publication No. 2009/017104) discloses that infrared rays are prevented from reaching tissues deeper than skin tissues, and infrared rays protect those tissues. As a technique related to an inhibitor for preventing damage, an agent for preventing near-infrared damage to living tissue containing an infrared transmission shielding agent consisting of titanium oxide powder and zinc oxide powder has been disclosed. Patent Document 2 (Japanese Patent Application Laid-Open No. 2017-95361) discloses a near-infrared protective cosmetic composition composed of titanium oxide powder and zinc oxide powder, which achieves both excellent near-infrared protective effect and high transparency. ing.
In addition, Patent Document 3 (International Publication No. 2020/138431), Patent Document 4 (JP 2020-105175), Patent Document 5 (JP 2020-105176) and Patent Document 6 (JP 2020-105177) Publication) discloses an external preparation for skin containing a plate-like metal oxide having a predetermined shape as an external preparation for skin having a more excellent infrared protection effect.
 本発明は、下記に関する。
[1]成分(A):平均粒径350nm以上2,500nm以下の球状金属酸化物(A1)及び板状金属酸化物(A2)からなる群から選ばれる1種以上の金属酸化物、並びに
 成分(B):不揮発性油、
を含有する皮膚外用剤であって、該皮膚外用剤中の成分(A)の含有量が2質量%以上50質量%以下であり、25℃における粘度が2,500mPa・s以上である、皮膚外用剤。
[2]前記[1]に記載の皮膚外用剤を皮膚に適用する工程を有する、皮膚の赤外線防御方法。
The present invention relates to the following.
[1] Component (A): one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less, and a component (B): non-volatile oil,
wherein the content of component (A) in the external skin preparation is 2% by mass or more and 50% by mass or less, and the viscosity at 25°C is 2,500 mPa·s or more. External agent.
[2] A method for protecting the skin from infrared radiation, which comprises applying the external preparation for skin according to [1] to the skin.
実施例9の皮膚外用剤の塗膜均一性評価における、IR顕微鏡による観察写真(スコア5)である。10 is an IR microscope observation photograph (score 5) in evaluation of coating film uniformity of the external preparation for skin of Example 9. FIG. 比較例2の皮膚外用剤の塗膜均一性評価における、IR顕微鏡による観察写真(スコア1)である。4 is an IR microscope observation photograph (score 1) in evaluation of coating film uniformity of the external preparation for skin of Comparative Example 2. FIG.
発明の詳細な説明Detailed description of the invention
[皮膚外用剤]
 本発明の皮膚外用剤は、
 成分(A):平均粒径350nm以上2,500nm以下の球状金属酸化物(A1)及び板状金属酸化物(A2)からなる群から選ばれる1種以上の金属酸化物、並びに
 成分(B):不揮発性油、
を含有する皮膚外用剤であって、該皮膚外用剤中の成分(A)の含有量が2質量%以上50質量%以下であり、25℃における粘度が2,500mPa・s以上である。
 本発明の皮膚外用剤は上記構成であることにより、紫外線、赤外線等の防御効果に優れ、且つ、皮膚に塗布した際の白浮きが少ない皮膚外用剤となる。
[External preparation for skin]
The skin external preparation of the present invention is
Component (A): one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less, and component (B) : non-volatile oil,
wherein the content of component (A) in the external skin preparation is 2% by mass or more and 50% by mass or less, and the viscosity at 25°C is 2,500 mPa·s or more.
The external preparation for skin of the present invention having the above-described constitution is excellent in the protective effect against ultraviolet rays, infrared rays, etc., and produces less whitening when applied to the skin.
 太陽光に対する皮膚防御のため、特に紫外線、赤外線等の防御効果をさらに向上させた皮膚外用剤が望まれている。さらに皮膚外用剤としては、皮膚に塗布した際に白くなりにくいこと(以下「白浮き」ともいう)も求められる。
 本発明の課題は、紫外線、赤外線等の防御効果に優れ、且つ、皮膚に塗布した際の白浮きが少ない皮膚外用剤を提供することにある。
In order to protect the skin against sunlight, there is a demand for an external preparation for skin that has further improved protection against ultraviolet rays, infrared rays, and the like. Furthermore, external skin preparations are also required to be less likely to turn white when applied to the skin (hereinafter also referred to as “whitening”).
An object of the present invention is to provide an external preparation for skin which has excellent protective effect against ultraviolet rays, infrared rays, etc., and which causes less whitening when applied to the skin.
 本発明者は、所定の形状及び所定量の金属酸化物、並びに不揮発性油を含有し、且つ所定値以上の粘度の皮膚外用剤が、上記課題を解決できることを見出した。 The present inventor found that an external preparation for skin containing a predetermined shape, a predetermined amount of metal oxide, and a non-volatile oil and having a viscosity of a predetermined value or more can solve the above problems.
 本発明によれば、紫外線、赤外線等の防御効果に優れ、且つ、皮膚に塗布した際の白浮きが少ない皮膚外用剤を提供できる。該皮膚外用剤を皮膚に適用すると、紫外線、赤外線等から皮膚を防御することができ、更に、太陽光照射による皮膚温度上昇抑制効果及び疲労抑制効果も得ることができる。 According to the present invention, it is possible to provide an external preparation for skin that has excellent protective effects against ultraviolet rays, infrared rays, etc., and that leaves little whitening when applied to the skin. When the external preparation for skin is applied to the skin, it can protect the skin from ultraviolet rays, infrared rays, and the like, and can also provide an effect of suppressing an increase in skin temperature and an effect of suppressing fatigue due to sunlight irradiation.
 本発明の皮膚外用剤により上記効果が得られる理由については定かではないが、次のように考えられる。
 酸化チタン等の金属酸化物を含有する皮膚外用剤においては、粒子径が大きいものを用いた方が紫外線、赤外線等の防御効果も高くなることが知られている。しかしながら、単に粒子径が大きい金属酸化物を用いるだけでは、特に赤外線の防御効果の向上に限界があった。また、例えば粒子径の大きい球状金属酸化物を皮膚外用剤に配合した場合、皮膚に塗布した際に粒子表面で可視光の光散乱が生じるため、白浮きしやすいという欠点があった。したがって使用する金属酸化物の粒子径を調整するだけでは、紫外線、赤外線等の防御効果向上と、皮膚に塗布した際の白浮き抑制とを同時に達成することが困難であった。
 また、皮膚外用剤中の金属酸化物の含有量を多くすることでも紫外線、赤外線等の防御効果を向上させることができるが、該含有量を多くすると皮膚に塗布した際に白浮きしやすいという傾向もあった。
Although the reason why the external preparation for skin of the present invention provides the above effects is not clear, it is considered as follows.
It is known that skin preparations containing metal oxides such as titanium oxide with a larger particle size are more effective in protecting against ultraviolet rays and infrared rays. However, simply using a metal oxide having a large particle size limits the improvement in the infrared protection effect. In addition, for example, when a spherical metal oxide having a large particle size is added to an external preparation for skin, visible light is scattered on the surface of the particles when applied to the skin, which tends to cause whitening. Therefore, it has been difficult to simultaneously improve the protective effect against ultraviolet rays, infrared rays, etc. and suppress whitening when applied to the skin, simply by adjusting the particle size of the metal oxide used.
In addition, increasing the content of metal oxides in external preparations for skin can also improve the protective effect against ultraviolet rays, infrared rays, etc. However, it is said that when the content is increased, whitening tends to occur when applied to the skin. There was also a tendency
 本発明の皮膚外用剤は、成分(A)として所定の大きさ及び形状の金属酸化物を所定量用いることで、紫外線、赤外線等の防御効果が得られ、皮膚に塗布した際の白浮き抑制も可能となる。さらに本発明者は、金属酸化物を含有する皮膚外用剤において紫外線、赤外線等の防御効果をより向上させるためには、皮膚外用剤の均一塗布性、特に、紫外線、赤外線等を防御するための有効成分である成分(A)を皮膚表面に均一に配置させることが効果的であること、そのためには皮膚外用剤のレオロジー制御が重要であることを見出した。
 具体的には、低粘度の皮膚外用剤を皮膚に塗布した場合には、比重の高い成分(A)を塗布膜中に保持しにくいため、成分(A)が皮溝に沈降しやすくなると考えられる。特に粒径が大きい成分(A)は皮溝に沈降しやすく、皮膚表面に均一に配置させることができなくなり、紫外線、赤外線等の防御効果も低下すると考えられる。
 本発明の皮膚外用剤は成分(A)に加え、成分(B)として不揮発性油を含有し、且つ粘度が所定値以上であることにより、皮膚に塗布した際の成分(A)の皮溝への沈降を抑制し、均一塗布性を向上させることができるため、紫外線、赤外線等の防御効果をより高めることができたと考えられる。
By using a predetermined amount of metal oxide having a predetermined size and shape as the component (A), the external preparation for skin of the present invention has a protective effect against ultraviolet rays, infrared rays, etc., and suppresses whitening when applied to the skin. is also possible. Furthermore, in order to further improve the protective effect against ultraviolet rays, infrared rays, etc., in external preparations for skin containing metal oxides, the present inventors have found that the uniform applicability of the external preparations for skin, in particular, the ability to protect against ultraviolet rays, infrared rays, etc. It has been found that it is effective to evenly dispose the active ingredient (A) on the skin surface, and that rheological control of the external preparation for skin is important for this purpose.
Specifically, when a low-viscosity topical skin preparation is applied to the skin, component (A), which has a high specific gravity, is unlikely to be retained in the coating film, so component (A) is likely to settle in the sulcus cutis. be done. In particular, component (A), which has a large particle size, tends to settle in the sulcus cutis and cannot be distributed uniformly on the skin surface, and is considered to reduce the protective effect against ultraviolet rays, infrared rays, and the like.
The external preparation for skin of the present invention contains a non-volatile oil as component (B) in addition to component (A), and has a viscosity of a predetermined value or more, so that when applied to the skin, the skin groove of component (A) is reduced. Presumably, the sedimentation to the surface can be suppressed, and the uniform coating property can be improved, so that the protective effect against ultraviolet rays, infrared rays, etc. can be further enhanced.
<定義>
 本発明において紫外線とは、波長200~360nmの電磁波を意味し、赤外線とは、波長780nm~1mmの電磁波を意味する。このうち本発明の皮膚外用剤は、特に、波長780nm~2500nmの近赤外線防御効果に優れる。この近赤外線防御効果により、太陽光照射による皮膚温度上昇抑制効果、及び疲労抑制効果を得ることができる。
 なお本明細書においては、赤外線防御効果として波長825nmの赤外線防御率を指標とする。
<Definition>
In the present invention, ultraviolet light means electromagnetic waves with a wavelength of 200 to 360 nm, and infrared light means electromagnetic waves with a wavelength of 780 nm to 1 mm. Among these, the external preparation for skin of the present invention is particularly excellent in the near-infrared protective effect with a wavelength of 780 nm to 2500 nm. Due to this near-infrared protection effect, it is possible to obtain an effect of suppressing an increase in skin temperature due to sunlight irradiation and an effect of suppressing fatigue.
In this specification, the infrared protection rate at a wavelength of 825 nm is used as an indicator of the infrared protection effect.
<粘度>
 本発明の皮膚外用剤は、均一塗布性を向上させて皮膚に塗布した際の成分(A)の皮溝への沈降を抑制し、紫外線、赤外線等の防御効果を向上させる観点から、25℃における粘度が2,500mPa・s以上であり、好ましくは3,000mPa・s以上、より好ましくは5,000mPa・s以上、更に好ましくは8,000mPa・s以上、より更に好ましくは10,000mPa・s以上である。また、皮膚への塗り延ばしやすさの観点から、好ましくは200,000mPa・s以下、より好ましくは150,000mPa・s以下、更に好ましくは100,000mPa・s以下、より更に好ましくは50,000mPa・s以下、より更に好ましくは30,000mPa・s以下、より更に好ましくは20,000mPa・s以下である。
 そして、本発明の皮膚外用剤の25℃における粘度は、2,500mPa・s以上であり、好ましくは2,500mPa・s以上200,000mPa・s以下、より好ましくは3,000mPa・s以上200,000mPa・s以下、更に好ましくは5,000mPa・s以上150,000mPa・s以下、より更に好ましくは8,000mPa・s以上100,000mPa・s以下、より更に好ましくは8,000mPa・s以上50,000mPa・s以下、より更に好ましくは10,000mPa・s以上30,000mPa・s以下である。他の態様において、本発明の皮膚外用剤の25℃における粘度は、好ましくは2,500mPa・s以上150,000mPa・s以下、より好ましくは2,500mPa・s以上100,000mPa・s以下、更に好ましくは2,500mPa・s以上50,000mPa・s以下、より更に好ましくは2,500mPa・s以上30,000mPa・s以下、より更に好ましくは2,500mPa・s以上20,000mPa・s以下である。
 皮膚外用剤の25℃における粘度は、B型粘度計を用いて25℃において測定される値であり、具体的には実施例に記載の方法により測定することができる。
<Viscosity>
The skin preparation for external use of the present invention is applied at 25° C. from the viewpoint of improving uniform applicability, suppressing precipitation of component (A) in the skin grooves when applied to the skin, and improving the protective effect against ultraviolet rays, infrared rays, and the like. The viscosity at the That's it. In addition, from the viewpoint of ease of application to the skin, it is preferably 200,000 mPa·s or less, more preferably 150,000 mPa·s or less, even more preferably 100,000 mPa·s or less, and even more preferably 50,000 mPa·s or less. s or less, more preferably 30,000 mPa·s or less, and even more preferably 20,000 mPa·s or less.
The viscosity of the external preparation for skin of the present invention at 25° C. is 2,500 mPa·s or more, preferably 2,500 mPa·s or more and 200,000 mPa·s or less, more preferably 3,000 mPa·s or more and 200 mPa·s or more. 000 mPa s or less, more preferably 5,000 mPa s or more and 150,000 mPa s or less, even more preferably 8,000 mPa s or more and 100,000 mPa s or less, still more preferably 8,000 mPa s or more50, 000 mPa·s or less, more preferably 10,000 mPa·s or more and 30,000 mPa·s or less. In another embodiment, the viscosity of the external preparation for skin of the present invention at 25° C. is preferably 2,500 mPa·s or more and 150,000 mPa·s or less, more preferably 2,500 mPa·s or more and 100,000 mPa·s or less. It is preferably 2,500 mPa s or more and 50,000 mPa s or less, still more preferably 2,500 mPa s or more and 30,000 mPa s or less, still more preferably 2,500 mPa s or more and 20,000 mPa s or less. .
The viscosity of the external preparation for skin at 25°C is a value measured at 25°C using a Brookfield viscometer, and can be specifically measured by the method described in Examples.
 本発明の皮膚外用剤の粘度を上記範囲に調整する手段としては、皮膚外用剤に用いる成分(A)の種類及び含有量の選択、成分(B)の種類及び含有量の選択、後述する増粘剤、乳化剤、分散剤、水性媒体等の使用及びその含有量の選択、成分(A)の分散方法の選択等が挙げられる。 Means for adjusting the viscosity of the external preparation for skin of the present invention within the above range include selecting the type and content of component (A) used in the external preparation for skin, selecting the type and content of component (B), and increasing the viscosity described later. Selection of the use and content of viscosity agents, emulsifiers, dispersants, aqueous media, etc., and selection of dispersion methods for component (A) are included.
<剤型等>
 本発明の皮膚外用剤の剤型は、粘度が前記範囲である限り特に制限されず、皮膚への塗布しやすさの点から、液状、ゲル状、又はクリーム状であることが好ましい。本発明の皮膚外用剤の剤型は、粘度が前記範囲である限り、赤外線防御の観点から、スティック製剤等の固形状であることも好ましい。皮膚外用剤は非水系の組成物であっても、乳化組成物の形態であってもよく、乳化組成物としては水中油型乳化組成物、油中水型乳化組成物のいずれでもよい。水中油型乳化組成物であると粘度調整が容易であり、油中水型乳化組成物であると製剤化が容易であり、均一塗布性も向上する。
 本発明の皮膚外用剤は、使用感に優れる観点から、乳化組成物であることが好ましく、紫外線、赤外線等の防御効果並びに使用感に優れる観点から、油中水型乳化組成物であることが好ましい。
 また本発明の皮膚外用剤は、紫外線又は赤外線防御用の皮膚外用剤の他、化粧水、クリーム、乳液、美容液、サンタン、化粧下地化粧料等の皮膚化粧料であってもよい。
<Dosage type, etc.>
The dosage form of the external preparation for skin of the present invention is not particularly limited as long as the viscosity is within the above range, and from the viewpoint of ease of application to the skin, it is preferably liquid, gel or cream. As long as the viscosity is within the above range, the dosage form of the external skin preparation of the present invention is preferably a solid form such as a stick preparation from the viewpoint of infrared protection. The external preparation for skin may be a non-aqueous composition or an emulsified composition, and the emulsified composition may be either an oil-in-water emulsified composition or a water-in-oil emulsified composition. When it is an oil-in-water emulsion composition, it is easy to adjust the viscosity, and when it is a water-in-oil emulsion composition, it is easy to formulate, and the uniform coating property is also improved.
The external preparation for skin of the present invention is preferably an emulsified composition from the viewpoint of excellent feeling in use, and is preferably a water-in-oil type emulsified composition from the viewpoint of excellent protective effect against ultraviolet rays, infrared rays, etc. and excellent feeling in use. preferable.
The external preparation for skin of the present invention may be a skin preparation for protecting against ultraviolet rays or infrared rays, or a skin cosmetic such as lotion, cream, milky lotion, serum, suntan, makeup base cosmetic, and the like.
<成分(A):金属酸化物>
 本発明の皮膚外用剤は、成分(A)として、平均粒径350nm以上2,500nm以下の球状金属酸化物(A1)及び板状金属酸化物(A2)からなる群から選ばれる1種以上の金属酸化物を含有する。本発明の皮膚外用剤は成分(A)を含有することにより、紫外線、赤外線等の防御効果に優れ、皮膚温度上昇抑制効果及び疲労抑制効果も得られるとともに、皮膚に塗布した際の白浮きを抑制できるという効果を奏する。
<Component (A): Metal oxide>
The skin external preparation of the present invention contains, as component (A), one or more selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less. Contains metal oxides. By containing the component (A), the topical preparation for skin of the present invention has an excellent protective effect against ultraviolet rays, infrared rays, etc., provides a skin temperature rise suppressing effect and fatigue suppressing effect, and prevents whitening when applied to the skin. It has the effect of being able to suppress it.
(成分(A1):平均粒径350nm以上2,500nm以下の球状金属酸化物)
 本発明に用いられる成分(A1)は、平均粒径350nm以上2,500nm以下の球状金属酸化物である。ここでいう「球状」には、真球状及び略真球状も含まれる。また成分(A1)は、金属酸化物の一次粒子又は二次粒子のいずれかの形状が球状であればよい。成分(A1)が二次粒子として存在している場合は、成分(A1)の平均粒径とは、二次粒子の粒径の平均値を意味する。
 成分(A1)の平均粒径は、紫外線、赤外線等の防御効果の観点から、350nm以上であり、好ましくは400nm以上、より好ましくは700nm以上、更に好ましくは800nm以上である。また、紫外線、赤外線等の防御効果の観点、及び、皮膚に塗布した際の白浮きを抑制する観点から、2,500nm以下であり、好ましくは2,000nm以下、より好ましくは1,800nm以下、更に好ましくは1,500nm以下、より更に好ましくは1,200nm以下である。そして、成分(A1)の平均粒径は、350nm以上2,500nm以下であり、好ましくは400nm以上2,000nm以下、より好ましくは700nm以上2,000nm以下、更に好ましくは700nm以上1,800nm以下、より更に好ましくは700nm以上1,500nm以下、より更に好ましくは800nm以上1,200nm以下である。
 成分(A1)の平均粒径は、メジアン径(d50)であり、例えばレーザー回折/光散乱式粒径分布測定により求めることができる。測定において成分(A1)が分散しやすい溶媒を適宜用いることができ、例えば、表面処理がされていない金属酸化物については精製水を用い、シリコーン等で表面処理がされている金属酸化物についてはシリコーン油(例えば、メチルポリシロキサン、シクロペンタシロキサン等)を用いることができる。
(Component (A1): spherical metal oxide having an average particle size of 350 nm or more and 2,500 nm or less)
Component (A1) used in the present invention is a spherical metal oxide having an average particle size of 350 nm or more and 2,500 nm or less. The term "spherical" as used herein includes a spherical shape and a substantially spherical shape. In component (A1), the shape of either the primary particles or the secondary particles of the metal oxide may be spherical. When the component (A1) exists as secondary particles, the average particle size of the component (A1) means the average particle size of the secondary particles.
The average particle diameter of component (A1) is 350 nm or more, preferably 400 nm or more, more preferably 700 nm or more, and still more preferably 800 nm or more, from the viewpoint of protection against ultraviolet rays, infrared rays, and the like. In addition, from the viewpoint of the protective effect against ultraviolet rays, infrared rays, etc., and from the viewpoint of suppressing whitening when applied to the skin, it is 2,500 nm or less, preferably 2,000 nm or less, more preferably 1,800 nm or less. It is more preferably 1,500 nm or less, still more preferably 1,200 nm or less. The average particle diameter of component (A1) is 350 nm or more and 2,500 nm or less, preferably 400 nm or more and 2,000 nm or less, more preferably 700 nm or more and 2,000 nm or less, still more preferably 700 nm or more and 1,800 nm or less, More preferably 700 nm or more and 1,500 nm or less, still more preferably 800 nm or more and 1,200 nm or less.
The average particle diameter of component (A1) is the median diameter (d 50 ), which can be determined, for example, by laser diffraction/light scattering particle size distribution measurement. In the measurement, a solvent in which the component (A1) is easily dispersed can be used as appropriate. For example, purified water is used for metal oxides that are not surface-treated, and metal oxides that are surface-treated with silicone or the like are used. Silicone oils (eg, methylpolysiloxane, cyclopentasiloxane, etc.) can be used.
(成分(A2):板状金属酸化物)
 本発明に用いられる成分(A2)は、板状金属酸化物である。成分(A2)は板状であり、好ましくは後述する範囲の厚さ及びアスペクト比を有する。ここで、成分(A2)を含む皮膚外用剤を用いて皮膚表面に塗膜を形成すると、皮膚上面側で観測される光の反射率が、光の干渉効果により赤外線領域の波長の光に対しては高くなり、且つ、可視領域の波長の光に対しては低くなる。そのため、より高い赤外線防御効果が得られるとともに、皮膚に塗布した際の白浮きも抑制しやすくなる。
(Component (A2): Plate-shaped metal oxide)
Component (A2) used in the present invention is a plate-like metal oxide. Component (A2) is plate-shaped and preferably has a thickness and an aspect ratio within the ranges described below. Here, when a coating film is formed on the skin surface using an external preparation for skin containing component (A2), the reflectance of light observed on the upper surface side of the skin is reduced to light with a wavelength in the infrared region due to the light interference effect. is higher for light in the visible region, and lower for light with wavelengths in the visible region. As a result, a higher infrared protection effect can be obtained, and whitening when applied to the skin can be easily suppressed.
 成分(A2)の厚さは、赤外線防御効果向上の観点から、好ましくは30nm以上、より好ましくは50nm以上、更に好ましくは60nm以上、より更に好ましくは75nm以上、より更に好ましくは90nm以上、より更に好ましくは100nm以上である。また、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、成分(A2)の厚さは、好ましくは360nm以下、より好ましくは330nm以下、更に好ましくは310nm以下、更に好ましくは280nm以下、より更に好ましくは270nm以下、より更に好ましくは230nm以下、より更に好ましくは200nm以下、より更に好ましくは180nm以下である。そして、成分(A2)の厚さは、好ましくは30nm以上360nm以下、より好ましくは50nm以上330nm以下、更に好ましくは60nm以上310nm以下、より更に好ましくは75nm以上280nm以下、より更に好ましくは90nm以上270nm以下、より更に好ましくは100nm以上230nm以下、より更に好ましくは100nm以上200nm以下、より更に好ましくは100nm以上180nm以下である。
 なお、本発明において成分(A2)の厚さとは、板状金属酸化物粒子において最も短い軸の長さを意味する。
 成分(A2)の厚さは、走査電子顕微鏡(SEM)による観察画像から求めることができる。具体的には、成分(A2)をSEMにより観察倍率10,000倍の条件にて観察し、観察画像中の50個の粒子の厚さを測定して、個数あたりの厚さの平均値を算出することにより求められる。
The thickness of the component (A2) is preferably 30 nm or more, more preferably 50 nm or more, still more preferably 60 nm or more, still more preferably 75 nm or more, still more preferably 90 nm or more, and still more preferably 90 nm or more, from the viewpoint of improving the infrared protection effect. It is preferably 100 nm or more. In addition, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin, the thickness of the component (A2) is preferably 360 nm or less, more preferably 330 nm or less, still more preferably 310 nm or less. It is more preferably 280 nm or less, still more preferably 270 nm or less, still more preferably 230 nm or less, still more preferably 200 nm or less, and even more preferably 180 nm or less. The thickness of component (A2) is preferably 30 nm or more and 360 nm or less, more preferably 50 nm or more and 330 nm or less, still more preferably 60 nm or more and 310 nm or less, still more preferably 75 nm or more and 280 nm or less, still more preferably 90 nm or more and 270 nm or less. 100 nm or more and 230 nm or less, still more preferably 100 nm or more and 200 nm or less, and still more preferably 100 nm or more and 180 nm or less.
In the present invention, the thickness of component (A2) means the length of the shortest axis in the plate-like metal oxide particles.
The thickness of component (A2) can be obtained from an image observed by a scanning electron microscope (SEM). Specifically, the component (A2) was observed with an SEM at an observation magnification of 10,000 times, the thickness of 50 particles in the observed image was measured, and the average thickness per number was calculated. It is obtained by calculating
 また、成分(A2)のアスペクト比は、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、好ましくは3以上、より好ましくは5以上、更に好ましくは10以上、より更に好ましくは30以上、より更に好ましくは50以上、より更に好ましくは55以上であり、また、好ましくは300以下、より好ましくは230以下、更に好ましくは200以下、より更に好ましくは140以下、より更に好ましくは125以下、より更に好ましくは120以下である。そして、成分(A2)のアスペクト比は、好ましくは3以上300以下、より好ましくは3以上230以下、更に好ましくは10以上230以下、より更に好ましくは30以上230以下、より更に好ましくは50以上200以下、より更に好ましくは55以上140以下、より更に好ましくは55以上125以下、より更に好ましくは55以上120以下である。
 成分(A2)のアスペクト比は、前記と同様の条件でSEM観察を行い、観察画像中の50個の粒子において、最も短い軸の長さ(厚さ)及び最も長い軸の長さ(長径)を測定して各々の粒子のアスペクト比(長径/厚さ)を算出し、その平均値より求められる。成分(A2)のアスペクト比は、具体的には実施例に記載の方法で測定できる。
In addition, the aspect ratio of the component (A2) is preferably 3 or more, more preferably 5 or more, still more preferably 10 or more, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin. Still more preferably 30 or more, still more preferably 50 or more, still more preferably 55 or more, preferably 300 or less, more preferably 230 or less, still more preferably 200 or less, still more preferably 140 or less, and more More preferably 125 or less, still more preferably 120 or less. The aspect ratio of component (A2) is preferably 3 or more and 300 or less, more preferably 3 or more and 230 or less, still more preferably 10 or more and 230 or less, still more preferably 30 or more and 230 or less, still more preferably 50 or more and 200 Below, more preferably 55 or more and 140 or less, still more preferably 55 or more and 125 or less, and still more preferably 55 or more and 120 or less.
The aspect ratio of component (A2) was determined by SEM observation under the same conditions as above, and the length of the shortest axis (thickness) and the length of the longest axis (major axis) in 50 particles in the observed image. is measured to calculate the aspect ratio (major diameter/thickness) of each particle, and the average value is obtained. Specifically, the aspect ratio of component (A2) can be measured by the method described in Examples.
 成分(A2)は、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、好ましくは、厚さ30nm以上360nm以下、かつアスペクト比が3以上300以下であり、より好ましくは、厚さ50nm以上330nm以下、かつアスペクト比が3以上230以下であり、更に好ましくは、厚さ60nm以上310nm以下、かつアスペクト比が10以上230以下であり、より更に好ましくは、厚さ75nm以上280nm以下、かつアスペクト比が30以上230以下であり、より更に好ましくは、厚さ90nm以上270nm以下、かつアスペクト比が50以上200以下であり、より更に好ましくは、厚さ100nm以上230nm以下、かつアスペクト比が55以上140以下であり、より更に好ましくは、厚さ100nm以上200nm以下、かつアスペクト比が55以上125以下であり、より更に好ましくは、厚さ100nm以上180nm以下、かつアスペクト比が55以上120以下である。 Component (A2) preferably has a thickness of 30 nm or more and 360 nm or less and an aspect ratio of 3 or more and 300 or less from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin. Preferably, the thickness is 50 nm or more and 330 nm or less, and the aspect ratio is 3 or more and 230 or less, more preferably the thickness is 60 nm or more and 310 nm or less, and the aspect ratio is 10 or more and 230 or less, and still more preferably the thickness 75 nm or more and 280 nm or less, and an aspect ratio of 30 or more and 230 nm or less, more preferably a thickness of 90 nm or more and 270 nm or less, and an aspect ratio of 50 or more and 200 or less, and still more preferably a thickness of 100 nm or more and 230 nm or less. and an aspect ratio of 55 to 140, more preferably a thickness of 100 nm to 200 nm, and an aspect ratio of 55 to 125, still more preferably a thickness of 100 nm to 180 nm, and an aspect ratio is 55 or more and 120 or less.
 皮膚外用剤は、成分(A)として成分(A1)及び成分(A2)のうちいずれか一方を含有していてもよく、成分(A1)及び成分(A2)の両方を含有していてもよい。成分(A)が成分(A1)及び成分(A2)の両方を含有する場合、その質量比は特に制限されず、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、質量比(A1)/(A2)として、好ましくは10/90~90/10、より好ましくは20/80~80/20、更に好ましくは30/70~70/30の範囲である。
 また皮膚外用剤は、成分(A)として2種以上の成分(A1)を含有してもよく、2種以上の成分(A2)を含有することもできる。
The external preparation for skin may contain either component (A1) or component (A2) as component (A), or may contain both component (A1) and component (A2). . When the component (A) contains both the component (A1) and the component (A2), the mass ratio is not particularly limited, from the viewpoint of improving the infrared protection effect and from the viewpoint of suppressing whitening when applied to the skin. Therefore, the mass ratio (A1)/(A2) is preferably 10/90 to 90/10, more preferably 20/80 to 80/20, still more preferably 30/70 to 70/30.
In addition, the external preparation for skin may contain two or more components (A1) as component (A), and may contain two or more components (A2).
 成分(A1)及び成分(A2)における金属酸化物としては、例えば、酸化チタン、酸化亜鉛、酸化ジルコニウム、酸化鉄、酸化アルミニウム、酸化セリウム等が挙げられる。
これらの中でも、紫外線、赤外線等の防御効果の観点、特に赤外線防御効果向上の観点から、好ましくは酸化チタン及び酸化亜鉛からなる群から選ばれる1種以上であり、より好ましくは酸化チタンである。
 酸化チタンの結晶構造は、ルチル型、アナターゼ型、アモルファスのいずれでもよいが、紫外線、赤外線等の防御効果の観点からはルチル型が好ましい。
Examples of metal oxides in components (A1) and (A2) include titanium oxide, zinc oxide, zirconium oxide, iron oxide, aluminum oxide, and cerium oxide.
Among these, one or more selected from the group consisting of titanium oxide and zinc oxide is preferred, and titanium oxide is more preferred, from the viewpoint of the protective effect against ultraviolet rays, infrared rays, etc., particularly from the viewpoint of improving the infrared protective effect.
The crystal structure of titanium oxide may be any of rutile type, anatase type and amorphous type, but the rutile type is preferable from the viewpoint of protection against ultraviolet rays, infrared rays and the like.
 成分(A1)及び成分(A2)は、表面処理されていない金属酸化物でもよく、皮膚外用剤への分散性を高めるために、必要に応じて公知の方法で疎水性処理等の表面処理を行った金属酸化物でもよい。なお、成分(A1)及び成分(A2)は、金属酸化物以外の粒子の表面を金属酸化物で表面処理したものとは区別される。 Component (A1) and component (A2) may be metal oxides that have not been surface-treated, and in order to enhance dispersibility in external skin preparations, surface treatment such as hydrophobic treatment is performed by a known method as necessary. It may be a metal oxide that has been used. The component (A1) and the component (A2) are distinguished from particles other than metal oxide whose surface is treated with a metal oxide.
 金属酸化物の表面処理に用いられる表面処理剤としては、シリコーン;アルキルアルコキシシラン;パーフルオロアルキルリン酸エステル、パーフルオロアルコール等のフッ素含有化合物;N-アシルグルタミン酸等によるアミノ酸;その他、レシチン;金属石鹸;ステアリン酸等の脂肪酸;アルキルリン酸エステル等が挙げられる。これらの中でも、シリコーン及びアルキルアルコキシシランからなる群から選ばれる1種以上が好ましい。
 表面処理剤としてのシリコーンは特に制限されず、例えば、メチルポリシロキサン、ジメチルポリシロキサン、メチルフェニルポリシロキサン、メチルハイドロジェンポリシロキサン〔ハイドロゲンジメチコン〕、メチルシクロポリシロキサン、オクタメチルシクロテトラシロキサン、デカメチルシクロペンタシロキサン、ドデカメチルシクロヘキサシロキサン、オクタメチルトリシロキサン、テトラデカメチルヘキサシロキサン、ジメチルシロキサン・メチル(ポリオキシエチレン)シロキサン・メチル(ポリオキシプロピレン)シロキサン共重合体、ジメチルシロキサン・メチル(ポリオキシエチレン)シロキサン共重合体、ジメチルシロキサン・メチル(ポリオキシプロピレン)シロキサン共重合体、ジメチルシロキサン・メチルセチルオキシシロキサン共重合体、ジメチルシロキサン・メチルステアロキシシロキサン共重合体、(アクリル酸アルキル/ジメチコン)共重合体(ASC)等の各種シリコーン油を挙げることができる。
 表面処理剤としてのアルキルアルコキシシランとしては、炭素数6~20の分岐又は直鎖のアルキル基を有するものが好ましく、特に、オクチルトリエトキシシラン、オクチルトリメトキシシランを挙げることができる。
Examples of surface treatment agents used for surface treatment of metal oxides include silicones; alkylalkoxysilanes; fluorine-containing compounds such as perfluoroalkyl phosphates and perfluoroalcohols; amino acids such as N-acylglutamic acid; Soap; fatty acids such as stearic acid; alkyl phosphates; Among these, at least one selected from the group consisting of silicones and alkylalkoxysilanes is preferred.
Silicone as a surface treatment agent is not particularly limited, and examples include methylpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane [hydrogen dimethicone], methylcyclopolysiloxane, octamethylcyclotetrasiloxane, decamethyl Cyclopentasiloxane, dodecamethylcyclohexasiloxane, octamethyltrisiloxane, tetradecamethylhexasiloxane, dimethylsiloxane-methyl (polyoxyethylene) siloxane-methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane-methyl (polyoxy Ethylene)siloxane copolymer, dimethylsiloxane/methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane/methylcetyloxysiloxane copolymer, dimethylsiloxane/methylstearoxysiloxane copolymer, (alkyl acrylate/dimethicone) Various silicone oils such as copolymers (ASC) can be mentioned.
As the alkylalkoxysilane as the surface treatment agent, those having a branched or linear alkyl group of 6 to 20 carbon atoms are preferred, and octyltriethoxysilane and octyltrimethoxysilane are particularly exemplified.
 皮膚外用剤への成分(A)の分散性を高め、紫外線、赤外線等の防御効果をより向上させる観点からは、金属酸化物の表面処理に用いられる表面処理剤としてはメチルポリシロキサン、ジメチルポリシロキサン、メチルハイドロジェンポリシロキサン、(アクリル酸アルキル/ジメチコン)共重合体、及びオクチルトリエトキシシランからなる群から選ばれる1種以上が好ましい。
 成分(A1)又は成分(A2)が表面処理された金属酸化物である場合、表面処理剤による被覆量は、皮膚外用剤中への分散性を高める観点から、成分(A1)又は成分(A2)の総量に対して、好ましくは1質量%以上9質量%以下、より好ましくは2質量%以上8質量%以下である。
From the viewpoint of enhancing the dispersibility of the component (A) in the external preparation for skin and further improving the protective effect against ultraviolet rays, infrared rays, etc., methylpolysiloxane, dimethylpolysiloxane, At least one selected from the group consisting of siloxane, methylhydrogenpolysiloxane, (alkyl acrylate/dimethicone) copolymer, and octyltriethoxysilane is preferred.
When component (A1) or component (A2) is a surface-treated metal oxide, the amount of coating with the surface treatment agent is adjusted from the viewpoint of increasing the dispersibility in the skin preparation for external use. ), preferably 1% by mass or more and 9% by mass or less, more preferably 2% by mass or more and 8% by mass or less.
 赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点からは、成分(A)は成分(A2)を含むことが好ましい。
 ここで、成分(A2)を構成する金属酸化物は、高屈折率材料である方が高い光干渉効果が得られる。そのため成分(A)は、成分(A2)として板状酸化チタン及び板状酸化亜鉛からなる群から選ばれる1種以上を含むことがより好ましく、板状酸化チタンを含むことが更に好ましい。
 成分(A)が成分(A2)を含む場合、成分(A)中の成分(A2)の含有量は、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、好ましくは50質量%以上、より好ましくは60質量%以上、更に好ましくは70質量%以上、より更に好ましくは80質量%以上、より更に好ましくは90質量%以上であり、100質量%以下である。
Component (A) preferably contains component (A2) from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin.
Here, when the metal oxide constituting the component (A2) is a material with a high refractive index, a higher optical interference effect can be obtained. Therefore, component (A) more preferably contains at least one selected from the group consisting of plate-like titanium oxide and plate-like zinc oxide as component (A2), and more preferably contains plate-like titanium oxide.
When the component (A) contains the component (A2), the content of the component (A2) in the component (A) is, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin, It is preferably 50% by mass or more, more preferably 60% by mass or more, still more preferably 70% by mass or more, still more preferably 80% by mass or more, still more preferably 90% by mass or more and 100% by mass or less.
 皮膚外用剤中の成分(A)の含有量は、紫外線、赤外線等の防御効果向上の観点から、2質量%以上であり、好ましくは3質量%以上、より好ましくは5質量%以上である。また、皮膚に塗布した際の白浮き抑制の観点から、50質量%以下である。
 また、赤外線防御効果向上の観点、及び、皮膚に塗布した際の白浮き抑制の観点から、皮膚外用剤中の成分(A)の含有量は、更に好ましくは下記の範囲である。
 成分(A)が平均粒径350nm以上800nm未満の球状酸化チタンである場合、皮膚外用剤中の該球状酸化チタンの含有量は、更に好ましくは5質量%以上30質量%以下、より更に好ましくは5質量%以上25質量%以下である。
 成分(A)が平均粒径800nm以上2,500nm以下の球状酸化チタンである場合、皮膚外用剤中の該球状酸化チタンの含有量は、更に好ましくは5質量%以上40質量%以下、より更に好ましくは5質量%以上30質量%以下である。
 成分(A)が板状酸化チタンである場合、皮膚外用剤中の該板状酸化チタンの含有量は、更に好ましくは5質量%以上30質量%以下である。
 成分(A)が平均粒径350nm以上2,500nm以下の球状酸化亜鉛、又は板状酸化亜鉛である場合、皮膚外用剤中の該球状酸化亜鉛又は板状酸化亜鉛の含有量は、更に好ましくは7質量%以上50質量%以下、より更に好ましくは10質量%以上50質量%以下である。
The content of component (A) in the external preparation for skin is 2% by mass or more, preferably 3% by mass or more, more preferably 5% by mass or more, from the viewpoint of improving the protective effect against ultraviolet rays, infrared rays, and the like. In addition, from the viewpoint of suppression of whitening when applied to the skin, the content is 50% by mass or less.
In addition, from the viewpoint of improving the infrared protection effect and suppressing whitening when applied to the skin, the content of component (A) in the external preparation for skin is more preferably within the following range.
When the component (A) is spherical titanium oxide having an average particle diameter of 350 nm or more and less than 800 nm, the content of the spherical titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 30% by mass or less, still more preferably It is 5 mass % or more and 25 mass % or less.
When the component (A) is spherical titanium oxide having an average particle diameter of 800 nm or more and 2,500 nm or less, the content of the spherical titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 40% by mass or less. It is preferably 5% by mass or more and 30% by mass or less.
When the component (A) is plate-like titanium oxide, the content of the plate-like titanium oxide in the external preparation for skin is more preferably 5% by mass or more and 30% by mass or less.
When component (A) is spherical zinc oxide or plate-like zinc oxide having an average particle size of 350 nm or more and 2,500 nm or less, the content of said spherical zinc oxide or plate-like zinc oxide in the external preparation for skin is more preferably 7 mass % or more and 50 mass % or less, more preferably 10 mass % or more and 50 mass % or less.
 また、皮膚外用剤の不揮発性成分中の成分(A)の含有量は、紫外線、赤外線等の防御効果向上の観点から、好ましくは3質量%以上、より好ましくは5質量%以上、更に好ましくは10質量%以上である。また、皮膚に塗布した際の白浮き抑制の観点から、好ましくは50質量%以下、より好ましくは40質量%以下、更に好ましくは30質量%以下、より更に好ましくは20質量%以下である。そして、皮膚外用剤の不揮発性成分中の成分(A)の含有量は、好ましくは3質量%以上50質量%以下、より好ましくは5質量%以上40質量%以下、更に好ましくは10質量%以上30質量%以下、より更に好ましくは10質量%以上20質量%以下である。
 ここでいう「皮膚外用剤中の不揮発性成分」とは、皮膚外用剤の全量から水、後述する水性媒体、及び揮発性油(成分(B)以外の油剤)を除いた成分を意味する。
In addition, the content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more, more preferably 5% by mass or more, still more preferably 5% by mass or more, from the viewpoint of improving the protective effect against ultraviolet rays, infrared rays, and the like. It is 10% by mass or more. From the viewpoint of suppressing whitening when applied to the skin, the content is preferably 50% by mass or less, more preferably 40% by mass or less, even more preferably 30% by mass or less, and even more preferably 20% by mass or less. The content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more and 50% by mass or less, more preferably 5% by mass or more and 40% by mass or less, and still more preferably 10% by mass or more. It is 30% by mass or less, more preferably 10% by mass or more and 20% by mass or less.
The term "non-volatile component in the external skin preparation" as used herein means a component obtained by excluding water, an aqueous medium described later, and a volatile oil (an oil other than component (B)) from the total amount of the external skin preparation.
 皮膚外用剤中の成分(A)の含有量(質量%)に対する前記皮膚外用剤の粘度(mPa・s)は、成分(A)の含有量に応じた粘度とすることにより均一塗布性を高め、成分(A)を皮膚表面に均一に配置させる観点から、[皮膚外用剤の粘度(mPa・s)/皮膚外用剤中の成分(A)の含有量(質量%)]として、好ましくは100以上、より好ましくは250以上、更に好ましくは300以上、より更に好ましくは350以上であり、また、好ましくは25,000以下、より好ましくは20,000以下、更に好ましくは15,000以下、より更に好ましくは10,000以下、より更に好ましくは5,000以下、より更に好ましくは3,000以下である。そして、[皮膚外用剤の粘度(mPa・s)/皮膚外用剤中の成分(A)の含有量(質量%)]は、好ましくは100以上25,000以下、より好ましくは250以上20,000以下、更に好ましくは300以上15,000以下、より更に好ましくは350以上10,000以下、より更に好ましくは350以上5,000以下、より更に好ましくは350以上3,000以下である。 The viscosity (mPa s) of the topical skin preparation relative to the content (% by mass) of component (A) in the topical skin preparation is adjusted according to the content of component (A) to improve uniform applicability. , From the viewpoint of uniformly disposing the component (A) on the skin surface, the [viscosity of the external preparation for skin (mPa s) / content of component (A) in the external preparation for skin (% by mass)] is preferably 100. above, more preferably 250 or more, still more preferably 300 or more, still more preferably 350 or more, preferably 25,000 or less, more preferably 20,000 or less, still more preferably 15,000 or less, still more It is preferably 10,000 or less, more preferably 5,000 or less, and even more preferably 3,000 or less. The [viscosity of the external skin preparation (mPa·s)/content of component (A) in the external skin preparation (% by mass)] is preferably 100 or more and 25,000 or less, more preferably 250 or more and 20,000. 300 or more and 15,000 or less, still more preferably 350 or more and 10,000 or less, still more preferably 350 or more and 5,000 or less, still more preferably 350 or more and 3,000 or less.
 成分(A)として、市販の金属酸化物を用いることもできる。
 例えば、成分(A1)として用いられる市販の球状酸化チタンとしては、チタン工業(株)製「ST-750EC」、堺化学工業(株)製「R-38L」等が挙げられ、市販の球状酸化亜鉛としては、堺化学工業(株)製「LP-ZINC-2KS」等が挙げられる。
 成分(A2)として用いられる市販の板状酸化チタンとしては、CQV社製「Featheleve PT-9001K」、「Featheleve PT-7001K」、「Featheleve PT-7401K」、「Featheleve PT-7801K」、「Featheleve PT-7901K」、及びこれらの表面被覆処理品等が挙げられ、市販の板状酸化亜鉛としては、堺化学工業(株)製「XZ-1000F-LP」等が挙げられる。
A commercially available metal oxide can also be used as component (A).
For example, commercially available spherical titanium oxide used as the component (A1) includes "ST-750EC" manufactured by Titan Kogyo Co., Ltd., "R-38L" manufactured by Sakai Chemical Industry Co., Ltd., and the like. Zinc includes "LP-ZINC-2KS" manufactured by Sakai Chemical Industry Co., Ltd., and the like.
Commercially available plate-like titanium oxide used as component (A2) includes "Featheleve PT-9001K", "Featheleve PT-7001K", "Featheleve PT-7401K", "Featheleve PT-7801K" and "Featheleve PT" manufactured by CQV. -7901K", surface-coated products thereof, and the like, and commercially available plate-like zinc oxide includes "XZ-1000F-LP" manufactured by Sakai Chemical Industry Co., Ltd., and the like.
<成分(B):不揮発性油>
 本発明の皮膚外用剤は、所望の粘度に調整しやすく、均一塗布性を高めることにより紫外線、赤外線等の防御効果を高める観点から、成分(B)として不揮発性油を含有する。不揮発性油とは、以下の方法(1)により測定される、25℃、6時間での蒸発量が20%未満のものをいう。
 方法(1):直径120mmのガラス製シャーレの中に、直径90mmの濾紙を入れ、濾紙にサンプルを1gのせて、65%RHの室内(25℃)に保存する。そして6時間後のサンプルの残留物を測定し、蒸発量を算出する。
<Component (B): non-volatile oil>
The external preparation for skin of the present invention contains a non-volatile oil as component (B) from the viewpoints of easily adjusting the viscosity to a desired level and improving the protective effect against ultraviolet rays, infrared rays, etc. by improving uniform application properties. A non-volatile oil refers to an oil having an evaporation rate of less than 20% at 25° C. for 6 hours, as measured by the following method (1).
Method (1): Place a filter paper with a diameter of 90 mm in a glass petri dish with a diameter of 120 mm. After 6 hours, the residue of the sample is measured and the amount of evaporation is calculated.
 また、成分(B)は1気圧下、25℃において液状であることが好ましい。より具体的には、成分(B)は、25℃における粘度が好ましくは500mPa・s以下であり、より好ましくは300mPa・s以下であり、更に好ましくは100mPa・s以下であり、より更に好ましくは50mPa・s以下であり、好ましくは5mPa・s以上である。
 当該粘度は、B型粘度計「TVB-10」(東機産業(株)製)を用いて、ローターNo.1、25℃、60rpm、1分間の条件で測定できる。
In addition, component (B) is preferably liquid at 25° C. under 1 atm. More specifically, component (B) has a viscosity at 25° C. of preferably 500 mPa·s or less, more preferably 300 mPa·s or less, even more preferably 100 mPa·s or less, and still more preferably It is 50 mPa·s or less, preferably 5 mPa·s or more.
The viscosity was measured using a Brookfield viscometer "TVB-10" (manufactured by Toki Sangyo Co., Ltd.). 1. It can be measured under the conditions of 25° C., 60 rpm, and 1 minute.
 成分(B)の具体例としては、25℃で液状である不揮発性油であり、例えばエステル油、シリコーン油、炭化水素油、高級脂肪酸、及び高級アルコールからなる群から選ばれる1種以上が挙げられる。 Specific examples of component (B) include non-volatile oils that are liquid at 25°C, such as one or more selected from the group consisting of ester oils, silicone oils, hydrocarbon oils, higher fatty acids, and higher alcohols. be done.
 不揮発性の液状のエステル油としては、例えば、炭素数8以上18以下の脂肪酸と炭素数2以上22以下の分岐アルコールとのモノエステル、炭素数6以上18以下の分岐脂肪酸とグリセリンとのトリエステル、炭素数2以上18以下のジカルボン酸と炭素数2以上18以下の分岐アルコールとのジエステル、炭素数6以上18以下の脂肪酸と炭素数2以上10以下のジアルコールとのジエステル、及び安息香酸アルキルからなる群から選ばれる1種以上が挙げられる。
 炭素数8以上18以下の脂肪酸と炭素数2以上22以下の分岐アルコールとのモノエステルとしては、イソノナン酸イソノニル、イソノナン酸イソトリデシル、ミリスチン酸イソプロピル、ミリスチン酸イソセチル、ミリスチン酸オクチルドデシル、パルミチン酸イソプロピル、パルミチン酸エチルヘキシル、パルミチン酸2-ヘキシルデシル等が挙げられる。
 炭素数6以上18以下の脂肪酸とグリセリンとのトリエステルとしては、トリ2-エチルヘキサン酸グリセリル、トリ(カプリル酸/カプリン酸)グリセリル等が挙げられる。
 炭素数2以上18以下のジカルボン酸と炭素数2以上18以下の分岐アルコールとのジエステルとしては、セバシン酸ジ2-エチルヘキシル、セバシン酸ジイソプロピル、リンゴ酸ジイソステアリル等が挙げられる。
 炭素数6以上18以下の脂肪酸と炭素数2以上10以下のジアルコールとのジエステルとしては、ジカプリン酸ジエチレングリコール、ジカプリン酸ネオペンチルグリコール、ジ2-エチルヘキサン酸ネオペンチルグリコール等が挙げられる。
 また安息香酸アルキルとしては、安息香酸アルキル(C12~C15)(例えば、フィンソルブTN;Innospec Active Chemicals LLC製)等が挙げられる。
Examples of non-volatile liquid ester oils include monoesters of fatty acids having 8 to 18 carbon atoms and branched alcohols having 2 to 22 carbon atoms, and triesters of branched fatty acids having 6 to 18 carbon atoms and glycerin. , a diester of a dicarboxylic acid having 2 to 18 carbon atoms and a branched alcohol having 2 to 18 carbon atoms, a diester of a fatty acid having 6 to 18 carbon atoms and a dialcohol having 2 to 10 carbon atoms, and an alkyl benzoate One or more selected from the group consisting of
Monoesters of fatty acids having 8 to 18 carbon atoms and branched alcohols having 2 to 22 carbon atoms include isononyl isononanoate, isotridecyl isononanoate, isopropyl myristate, isocetyl myristate, octyldodecyl myristate, isopropyl palmitate, Examples include ethylhexyl palmitate and 2-hexyldecyl palmitate.
Examples of triesters of fatty acids having 6 to 18 carbon atoms and glycerin include glyceryl tri-2-ethylhexanoate and glyceryl tri(caprylate/caprate).
Examples of diesters of dicarboxylic acids having 2 to 18 carbon atoms and branched alcohols having 2 to 18 carbon atoms include di-2-ethylhexyl sebacate, diisopropyl sebacate and diisostearyl malate.
Examples of diesters of fatty acids having 6 to 18 carbon atoms and dialcohols having 2 to 10 carbon atoms include diethylene glycol dicaprate, neopentyl glycol dicaprate, and neopentyl glycol di-2-ethylhexanoate.
Examples of the alkyl benzoate include alkyl benzoate (C12 to C15) (eg Finsolv TN; manufactured by Innospec Active Chemicals LLC).
 成分(B)として用いられるエステル油の中でも、粘度調整の容易性の観点、後述する増粘剤等の溶解性向上の観点、及び、皮膚に塗布した際のべたつき抑制の観点から、炭素数12以上18以下の脂肪酸と炭素数2以上22以下の分岐アルコールとのモノエステル、炭素数6以上18以下の分岐脂肪酸とグリセリンとのトリエステル、炭素数2以上18以下のジカルボン酸と炭素数2以上18以下の分岐アルコールとのジエステル、炭素数6以上18以下の脂肪酸と炭素数2以上10以下の分岐ジアルコールとのジエステル、及び安息香酸アルキル(C12~C15)からなる群から選ばれる1種以上が好ましく、ミリスチン酸イソプロピル、ミリスチン酸イソセチル、ミリスチン酸オクチルドデシル、パルミチン酸イソプロピル、パルミチン酸エチルヘキシル、パルミチン酸2-ヘキシルデシル、トリ2-エチルヘキサン酸グリセリル、セバシン酸ジイソプロピル、セバシン酸ジ2-エチルヘキシル、リンゴ酸ジイソステアリル、ジ2-エチルヘキサン酸ネオペンチルグリコール、ジカプリン酸ネオペンチルグリコール、及び安息香酸アルキル(C12~C15)からなる群から選ばれる1種以上がより好ましく、パルミチン酸イソプロピルが更に好ましい。 Among the ester oils used as component (B), from the viewpoint of ease of viscosity adjustment, the viewpoint of improving the solubility of thickeners and the like described later, and the viewpoint of suppressing stickiness when applied to the skin, C 12 Monoesters of fatty acids having 18 or more and branched alcohols having 2 to 22 carbon atoms, triesters of branched fatty acids having 6 to 18 carbon atoms and glycerin, dicarboxylic acids having 2 to 18 carbon atoms and 2 or more carbon atoms One or more selected from the group consisting of diesters with branched alcohols of 18 or less, diesters of fatty acids with 6 to 18 carbon atoms and branched dialcohols with 2 to 10 carbon atoms, and alkyl benzoates (C12 to C15) isopropyl myristate, isocetyl myristate, octyldodecyl myristate, isopropyl palmitate, ethylhexyl palmitate, 2-hexyldecyl palmitate, glyceryl tri-2-ethylhexanoate, diisopropyl sebacate, di-2-ethylhexyl sebacate, One or more selected from the group consisting of diisostearyl malate, neopentyl glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, and alkyl benzoate (C12-C15) is more preferred, and isopropyl palmitate is even more preferred. .
 不揮発性の液状のシリコーン油としては、メチルポリシロキサンが好ましく、25℃における粘度が20mPa・s以下のメチルポリシロキサンがより好ましい。 As the nonvolatile liquid silicone oil, methylpolysiloxane is preferable, and methylpolysiloxane having a viscosity of 20 mPa·s or less at 25°C is more preferable.
 不揮発性の液状の炭化水素油としては、流動パラフィン、水添ポリイソブテン等の軽質流動イソパラフィン、重質流動イソパラフィン、流動オゾケライト、スクワラン、プリスタン、スクワレン、イソヘキサデカン等が挙げられる。 Non-volatile liquid hydrocarbon oils include liquid paraffin, light liquid isoparaffins such as hydrogenated polyisobutene, heavy liquid isoparaffins, liquid ozokerite, squalane, pristane, squalene, and isohexadecane.
 不揮発性の液状の高級脂肪酸としては、炭素数12以上22以下の脂肪酸が挙げられ、具体的には、オレイン酸、イソステアリン酸、リノール酸、リノレン酸等が挙げられる。
 不揮発性の液状の高級アルコールとしては、例えば、炭素数12以上28以下のアルコールが挙げられ、具体的には、オレイルアルコール、2-デシルテトラデシノール、ドデカノール、イソステアリルアルコール、オクチルドデカノール等が挙げられる。
Non-volatile liquid higher fatty acids include fatty acids having 12 to 22 carbon atoms, and specific examples include oleic acid, isostearic acid, linoleic acid, and linolenic acid.
Nonvolatile liquid higher alcohols include, for example, alcohols having 12 to 28 carbon atoms, and specific examples include oleyl alcohol, 2-decyltetradecinol, dodecanol, isostearyl alcohol, octyldodecanol, and the like. mentioned.
 成分(B)は、25℃で液状である不揮発性油のうち、粘度調整の容易性の観点、後述する増粘剤等の溶解性向上の観点、及び、皮膚に塗布した際のべたつき抑制の観点から、好ましくはエステル油、シリコーン油及び炭化水素油からなる群から選ばれる1種以上であり、より好ましくはエステル油及びシリコーン油からなる群から選ばれる1種以上であり、更に好ましくはエステル油及びシリコーン油である。 Component (B) is a non-volatile oil that is liquid at 25 ° C., from the viewpoint of ease of viscosity adjustment, from the viewpoint of improving the solubility of thickeners described later, and from the viewpoint of suppressing stickiness when applied to the skin. From the viewpoint, it is preferably one or more selected from the group consisting of ester oil, silicone oil and hydrocarbon oil, more preferably one or more selected from the group consisting of ester oil and silicone oil, and still more preferably ester oils and silicone oils.
 本発明の皮膚外用剤中の成分(B)の含有量は、所望の粘度に調整しやすく、均一塗布性を高めることにより紫外線、赤外線等の防御効果を高める観点から、好ましくは1質量%以上、より好ましくは5質量%以上である。また、皮膚に塗布した際のべたつき抑制の観点から、好ましくは90質量%以下、より好ましくは80質量%以下、更に好ましくは70質量%以下、より更に好ましくは65質量%以下である。
 なお、本発明の皮膚外用剤が油中水型乳化組成物である場合、皮膚外用剤中の成分(B)の含有量は、油中水型とする観点から、更に好ましくは15質量%以上、より更に好ましくは20質量%以上、より更に好ましくは25質量%以上、より更に好ましくは30質量%以上、より更に好ましくは35質量%以上である。
 本発明の皮膚外用剤が水中油型乳化組成物である場合は、皮膚外用剤中の成分(B)の含有量は、水中油型とする観点から、より更に好ましくは30質量%以下、より更に好ましくは20質量%以下、より更に好ましくは10質量%以下である。
The content of the component (B) in the external preparation for skin of the present invention is preferably 1% by mass or more from the viewpoint of easy adjustment to a desired viscosity and enhancement of the protective effect against ultraviolet rays, infrared rays, etc. by enhancing uniform application properties. , more preferably 5% by mass or more. In addition, from the viewpoint of suppressing stickiness when applied to the skin, it is preferably 90% by mass or less, more preferably 80% by mass or less, even more preferably 70% by mass or less, and even more preferably 65% by mass or less.
When the external preparation for skin of the present invention is a water-in-oil emulsified composition, the content of component (B) in the external preparation for skin is more preferably 15% by mass or more from the viewpoint of water-in-oil type. , Still more preferably 20% by mass or more, still more preferably 25% by mass or more, still more preferably 30% by mass or more, and even more preferably 35% by mass or more.
When the external preparation for skin of the present invention is an oil-in-water emulsified composition, the content of component (B) in the external preparation for skin is more preferably 30% by mass or less from the viewpoint of making it oil-in-water. More preferably 20 mass % or less, still more preferably 10 mass % or less.
 本発明の皮膚外用剤において、成分(A)の含有量に対する成分(B)の含有量の質量比[(B)/(A)]は、均一塗布性を高めることにより紫外線、赤外線等の防御効果を高める観点、及び使用感向上の観点から、好ましくは0.05以上、より好ましくは0.1以上、更に好ましくは0.2以上、より更に好ましくは0.5以上、より更に好ましくは1以上、より更に好ましくは2以上、より更に好ましくは3以上、より更に好ましくは3.6以上であり、皮膚に塗布した際のべたつき抑制の観点から、好ましくは60以下、より好ましくは50以下、更に好ましくは30以下、より更に好ましくは20以下、より更に好ましくは10以下、より更に好ましくは8以下である。そして、質量比[(B)/(A)]は、好ましくは0.05以上60以下、より好ましくは0.1以上50以下、更に好ましくは0.2以上30以下、より更に好ましくは0.5以上20以下、より更に好ましくは1以上10以下、より更に好ましくは2以上10以下、より更に好ましくは3以上10以下、より更に好ましくは3.6以上8以下である。 In the external preparation for skin of the present invention, the mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] increases the uniformity of application, thereby protecting against ultraviolet rays, infrared rays, etc. From the viewpoint of enhancing the effect and improving the feeling of use, it is preferably 0.05 or more, more preferably 0.1 or more, still more preferably 0.2 or more, even more preferably 0.5 or more, and even more preferably 1 above, more preferably 2 or more, still more preferably 3 or more, still more preferably 3.6 or more, and from the viewpoint of suppressing stickiness when applied to the skin, preferably 60 or less, more preferably 50 or less, More preferably 30 or less, still more preferably 20 or less, still more preferably 10 or less, and even more preferably 8 or less. The mass ratio [(B)/(A)] is preferably 0.05 or more and 60 or less, more preferably 0.1 or more and 50 or less, still more preferably 0.2 or more and 30 or less, and even more preferably 0.2 or more. 5 or more and 20 or less, more preferably 1 or more and 10 or less, still more preferably 2 or more and 10 or less, still more preferably 3 or more and 10 or less, and even more preferably 3.6 or more and 8 or less.
 また紫外線、赤外線等の防御効果の観点、及び、皮膚に塗布した際の白浮きを抑制する観点から、皮膚外用剤中の成分(A)及び成分(B)の合計含有量は、好ましくは2質量%以上、より好ましくは10質量%以上、更に好ましくは20質量%以上、より更に好ましくは30質量%以上、より更に好ましくは40質量%以上、より更に好ましくは45質量%以上、より更に好ましくは47質量%以上、より更に好ましくは50質量%以上であり、また、100質量%以下である。 In addition, from the viewpoint of the protective effect against ultraviolet rays, infrared rays, etc., and from the viewpoint of suppressing whitening when applied to the skin, the total content of the component (A) and the component (B) in the external preparation for skin is preferably 2. % by mass or more, more preferably 10% by mass or more, still more preferably 20% by mass or more, even more preferably 30% by mass or more, even more preferably 40% by mass or more, still more preferably 45% by mass or more, and even more preferably is 47% by mass or more, more preferably 50% by mass or more, and 100% by mass or less.
<増粘剤>
 本発明の皮膚外用剤は、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、さらに増粘剤を含有することが好ましい。本発明において「増粘剤」とは、皮膚外用剤を増粘させる作用を有する添加剤を意味する。
 増粘剤としては、油増粘剤、水溶性増粘剤等が挙げられ、皮膚外用剤の剤型等に応じて適宜選択することができる。例えば、皮膚外用剤が油中水型乳化組成物である場合には、処方の変更なしに容易に増粘できる観点で、油増粘剤(油ゲル化剤)が好ましい。
 油増粘剤としては、通常の皮膚外用剤に用いられるものが挙げられ、例えば、固形ワックス、有機変性粘土鉱物、ヒュームドシリカ、コロイダルシリカ、デキストリン脂肪酸エステル、金属石鹸、ショ糖脂肪酸エステル、アミノ酸系ゲル化剤等が挙げられる。これらのうち、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、好ましくは固形のワックス、有機変性粘土鉱物、デキストリン脂肪酸エステル、及びアミノ酸系ゲル化剤からなる群から選ばれる1種以上であり、より好ましくは固形のワックス、有機変性粘土鉱物、及びデキストリン脂肪酸エステルらなる群から選ばれる1種以上である。
<Thickener>
The external preparation for skin of the present invention preferably further contains a thickening agent from the viewpoints of facilitating viscosity adjustment, improving uniform applicability, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. In the present invention, the "thickener" means an additive that acts to thicken the external preparation for skin.
Examples of thickeners include oil thickeners, water-soluble thickeners, and the like, which can be appropriately selected according to the dosage form of the external preparation for skin. For example, when the external preparation for skin is a water-in-oil emulsified composition, an oil thickener (oil gelling agent) is preferable from the viewpoint of easy thickening without changing the formulation.
Examples of oil thickeners include those used in ordinary external skin preparations, such as solid waxes, organically modified clay minerals, fumed silica, colloidal silica, dextrin fatty acid esters, metallic soaps, sucrose fatty acid esters, amino acids. system gelling agents and the like. Among these, solid waxes, organically modified clay minerals, dextrin fatty acid esters, and amino acid-based waxes are preferred from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. It is one or more selected from the group consisting of gelling agents, and more preferably one or more selected from the group consisting of solid waxes, organically modified clay minerals, and dextrin fatty acid esters.
 固形のワックスとしては、融点61℃以上のワックスが挙げられる。融点61℃以上のワックスは、25℃において固体の性状を示す。
 本発明において、融点は、医薬部外品原料規格、一般試験法の第1法、第2法、又は第3法のいずれかにより、測定されるものである。いずれの方法を採用するかは、各成分について、医薬部外品原料規格において測定法の記載がある場合には、それに従う。記載がない場合には、融点を考慮して測定法を選択する。具体的には、融点が80℃を大きく超えるような高い場合には第1法、これより融点が低い固体脂には第2法、カタログ等でペースト油と呼ばれるものには第3法を用いるのが一般的であるが、測定できる方法であればいずれの方法であってもよい。
Solid waxes include waxes having a melting point of 61° C. or higher. Waxes with a melting point of 61°C or higher exhibit solid properties at 25°C.
In the present invention, the melting point is measured according to the Standards for Quasi-drug Ingredients, Method 1, Method 2, or Method 3 of general test methods. As for which method to use, if there is a measurement method described in the standards for quasi-drug raw materials for each component, follow that method. If there is no description, select the measurement method in consideration of the melting point. Specifically, Method 1 is used when the melting point is much higher than 80°C, Method 2 is used for solid fats with a lower melting point, and Method 3 is used for what is called paste oil in catalogs. However, any method may be used as long as it can be measured.
 融点61℃以上のワックスとしては、通常の皮膚外用剤に用いられるものであれば特に制限されず、例えば、オゾケライト、セレシン等の鉱物系ワックス;パラフィン、マイクロクリスタリンワックス等の石油系ワックス;フィッシャー・トロプシュワックス、ポリエチレンワックス、合成炭化水素ワックス等の合成炭化水素;カルナウバロウ、キャンデリラロウ、ライスワックス、サンフラワーワックス等の植物系ワックス;ミツロウ、鯨ロウ等の動物性ワックス;シリコーンワックス、合成ミツロウ等の合成ワックス;等が挙げられる。
 これらのうち、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、石油系ワックス及びシリコーンワックスからなる群から選ばれる1種以上が好ましい。
 また、これらのワックスは、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、融点65℃以上、140℃以下が好ましく、70℃以上、110℃以下がより好ましい。
Waxes having a melting point of 61° C. or higher are not particularly limited as long as they are used in ordinary external skin preparations. Examples include mineral waxes such as ozokerite and ceresin; petroleum waxes such as paraffin and microcrystalline wax; Synthetic hydrocarbons such as tropsch wax, polyethylene wax, synthetic hydrocarbon wax; vegetable waxes such as carnauba wax, candelilla wax, rice wax, sunflower wax; animal waxes such as beeswax and whale wax; silicone wax, synthetic beeswax, etc. synthetic wax; and the like.
Among these, one or more selected from the group consisting of petroleum waxes and silicone waxes is preferable from the viewpoint of facilitating viscosity adjustment, improving uniform coating properties, and improving the protective effect against ultraviolet rays, infrared rays, and the like.
These waxes preferably have a melting point of 65° C. or higher and 140° C. or lower, 70° C. or higher, and 70° C. or higher, from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. 110° C. or less is more preferable.
 有機変性粘土鉱物としては、通常の皮膚外用剤に用いられるものであれば特に制限されず、例えば、ベントナイト、ラポナイト、ヘクトライト、モンモリロナイト、ケイ酸アルミニウムマグネシウム等の層状粘土鉱物を、第四級アンモニウム塩型カチオン界面活性剤で処理して得られるカチオン変性粘土鉱物が挙げられる。
 具体的には、ベンジルジメチルステアリルアンモニウムクロリド、及びジメチルジステアリルアンモニウムクロリドからなる群から選ばれる1種以上が好ましく、ジメチルジステアリルアンモニウムクロリドがより好ましい。
 有機変性粘土鉱物の市販品としては、エレメンティスジャパン社製「ベントン38」、「ベントン38VCG」、「ベントン27」等が挙げられる。
The organically modified clay mineral is not particularly limited as long as it is used in usual external preparations for skin. Cation-modified clay minerals obtained by treatment with salt-type cationic surfactants can be mentioned.
Specifically, one or more selected from the group consisting of benzyldimethylstearylammonium chloride and dimethyldistearylammonium chloride is preferable, and dimethyldistearylammonium chloride is more preferable.
Commercially available organic modified clay minerals include "Bentone 38", "Bentone 38VCG" and "Bentone 27" manufactured by Elementis Japan.
 有機変性粘土鉱物は、作業性向上及び増粘効果向上の観点から、溶媒によって希釈されたプレミックスゲルとして用いることもできる。
 具体的には、有機変性粘土鉱物を予め溶媒に分散させたプレミックスゲルが好ましい。該溶媒としては、有機変性粘土鉱物によってゲル化可能であれば制限されず、増粘効果向上の観点から、オクチルドデカノール、ミネラルオイル等が好ましい。また、有機変性粘土鉱物を効率よく分散させる点から、炭酸プロピレン、エタノール、水、各種界面活性剤等の極性添加剤をさらに含有させることが好ましい。
 プレミックスゲル中の有機変性粘土鉱物の含有量は、作業性向上及び増粘効果向上の観点、並びにプレミックスゲル自体の油分離を抑制する点から、好ましくは5質量%以上、より好ましくは8質量%以上、更に好ましくは10質量%以上であり、好ましくは25質量%以下、より好ましくは20質量%以下、更に好ましくは18質量%以下である。
 プレミックスゲルの市販品としては、エレメンティスジャパン社製「ベントンゲルEUGV」、「ベントンゲルMIOV」、「ベントンゲルVS-5 PCV」、「ベントンゲルPTM V」、「ベントンゲル GTCC V」等が挙げられる。
The organically modified clay mineral can also be used as a premixed gel diluted with a solvent from the viewpoint of improving workability and thickening effect.
Specifically, a premixed gel in which an organically modified clay mineral is previously dispersed in a solvent is preferred. The solvent is not limited as long as it can be gelled by an organically modified clay mineral, and octyldodecanol, mineral oil, and the like are preferable from the viewpoint of improving the thickening effect. Moreover, from the viewpoint of efficiently dispersing the organically modified clay mineral, it is preferable to further contain a polar additive such as propylene carbonate, ethanol, water, and various surfactants.
The content of the organically modified clay mineral in the premix gel is preferably 5% by mass or more, more preferably 8% by mass, from the viewpoint of improving workability and thickening effect, and suppressing oil separation of the premix gel itself. % by mass or more, more preferably 10% by mass or more, preferably 25% by mass or less, more preferably 20% by mass or less, and even more preferably 18% by mass or less.
Commercially available premixed gels include "Bentongel EUGV", "Bentongel MIOV", "Bentongel VS-5 PCV", "Bentongel PTM V", and "Bentongel GTCC V" manufactured by Elementis Japan.
 デキストリン脂肪酸エステルとしては、通常の皮膚外用剤に用いられるものであれば特に制限されず、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、炭素数8以上24以下の脂肪酸とデキストリンのエステルが好ましく、炭素数14以上20以下の脂肪酸とデキストリンのエステルがより好ましい。また、デキストリンの平均重合度が3以上150以下であるものが好ましい。
 具体的には、パルミチン酸デキストリン、ステアリン酸デキストリン、パルミチン酸・ステアリン酸デキストリン、オレイン酸デキストリン、イソパルミチン酸デキストリン、イソステアリン酸デキストリン、ミリスチン酸デキストリン、パルミチン酸・2-エチルヘキサン酸デキストリン等が挙げられる。
 これらのうち、粘度調整を容易にする観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、パルミチン酸デキストリン、ミリスチン酸デキストリン、パルミチン酸・2-エチルヘキサン酸デキストリンが好ましく、少なくともパルミチン酸デキストリンを含むものがより好ましい。
 デキストリン脂肪酸エステルの市販品としては、千葉製粉(株)製のパルミチン酸デキストリン(「レオパール KL2」、「レオパール KS2」、「レオパール TL2」)、パルミチン酸・2-エチルヘキサン酸デキストリン「レオパール TT2」、ミリスチン酸デキストリン「レオパール MKL2」等が挙げられる。
The dextrin fatty acid ester is not particularly limited as long as it is used in ordinary skin preparations for external use. An ester of a fatty acid having 8 to 24 carbon atoms and dextrin is preferable, and an ester of a fatty acid having 14 to 20 carbon atoms and dextrin is more preferable. In addition, the dextrin preferably has an average degree of polymerization of 3 or more and 150 or less.
Specific examples include dextrin palmitate, dextrin stearate, dextrin palmitate/stearate, dextrin oleate, dextrin isopalmitate, dextrin isostearate, dextrin myristate, dextrin palmitate/2-ethylhexanoate, and the like. .
Among these, dextrin palmitate, dextrin myristate, and dextrin palmitate/2-ethylhexanoate are used from the viewpoints of facilitating viscosity adjustment, improving uniform coating properties, and enhancing the protective effect against ultraviolet rays, infrared rays, and the like. Preferred are those containing at least dextrin palmitate.
Commercially available dextrin fatty acid esters include dextrin palmitate manufactured by Chiba Flour Mills Co., Ltd. (“Leopal KL2”, “Leopal KS2”, “Leopal TL2”), dextrin palmitate/2-ethylhexanoate “Leopal TT2”, Dextrin myristate "Rheopearl MKL2" and the like can be mentioned.
 アミノ酸系ゲル化剤としては、通常の皮膚外用剤に用いられるものであれば特に制限されずに用いることができる。具体的には、ジブチルラウロイルグルタミド、ジブチルエチルヘキサノイルグルタミドが好ましい。
 アミノ酸系ゲル化剤の市販品としては、味の素(株)製のジブチルラウロイルグルタミド「GP-1」、ジブチルエチルヘキサノイルグルタミド「EB-21」等が挙げられる。
As the amino acid-based gelling agent, any amino acid-based gelling agent can be used without particular limitation as long as it is used in usual external preparations for skin. Specifically, dibutyl lauroyl glutamide and dibutylethylhexanoyl glutamide are preferred.
Commercially available amino acid-based gelling agents include dibutyl lauroyl glutamide "GP-1" and dibutyl ethylhexanoyl glutamide "EB-21" manufactured by Ajinomoto Co., Inc., and the like.
 アミノ酸系ゲル化剤は、作業性向上及び増粘効果向上の観点から、溶媒によって希釈溶解されたプレミックスゲルとして用いることもできる。
 具体的には、アミノ酸系ゲル化剤を予め溶媒に溶解させたプレミックスゲルが好ましい。該溶媒としては、アミノ酸系ゲル化剤によってゲル化可能であれば制限されないが、増粘効果向上の観点から、オクチルドデカノール、イソステアリン酸等が好ましい。
 プレミックスゲル中のアミノ酸系ゲル化剤の含有量は、作業性向上及び増粘効果向上の観点、並びにプレミックスゲル自体の油分離を抑制する点から、好ましくは10質量%以上、より好ましくは15質量%以上、更に好ましくは20質量%以上であり、好ましくは45質量%以下、より好ましくは40質量%以下、更に好ましくは36質量%以下である。
 プレミックスゲルの市販品としては、高級アルコール工業(株)「AJK-OD2046」(アミノ酸系ゲル化剤を20質量%含有)、「AJK-IS3613」(アミノ酸系ゲル化剤を36質量%含有)等が挙げられる。
The amino acid-based gelling agent can also be used as a premixed gel diluted and dissolved with a solvent from the viewpoint of improving workability and thickening effect.
Specifically, a premixed gel obtained by previously dissolving an amino acid-based gelling agent in a solvent is preferred. The solvent is not limited as long as it can be gelled by an amino acid-based gelling agent, but octyldodecanol, isostearic acid, and the like are preferable from the viewpoint of improving the thickening effect.
The content of the amino acid-based gelling agent in the premix gel is preferably 10% by mass or more, more preferably 10% by mass or more, from the viewpoint of improving workability and thickening effect, and suppressing oil separation of the premix gel itself. It is 15% by mass or more, more preferably 20% by mass or more, preferably 45% by mass or less, more preferably 40% by mass or less, and even more preferably 36% by mass or less.
Commercially available premix gels include "AJK-OD2046" (containing 20% by mass of an amino acid-based gelling agent) and "AJK-IS3613" (containing 36% by mass of an amino acid-based gelling agent) manufactured by Kokyu Alcohol Kogyo Co., Ltd. etc.
 増粘剤は、1種又は2種以上を用いることができる。皮膚外用剤が増粘剤を含有する場合、皮膚外用剤中の増粘剤の含有量は、粘度調整の観点、及び、均一塗布性を高め、紫外線、赤外線等の防御効果を高める観点から、好ましくは0.5質量%以上、より好ましくは1質量%以上、更に好ましくは2質量%以上、より更に好ましくは3質量%以上であり、また、好ましくは50質量%以下、より好ましくは30質量%以下、更に好ましくは25質量%以下、より更に好ましくは20質量%以下、より更に好ましくは15質量%以下である。そして、皮膚外用剤中の増粘剤の含有量は、好ましくは0.5質量%以上50質量%以下、より好ましくは0.5質量%以上30質量%以下、更に好ましくは1質量%以上25質量%以下、より更に好ましくは2質量%以上20質量%以下、より更に好ましくは3質量%以上15質量%以下である。 One or two or more thickeners can be used. When the external preparation for skin contains a thickening agent, the content of the thickening agent in the external preparation for skin is adjusted from the viewpoint of adjusting the viscosity, improving the uniform application property, and improving the protective effect against ultraviolet rays, infrared rays, etc. Preferably 0.5% by mass or more, more preferably 1% by mass or more, still more preferably 2% by mass or more, still more preferably 3% by mass or more, and preferably 50% by mass or less, more preferably 30% by mass % or less, more preferably 25 mass % or less, still more preferably 20 mass % or less, still more preferably 15 mass % or less. The content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more and 50% by mass or less, more preferably 0.5% by mass or more and 30% by mass or less, and still more preferably 1% by mass or more and 25% by mass. % by mass or less, more preferably 2% by mass or more and 20% by mass or less, and even more preferably 3% by mass or more and 15% by mass or less.
<乳化剤>
 本発明の皮膚外用剤は、成分(A)の分散性を高める観点、及び乳化組成物を調製する観点から、さらに乳化剤を含有することができる。本発明において「乳化剤」とは、乳化性能を有する、前記増粘剤以外の添加剤を意味する。
 本発明に用いる乳化剤としては、低分子乳化剤、高分子乳化剤のいずれでもよいが、成分(A)の分散性を高める観点、及び粘度調整の容易性の観点からは高分子乳化剤が好ましい。
 高分子乳化剤としては、親水性部位及び疎水性部位を有する高分子乳化剤が好ましく、例えば、アルキル変性ポリアクリル酸系ポリマー、アルキル変性多糖類系ポリマー、オキサゾリン変性シリコーンが挙げられる。
<Emulsifier>
The external preparation for skin of the present invention may further contain an emulsifier from the viewpoint of enhancing the dispersibility of component (A) and from the viewpoint of preparing an emulsified composition. In the present invention, the "emulsifier" means an additive other than the thickener, which has emulsifying properties.
The emulsifier used in the present invention may be either a low-molecular-weight emulsifier or a high-molecular-weight emulsifier, but a high-molecular-weight emulsifier is preferable from the viewpoint of enhancing the dispersibility of component (A) and facilitating viscosity adjustment.
As the polymer emulsifier, a polymer emulsifier having a hydrophilic site and a hydrophobic site is preferable, and examples thereof include alkyl-modified polyacrylic acid-based polymer, alkyl-modified polysaccharide-based polymer, and oxazoline-modified silicone.
 アルキル変性ポリアクリル酸系ポリマーとしては、例えば、(メタ)アクリル酸/(メタ)アクリル酸アルキル共重合体、アクリル酸アルキル・メタクリル酸アルキル・メタクリル酸ポリオキシエチレンステアリルエーテル共重合体等が挙げられる。 Examples of alkyl-modified polyacrylic acid-based polymers include (meth)acrylic acid/alkyl (meth)acrylate copolymers, alkyl acrylate/alkyl methacrylate/polyoxyethylene stearyl ether methacrylate copolymers, and the like. .
 アルキル変性多糖類系ポリマーとしては、例えば、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、カルボキシメチルセルロースナトリウム、ステアロキシヒドロキシプロピルメチルセルロース、ラウレス-13PGヒドロキシエチルセルロース、ステアロキシPGヒドロキシエチルセルローススルホン酸塩等が挙げられる。 Examples of alkyl-modified polysaccharide polymers include hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, stearoxyhydroxypropylmethylcellulose, laureth-13PG hydroxyethylcellulose, stearoxy PG hydroxyethylcellulose sulfonate, and the like. be done.
 オキサゾリン変性シリコーンとしては、N-アシルアルキレンイミンを繰り返し単位とする親水性セグメントと、オルガノポリシロキサンセグメントとを構成単位とするポリマーが挙げられ、例えばN-プロピオニルポリエチレンイミン・メチルポリシロキサン共重合体(POLYSILICONE-9)を例示することができる。 Examples of the oxazoline-modified silicone include polymers having a hydrophilic segment having N-acylalkyleneimine as a repeating unit and an organopolysiloxane segment as structural units. For example, N-propionylpolyethyleneimine/methylpolysiloxane copolymer ( POLYSILICONE-9) can be exemplified.
 乳化剤は、1種又は2種以上を用いることができる。上記の中でも、成分(A)の分散性を高める観点、及び粘度調整の容易性の観点からはオキサゾリン変性シリコーンが好ましい。 One or two or more emulsifiers can be used. Among the above, oxazoline-modified silicone is preferable from the viewpoint of enhancing the dispersibility of component (A) and the viewpoint of ease of viscosity adjustment.
 本発明の皮膚外用剤が乳化剤を含有する場合、皮膚外用剤中の乳化剤の含有量は、乳化性能の観点から、好ましくは0.1質量%以上、より好ましくは0.2質量%以上であり、また、好ましくは15質量%以下、より好ましくは10質量%以下、更に好ましくは5質量%以下、より更に好ましくは3質量%以下、より更に好ましくは1質量%以下である。そして、皮膚外用剤中の乳化剤の含有量は、好ましくは0.1質量%以上15質量%以下、より好ましくは0.1質量%以上10質量%以下、更に好ましくは0.1質量%以上5質量%以下、より更に好ましくは0.1質量%以上3質量%以下、より更に好ましくは0.2質量%以上1質量%以下である。 When the topical skin preparation of the present invention contains an emulsifier, the content of the emulsifier in the topical skin preparation is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, from the viewpoint of emulsifying performance. Also, it is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, even more preferably 3% by mass or less, and even more preferably 1% by mass or less. The content of the emulsifier in the external preparation for skin is preferably 0.1% by mass or more and 15% by mass or less, more preferably 0.1% by mass or more and 10% by mass or less, and still more preferably 0.1% by mass or more and 5 % by mass or less, more preferably 0.1% by mass or more and 3% by mass or less, and even more preferably 0.2% by mass or more and 1% by mass or less.
<分散剤>
 本発明の皮膚外用剤は、成分(A)の分散性を高める観点から、さらに分散剤を含有することができる。本発明において「分散剤」とは、主として成分(A)の分散性向上に寄与する添加剤を意味する。
<Dispersant>
The external preparation for skin of the present invention may further contain a dispersant from the viewpoint of enhancing the dispersibility of component (A). In the present invention, "dispersant" means an additive that mainly contributes to improving the dispersibility of component (A).
 本発明に用いる分散剤としては、成分(A)の分散性を高める観点から、ノニオン性界面活性剤が好ましい。該ノニオン性界面活性剤としては通常の皮膚外用剤に用いられるものであれば特に制限はなく、シリコーン系界面活性剤、フッ素含有系界面活性剤等も用いることができる。
 分散剤として用いられるノニオン性界面活性剤としては、例えば、アルカノールアミド、アミンオキサイド、ポリオキシエチレンアルキルエーテル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレン脂肪酸アミド、ポリオキシエチレンアルキルアミン、アルキルサッカライド、α-モノアルキルグリセリルエーテル、ポリエーテル変性シリコーン等が挙げられ、これらのうち1種又は2種以上を用いることができる。
As the dispersant used in the present invention, a nonionic surfactant is preferable from the viewpoint of enhancing the dispersibility of the component (A). The nonionic surfactant is not particularly limited as long as it is used in usual external preparations for skin, and silicone surfactants, fluorine-containing surfactants and the like can also be used.
Examples of nonionic surfactants used as dispersants include alkanolamides, amine oxides, polyoxyethylene alkyl ethers, polyoxyethylene hydrogenated castor oils, polyoxyethylene fatty acid amides, polyoxyethylene alkylamines, alkyl saccharides, α -monoalkyl glyceryl ether, polyether-modified silicone, etc., and one or more of these can be used.
 成分(A)の分散性をより高める観点から、分散剤はノニオン性のシリコーン系界面活性剤を含むことが好ましく、ポリエーテル変性シリコーンを含むことがより好ましい。
 分散剤として用いられるポリエーテル変性シリコーンの市販品としては、例えば、信越化学工業(株)製の「KF-6012」(ポリ(オキシエチレン・オキシプロピレン)メチルポリシロキサン共重合体)、信越化学工業(株)製の「KF-6015」、「KF-6017」、「KF-6028」、「KF-6038」、ダウ・東レ(株)製の「SH3775M」(以上、ポリオキシエチレン・メチルポリシロキサン共重合体)、ダウ・東レ(株)製の「SH3772C」等が挙げられる。
From the viewpoint of further enhancing the dispersibility of component (A), the dispersant preferably contains a nonionic silicone-based surfactant, and more preferably contains a polyether-modified silicone.
Examples of commercially available polyether-modified silicones used as dispersants include "KF-6012" (poly(oxyethylene/oxypropylene) methylpolysiloxane copolymer) manufactured by Shin-Etsu Chemical Co., Ltd., Shin-Etsu Chemical Co., Ltd. Co., Ltd. "KF-6015", "KF-6017", "KF-6028", "KF-6038", Dow Toray Co., Ltd. "SH3775M" (above, polyoxyethylene methyl polysiloxane copolymer), "SH3772C" manufactured by Dow Toray Industries, Inc., and the like.
 分散剤として用いられる上記以外のノニオン性界面活性剤としては、ポリオキシエチレンアルキルエーテル型のノニオン性界面活性剤がより好ましい。ポリオキシエチレンアルキルエーテル型のノニオン性界面活性剤の市販品としては、例えば、花王(株)製「エマルゲン121-G」(ポリオキシエチレン(21)ラウリルエーテル)、花王(株)製「エマルゲン1620G」(ポリオキシエチレン(20)2-ヘキシルデシルエーテル)、花王(株)製「エマルゲン2020G」(ポリオキシエチレン(20)オクチルドデシルエーテル)等が挙げられる。 As a nonionic surfactant other than the above used as a dispersant, a polyoxyethylene alkyl ether type nonionic surfactant is more preferable. Commercially available polyoxyethylene alkyl ether type nonionic surfactants include, for example, "EMULGEN 121-G" (polyoxyethylene (21) lauryl ether) manufactured by Kao Corporation, and "EMULGEN 1620G" manufactured by Kao Corporation. (polyoxyethylene (20) 2-hexyldecyl ether), Kao Corporation "EMULGEN 2020G" (polyoxyethylene (20) octyldodecyl ether), and the like.
 分散剤は、1種又は2種以上を用いることができる。本発明の皮膚外用剤が分散剤を含有する場合、皮膚外用剤中の分散剤の含有量は、成分(A)の分散性を高める観点から、好ましくは0.1質量%以上、より好ましくは0.3質量%以上、更に好ましくは0.5質量%以上であり、また、好ましくは15質量%以下、より好ましくは10質量%以下、更に好ましくは5質量%以下である。そして、皮膚外用剤中の分散剤の含有量は、好ましくは0.1質量%以上15質量%以下、より好ましくは0.3質量%以上10質量%以下、更に好ましくは0.5質量%以上5質量%以下である。 One or two or more dispersants can be used. When the external preparation for skin of the present invention contains a dispersant, the content of the dispersant in the external preparation for skin is preferably 0.1% by mass or more, more preferably 0.1% by mass or more, from the viewpoint of enhancing the dispersibility of component (A). It is 0.3% by mass or more, more preferably 0.5% by mass or more, and preferably 15% by mass or less, more preferably 10% by mass or less, and even more preferably 5% by mass or less. The content of the dispersant in the external preparation for skin is preferably 0.1% by mass or more and 15% by mass or less, more preferably 0.3% by mass or more and 10% by mass or less, and still more preferably 0.5% by mass or more. It is 5% by mass or less.
<水>
 本発明の皮膚外用剤は、さっぱりとした使用感を与える観点から、さらに水を含有することが好ましい。
 皮膚外用剤が水を含有する場合、皮膚外用剤中の水の含有量は剤型により適宜選択することができるが、好ましくは1質量%以上、より好ましくは5質量%以上、更に好ましくは8質量%以上、より更に好ましくは10質量%以上であり、好ましくは50質量%以下、より好ましくは30質量%以下、更に好ましくは25質量%以下である。
<Water>
The external preparation for skin of the present invention preferably further contains water from the viewpoint of giving a refreshing feel to the skin.
When the topical skin preparation contains water, the content of water in the topical skin preparation can be appropriately selected depending on the dosage form. % by mass or more, more preferably 10% by mass or more, preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 25% by mass or less.
<水性媒体>
 本発明の皮膚外用剤は、成分(A)を分散させ、及び他の配合成分を分散又は溶解させて均一塗布性をより向上させる観点から、さらに水以外の水性媒体を含有することができる。当該水性媒体としては、例えば、エタノール、イソプロピルアルコール、ブチルアルコール等の炭素数4以下の1価アルコール;1,3-ブチレングリコール、グリセリン、エチレングリコール、プロピレングリコール、ジエチレングリコール、ジプロピレングリコール等の炭素数6以下の低分子ジオール及びトリオールが挙げられる。これらの中でも、炭素数4以下の1価アルコールからなる群から選ばれる1種以上が好ましく、エタノールがより好ましい。
<Aqueous medium>
The external preparation for skin of the present invention may further contain an aqueous medium other than water from the viewpoint of dispersing the component (A) and dispersing or dissolving other ingredients to further improve uniform application properties. Examples of the aqueous medium include monohydric alcohols having 4 or less carbon atoms such as ethanol, isopropyl alcohol, and butyl alcohol; Low-molecular-weight diols and triols of 6 or less are included. Among these, one or more selected from the group consisting of monohydric alcohols having 4 or less carbon atoms are preferable, and ethanol is more preferable.
 皮膚外用剤が水性媒体を含有する場合、皮膚外用剤中の水性媒体の含有量は剤型により適宜選択することができるが、成分(A)を分散させ、及び他の配合成分を分散又は溶解させて均一塗布性をより向上させる観点から、好ましくは0.1質量%以上、より好ましくは0.5質量%以上であり、好ましくは50質量%以下、より好ましくは30質量%以下、更に好ましくは20質量%以下、より更に好ましくは10質量%以下である。そして、皮膚外用剤中の水性媒体の含有量は、好ましくは0.1質量%以上50質量%以下、より好ましくは0.1質量%以上30質量%以下、更に好ましくは0.1質量%以上20質量%以下、より更に好ましくは0.5質量%以上10質量%以下である。 When the topical skin preparation contains an aqueous medium, the content of the aqueous medium in the topical skin preparation can be appropriately selected depending on the dosage form. From the viewpoint of further improving uniform coating properties by increasing the is 20% by mass or less, more preferably 10% by mass or less. The content of the aqueous medium in the external preparation for skin is preferably 0.1% by mass or more and 50% by mass or less, more preferably 0.1% by mass or more and 30% by mass or less, and still more preferably 0.1% by mass or more. 20 mass % or less, more preferably 0.5 mass % or more and 10 mass % or less.
 また、皮膚外用剤中の水及び水性媒体の合計含有量は、さっぱりとした使用感をより向上させる観点から、好ましくは2質量%以上、より好ましくは5質量%以上、更に好ましくは10質量%以上であり、好ましくは70質量%以下、より好ましくは60質量%以下、更に好ましくは40質量%以下、より更に好ましくは35質量%以下である。 In addition, the total content of water and aqueous medium in the skin external preparation is preferably 2% by mass or more, more preferably 5% by mass or more, and still more preferably 10% by mass, from the viewpoint of further improving the refreshing feeling of use. above, preferably 70% by mass or less, more preferably 60% by mass or less, even more preferably 40% by mass or less, and even more preferably 35% by mass or less.
<その他の成分>
 本発明の皮膚外用剤は、上記成分以外に、必要に応じて他の成分、例えば、紫外線吸収剤、紫外線散乱剤、揮発性油、制汗剤、香料、保湿剤、殺菌剤、pH調整剤、酸化防止剤、防腐剤等を含有させることもできる。
<Other ingredients>
The external preparation for skin of the present invention may contain other ingredients, such as ultraviolet absorbers, ultraviolet scattering agents, volatile oils, antiperspirants, fragrances, moisturizers, bactericides, and pH adjusters, if necessary, in addition to the above ingredients. , antioxidants, preservatives and the like can also be contained.
(紫外線吸収剤)
 本発明の皮膚外用剤は、紫外線防御効果を向上させる観点から、さらに紫外線吸収剤を含有してもよい。
 紫外線吸収剤としては、成分(B)以外の有機紫外線吸収剤であることが好ましく、油溶性の有機紫外線吸収剤、又は水溶性の有機紫外線吸収剤を用いることができる。紫外線防御効果向上の観点、皮膚に塗布した際の白浮き抑制の観点、及びべたつき抑制の観点から、紫外線吸収剤は油溶性の有機紫外線吸収剤であることが好ましい。なお本発明において「油溶性」とは非水溶性であることを意味し、具体的には、25℃において水への溶解度が1w/w%以下であることをいう。
 なお、本発明の効果を得る観点から、紫外線吸収剤は、例えば無機充填材の表面を紫外線吸収性材料で被覆した紫外線吸収剤等の、無機系の紫外線吸収剤は含まないことが好ましい。
(Ultraviolet absorber)
The external preparation for skin of the present invention may further contain an ultraviolet absorber from the viewpoint of improving the ultraviolet protection effect.
The UV absorber is preferably an organic UV absorber other than the component (B), and an oil-soluble organic UV absorber or a water-soluble organic UV absorber can be used. From the viewpoint of improving the UV protection effect, suppressing whitening when applied to the skin, and suppressing stickiness, the UV absorber is preferably an oil-soluble organic UV absorber. In the present invention, "oil-soluble" means water-insoluble, and specifically, it means that the solubility in water at 25°C is 1 w/w% or less.
From the viewpoint of obtaining the effects of the present invention, it is preferable that the UV absorber does not contain an inorganic UV absorber such as a UV absorber obtained by coating the surface of an inorganic filler with a UV absorbing material.
 油溶性の有機紫外線吸収剤としては、サリチル酸系紫外線吸収剤、ケイ皮酸系紫外線吸収剤、ベンゾイルメタン系紫外線吸収剤、及びその他の有機紫外線吸収剤のうち油溶性のものを用いることができる。
 例えば、サリチル酸ホモメンチル、サリチル酸オクチル等のサリチル酸系紫外線吸収剤;
パラメトキシケイ皮酸2-エチルヘキシル(例えば、BASF製「ユビナールMC80」)、ジパラメトキシケイ皮酸モノ-2-エチルヘキサン酸グリセリル、2,5-ジイソプロピルケイ皮酸メチル、トリメトキシケイ皮酸メチルビス(トリメチルシロキシ)シリルイソペンチル、パラメトキシケイ皮酸イソプロピル・ジイソプロピルケイ皮酸エステル混合物等のケイ皮酸系紫外線吸収剤;
4-イソプロピルジベンゾイルメタン、4-tert-ブチル-4'-メトキシジベンゾイルメタン(例えば、DSMニュートリションジャパン社製「パラソール1789」)等のベンゾイルメタン系紫外線吸収剤;
オクトクリレン(例えば、DSMニュートリションジャパン社製「パラソール340」)、ジメトキシベンジリデンジオキソイミダゾリジンプロピオン酸2-エチルヘキシル(例えば、味の素(株)製「ソフトシェードDH」)、1-(3,4-ジメトキシフェニル)-4,4-ジメチル-1,3-ペンタンジオン、シノキサート、メチル-O-アミノベンゾエート、3-(4-メチルベンジリデン)カンフル、オクチルトリアゾン、ジエチルアミノヒドロキシベンゾイル安息香酸ヘキシル(2-(4-ジエチルアミノ-2-ヒドロキシベンゾイル)安息香酸ヘキシルエステル、例えば、BASF製「ユビナールAplus」)、ビスエチルヘキシルオキシフェノールメトキシフェニルトリアジン(2,4-ビス{[4-(2-エチルヘキシルオキシ)-2-ヒドロキシ]フェニル}-6-(4-メトキシフェニル)-1,3,5-トリアジン、例えば、BASF製「チノソーブS」)、メチレンビスベンゾトリアゾリルテトラメチルブチルフェノール(例えば、BASF製「チノソーブM」)、2,4,6-トリス[4-(2-エチルヘキシルオキシカルボニル)アニリノ]-1,3,5-トリアジン(以下、「エチルヘキシルトリアゾン」ともいう。例えば、BASF製「ユビナールT150」);等が挙げられる。
As the oil-soluble organic ultraviolet absorber, salicylic acid-based ultraviolet absorbers, cinnamic acid-based ultraviolet absorbers, benzoylmethane-based ultraviolet absorbers, and other organic ultraviolet absorbers that are oil-soluble can be used.
For example, salicylic acid-based ultraviolet absorbers such as homomenthyl salicylate and octyl salicylate;
2-Ethylhexyl paramethoxycinnamate (for example, "Ubinal MC80" manufactured by BASF), glyceryl mono-2-ethylhexanoate di-paramethoxycinnamate, methyl 2,5-diisopropylcinnamate, methylbis trimethoxycinnamate (Trimethylsiloxy)silyl isopentyl, cinnamic acid-based UV absorbers such as a mixture of isopropyl para-methoxycinnamate and diisopropyl cinnamate;
Benzoylmethane-based UV absorbers such as 4-isopropyldibenzoylmethane, 4-tert-butyl-4′-methoxydibenzoylmethane (for example, “Parsol 1789” manufactured by DSM Nutrition Japan);
Octocrylene (e.g., DSM Nutrition Japan Co., Ltd. "PARASOL 340"), dimethoxybenzylidene dioxoimidazolidine 2-ethylhexylpropionate (e.g., Ajinomoto Co., Ltd. "Soft Shade DH"), 1-(3,4-dimethoxyphenyl) )-4,4-dimethyl-1,3-pentanedione, cinoxate, methyl-O-aminobenzoate, 3-(4-methylbenzylidene)camphor, octyltriazone, diethylaminohydroxybenzoyl hexylbenzoate (2-(4- diethylamino-2-hydroxybenzoyl)benzoic acid hexyl ester, such as "Ubinal Aplus" manufactured by BASF), bisethylhexyloxyphenol methoxyphenyltriazine (2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy] Phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, such as "Tinosorb S" manufactured by BASF), methylenebisbenzotriazolyltetramethylbutylphenol (eg, "Tinosorb M" manufactured by BASF), 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine (hereinafter also referred to as "ethylhexyltriazone"; for example, "Ubinal T150" manufactured by BASF); mentioned.
 水溶性の有機紫外線吸収剤としては、サリチル酸系紫外線吸収剤、ケイ皮酸系紫外線吸収剤、ベンゾイルメタン系紫外線吸収剤、及びその他の有機紫外線吸収剤のうち水への溶解度が1w/w%を超えるものを用いることができ、例えば、サリチル酸トリエタノールアミン塩、p-メトキシハイドロケイ皮酸ジエタノールアミン塩等が挙げられる。 As the water-soluble organic UV absorber, a salicylic acid UV absorber, a cinnamic acid UV absorber, a benzoylmethane UV absorber, and other organic UV absorbers having a solubility in water of 1 w/w% are selected. More than one can be used, and examples thereof include salicylic acid triethanolamine salt, p-methoxyhydrocinnamic acid diethanolamine salt, and the like.
 上記の中でも、紫外線防御効果向上の観点から、紫外線吸収剤としてはパラメトキシケイ皮酸2-エチルヘキシル、4-tert-ブチル-4’-メトキシジベンゾイルメタン、オクトクリレン、ジメトキシベンジリデンジオキソイミダゾリジンプロピオン酸2-エチルヘキシル、ジエチルアミノヒドロキシベンゾイル安息香酸ヘキシル、ビスエチルヘキシルオキシフェノールメトキシフェニルトリアジン、メチレンビスベンゾトリアゾリルテトラメチルブチルフェノール、及び2,4,6-トリス[4-(2-エチルヘキシルオキシカルボニル)アニリノ]-1,3,5-トリアジンからなる群から選ばれる1種以上が好ましく、パラメトキシケイ皮酸2-エチルヘキシル、ジエチルアミノヒドロキシベンゾイル安息香酸ヘキシル、ビスエチルヘキシルオキシフェノールメトキシフェニルトリアジン、及び2,4,6-トリス[4-(2-エチルヘキシルオキシカルボニル)アニリノ]-1,3,5-トリアジンからなる群から選ばれる1種以上がより好ましく、UVA及びUVBを共に防御する観点からは、これらを2種以上組み合わせることが更に好ましい。より更に好ましくは、パラメトキシケイ皮酸2-エチルヘキシル、ジエチルアミノヒドロキシベンゾイル安息香酸ヘキシル、及びビスエチルヘキシルオキシフェノールメトキシフェニルトリアジンからなる群から選ばれる1種以上であり、これらを2種以上組み合わせることがより更に好ましい。 Among the above, from the viewpoint of improving the UV protection effect, the UV absorber includes 2-ethylhexyl paramethoxycinnamate, 4-tert-butyl-4′-methoxydibenzoylmethane, octocrylene, dimethoxybenzylidene dioxoimidazolidine propionic acid. 2-ethylhexyl, diethylaminohydroxybenzoylhexylbenzoate, bisethylhexyloxyphenol methoxyphenyltriazine, methylenebisbenzotriazolyltetramethylbutylphenol, and 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]- One or more selected from the group consisting of 1,3,5-triazines are preferable, and 2-ethylhexyl paramethoxycinnamate, hexyl diethylaminohydroxybenzoylbenzoate, bisethylhexyloxyphenol methoxyphenyltriazine, and 2,4,6- More preferably one or more selected from the group consisting of tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, and two or more of these from the viewpoint of protecting against both UVA and UVB. A combination is more preferable. More preferably, it is one or more selected from the group consisting of 2-ethylhexyl paramethoxycinnamate, hexyl diethylaminohydroxybenzoylbenzoate, and bisethylhexyloxyphenol methoxyphenyltriazine, and a combination of two or more thereof is more preferable. More preferred.
 本発明の皮膚外用剤が紫外線吸収剤を含有する場合、その含有量は、紫外線防御効果向上の観点から、皮膚外用剤中、好ましくは0.2質量%以上、より好ましくは1.5質量%以上、更に好ましくは5質量%以上、より更に好ましくは7質量%以上である。また、皮膚外用剤の使用感向上の観点から、好ましくは30質量%以下、より好ましくは25質量%以下、更に好ましくは20質量%以下であり、より更に好ましくは15質量%以下である。皮膚外用剤中の紫外線吸収剤の含有量の具体的範囲は、好ましくは0.2質量%以上30質量%以下であり、より好ましくは1.5質量%以上25質量%以下であり、更に好ましくは5質量%以上20質量%以下であり、より更に好ましくは7質量%以上15質量%以下である。 When the external preparation for skin of the present invention contains an ultraviolet absorber, the content thereof is preferably 0.2% by mass or more, more preferably 1.5% by weight, in the external preparation for skin from the viewpoint of improving the ultraviolet protection effect. Above, more preferably 5% by mass or more, still more preferably 7% by mass or more. From the viewpoint of improving the feeling of use of the external preparation for skin, the content is preferably 30% by mass or less, more preferably 25% by mass or less, even more preferably 20% by mass or less, and even more preferably 15% by mass or less. The specific range of the content of the ultraviolet absorber in the external preparation for skin is preferably 0.2% by mass or more and 30% by mass or less, more preferably 1.5% by mass or more and 25% by mass or less, and even more preferably. is 5% by mass or more and 20% by mass or less, and more preferably 7% by mass or more and 15% by mass or less.
(紫外線散乱剤)
 本発明の皮膚外用剤は、紫外線防御効果を向上させる観点から、さらに紫外線散乱剤を含有してもよい。
 紫外線散乱剤としては、紫外線を散乱する効果が高い点から、無機粒子が好ましく、成分(A)以外の金属酸化物粒子、すなわち、平均粒径350nm以上2,500nm以下の球状金属酸化物(A1)及び板状金属酸化物(A2)以外の金属酸化物粒子がより好ましい。該金属酸化物としては成分(A)以外の、酸化チタン、酸化亜鉛、酸化鉄、酸化ジルコニウム、酸化アルミニウム等が挙げられ、成分(A)以外の酸化チタン及び酸化亜鉛からなる群から選ばれる1種以上が更に好ましい。
(Ultraviolet scattering agent)
The external preparation for skin of the present invention may further contain an ultraviolet scattering agent from the viewpoint of improving the ultraviolet protection effect.
As the ultraviolet scattering agent, inorganic particles are preferable because they are highly effective in scattering ultraviolet rays. ) and metal oxide particles other than the plate-shaped metal oxide (A2) are more preferable. Examples of the metal oxide include titanium oxide, zinc oxide, iron oxide, zirconium oxide, and aluminum oxide other than component (A), and are selected from the group consisting of titanium oxide and zinc oxide other than component (A). Species or more are more preferred.
 紫外線散乱剤に用いられる上記無機粒子は、皮膚外用剤への分散性を高める観点から、表面処理により疎水化されたものであることが好ましい。疎水化のための表面処理方法としては、例えば、メチルハイドロジェンポリシロキサン(ハイドロゲンジメチコン)、メチルポリシロキサン(ジメチコン)、メチルハイドロジェンポリシロキサン・ジメチルポリシロキサン共重合体等によるシリコーン処理;パーフルオロアルキルリン酸エステル、パーフルオロアルコール等によるフッ素処理;N-アシルグルタミン酸等によるアミノ酸処理;ヘキシルトリメトキシシラン、オクチルトリメトキシシラン、デシルトリメトキシシラン、オクタデシルトリメトキシシラン、オクチルトリエトキシシラン、トリフルオロプロピルトリメトキシシラン、ヘプタデカフルオロデシルトリメトキシシラン等によるシラン化合物処理;ヘキサメチルジシラザン、オクチルジシラザン等によるシラザン処理;レシチン処理;金属石鹸処理;カプリル酸、ペラルゴン酸、カプリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、オレイン酸、リノール酸、リノレン酸、アラギン酸、アラキドン酸、ベヘン酸等による脂肪酸処理;アルキルリン酸エステル処理;シリカ、アルミナ、水酸化アルミニウム等による無機化合物処理;等が挙げられる。これら表面処理方法は、1種又は2種以上を用いることができる。 From the viewpoint of enhancing the dispersibility in external skin preparations, the inorganic particles used in the UV scattering agent are preferably hydrophobized by surface treatment. Examples of surface treatment methods for hydrophobization include silicone treatment with methylhydrogenpolysiloxane (hydrogendimethicone), methylpolysiloxane (dimethicone), methylhydrogenpolysiloxane/dimethylpolysiloxane copolymer, etc.; perfluoroalkyl Fluorine treatment with phosphate ester, perfluoroalcohol, etc.; amino acid treatment with N-acylglutamic acid, etc.; hexyltrimethoxysilane, octyltrimethoxysilane, decyltrimethoxysilane, octadecyltrimethoxysilane, octyltriethoxysilane, trifluoropropyltri Silane compound treatment with methoxysilane, heptadecafluorodecyltrimethoxysilane, etc.; silazane treatment with hexamethyldisilazane, octyldisilazane, etc.; lecithin treatment; metal soap treatment; caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid , fatty acid treatment with palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, araginic acid, arachidonic acid, behenic acid, etc.; alkyl phosphate ester treatment; inorganic compound treatment with silica, alumina, aluminum hydroxide, etc.; mentioned. One or more of these surface treatment methods can be used.
 紫外線散乱剤の粒子形状としては、平均粒径350nm未満の球状、あるいは、棒状、紡錘状、針状、不定形状等が挙げられるが、紫外線散乱効果を有するものであれば特に制限されない。
 紫外線散乱剤の平均粒径は、通常1nm以上であり、紫外線防御効果を向上させる観点から、好ましくは5nm以上であり、より好ましくは8nm以上であり、更に好ましくは10nm以上である。また、皮膚に塗布した際の白浮き抑制の観点から、好ましくは350nm未満であり、より好ましくは300nm以下であり、更に好ましくは100nm以下であり、より更に好ましくは60nm以下である。
 上記平均粒径は、成分(A1)の平均粒径と同様の方法で測定することができる。
The particle shape of the UV-scattering agent may be spherical with an average particle size of less than 350 nm, rod-like, spindle-like, needle-like, or amorphous, but is not particularly limited as long as it has an UV-scattering effect.
The average particle size of the UV scattering agent is usually 1 nm or more, preferably 5 nm or more, more preferably 8 nm or more, and still more preferably 10 nm or more from the viewpoint of improving the UV protection effect. In addition, from the viewpoint of suppressing whitening when applied to the skin, it is preferably less than 350 nm, more preferably 300 nm or less, even more preferably 100 nm or less, and even more preferably 60 nm or less.
The average particle size can be measured by the same method as for the average particle size of component (A1).
 紫外線散乱剤は市販品を用いることもできる。紫外線散乱剤として用いられる酸化チタン粒子の市販品としては、例えばテイカ(株)製の「MT-100TV」(水酸化アルミニウム、ステアリン酸処理)、「MTY-110M3S」(水酸化アルミニウム、シリカ、ハイドロジェンジメチコン処理)等が挙げられる。 Commercially available UV scattering agents can also be used. Examples of commercially available titanium oxide particles used as UV scattering agents include "MT-100TV" (aluminum hydroxide, stearic acid treatment) and "MTY-110M3S" (aluminum hydroxide, silica, hydro Gendimethicone treatment) and the like.
 紫外線散乱剤として用いられる酸化亜鉛粒子の市販品としては、例えば堺化学工業(株)製の「FINEX-50-LPTM」(ジメチコン処理)、「FINEX-25」(表面処理なし)、「FINEX-25LP」(ジメチコン処理)、テイカ(株)製の「MZ-300」(表面処理なし)、「MZ-504R3M」(ハイドロゲンジメチコン処理)、「MZY-303S」(ハイドロジメチコン処理)、「MZ-306X」(トリエトキシシリルエチルポリジメチルシロキシエチルヘキシルジメチコン処理)、「MZ-200」(表面処理なし)、「MZY-203S」(ハイドロゲンジメチコン処理)、「MZ-150」(表面処理なし)、「MZY-153S」(ハイドロゲンジメチコン処理)、「MZ-505S」、「MZY-505S」等が挙げられる。 Examples of commercially available zinc oxide particles used as UV scattering agents include "FINEX-50-LPTM" (dimethicone treatment), "FINEX-25" (no surface treatment), "FINEX- 25LP" (dimethicone treatment), "MZ-300" manufactured by Tayca Corporation (no surface treatment), "MZ-504R3M" (hydrogen dimethicone treatment), "MZY-303S" (hydrodimethicone treatment), "MZ-306X" "(triethoxysilylethylpolydimethylsiloxyethylhexyl dimethicone treatment),"MZ-200"(no surface treatment),"MZY-203S"(hydrogen dimethicone treatment),"MZ-150"(no surface treatment),"MZY- 153S” (hydrogen dimethicone treatment), “MZ-505S”, “MZY-505S” and the like.
 紫外線散乱剤は1種を単独で、又は2種以上を組み合わせて用いることができる。
 本発明の皮膚外用剤が紫外線散乱剤を含有する場合、その含有量は、紫外線防御効果向上の観点から、好ましくは1質量%以上、より好ましくは3質量%以上、更に好ましくは5質量%以上である。また、皮膚に塗布した際の白浮き抑制の観点から、当該含有量は、好ましくは20質量%以下、より好ましくは18質量%以下、更に好ましくは15質量%以下である。
The ultraviolet scattering agent can be used alone or in combination of two or more.
When the external preparation for skin of the present invention contains an ultraviolet scattering agent, the content thereof is preferably 1% by mass or more, more preferably 3% by mass or more, and still more preferably 5% by mass or more, from the viewpoint of improving the ultraviolet protection effect. is. In addition, from the viewpoint of suppressing whitening when applied to the skin, the content is preferably 20% by mass or less, more preferably 18% by mass or less, and even more preferably 15% by mass or less.
<用途>
 本発明の皮膚外用剤は、紫外線又は赤外線防御用、皮膚温度上昇抑制用、又は疲労抑制用の皮膚外用剤として用いることができる。
 本発明の皮膚外用剤を皮膚に適用することで、紫外線、赤外線、又は太陽光等の紫外~赤外線領域の波長を含む光が皮膚に照射されても皮膚を効果的に防御することができる。これにより、紫外線、赤外線、又は太陽光等の照射に起因する皮膚の光老化や皮膚温度上昇を抑制でき、皮膚の遮熱効果も得ることができる。
 また、太陽光照射環境下で人等の動物が持久運動を行った場合、太陽光照射量が多いと疲労が起こりやすいが、本発明の皮膚外用剤を用いることにより、このような太陽光照射に起因する疲労を抑制することができる。
<Application>
The external skin preparation of the present invention can be used as a skin external preparation for protecting against ultraviolet rays or infrared rays, for suppressing skin temperature rise, or for suppressing fatigue.
By applying the external preparation for skin of the present invention to the skin, it is possible to effectively protect the skin even when the skin is irradiated with ultraviolet light, infrared light, or light containing wavelengths in the ultraviolet to infrared region such as sunlight. As a result, it is possible to suppress the photoaging of the skin and the increase in skin temperature caused by the irradiation of ultraviolet rays, infrared rays, sunlight, etc., and also to obtain the heat shielding effect of the skin.
In addition, when an animal such as a human performs endurance exercise in a sunlight irradiation environment, fatigue is likely to occur if the amount of sunlight irradiation is large. It is possible to suppress fatigue caused by
 皮膚外用剤を用いることによる疲労抑制効果については、例えば次の方法で評価することができる。
 皮膚外用剤を、被験者の露光部位(顔、胸部、背部、腕、手の甲、足)に2mg/cmになるように塗布し、15分乾燥させる。次いで、被験者の前後左右に人工太陽光源を設置し、被験者の上半身に向けて疑似太陽光を照射しながら、エルゴメーター(例えば、モナーク社製「スタンダード・エルゴメーター 828E」)を用い、一定の心拍数を維持しながら運動を30分間継続する。被験者による、運動中の暑熱感覚と疲労感覚の自己評価を行い、皮膚外用剤を用いることによる運動パフォーマンスの影響を評価する。
The anti-fatigue effect of using an external preparation for skin can be evaluated, for example, by the following method.
The external preparation for skin is applied to the exposed areas (face, chest, back, arms, backs of hands, feet) of the test subject at a concentration of 2 mg/cm 2 and allowed to dry for 15 minutes. Next, artificial solar light sources are placed in front, back, left and right of the subject, and while irradiating simulated sunlight toward the upper body of the subject, an ergometer (for example, "Standard Ergometer 828E" manufactured by Monarch) is used to maintain a constant heart rate. Continue the exercise for 30 minutes while maintaining the number. Subjects self-evaluate heat sensation and fatigue sensation during exercise to evaluate the effect of topical skin preparations on exercise performance.
<皮膚外用剤の製造方法>
 本発明の皮膚外用剤の製造方法は特に限定されず、皮膚外用剤の剤型に応じて公知の方法を適宜用いることができる。例えば、成分(A)、(B)及びその他の全成分を配合し、ディスパー等により均一に混合する方法が挙げられる。又は、水及び水性媒体以外の全成分を配合し、ディスパー等により均一に混合した後に、水及び水性媒体を配合して更にホモジナイザー等により撹拌混合する方法も用いることができる。
 皮膚外用剤が油中水型乳化組成物、又は水中油型乳化組成物である場合は、水相と油相とをそれぞれ調製した後、両者を混合する方法も用いることができる。
<Method for producing external preparation for skin>
The method for producing the external preparation for skin of the present invention is not particularly limited, and a known method can be appropriately used depending on the dosage form of the external preparation for skin. For example, there is a method of blending components (A), (B) and all other components and uniformly mixing them with a disper or the like. Alternatively, a method of blending all components other than water and an aqueous medium and uniformly mixing them with a disper or the like, then adding water and an aqueous medium and further stirring and mixing with a homogenizer or the like can also be used.
When the external preparation for skin is a water-in-oil emulsified composition or an oil-in-water emulsified composition, a method of preparing an aqueous phase and an oil phase and then mixing the two can also be used.
[皮膚の赤外線防御方法]
 本発明はまた、本発明の皮膚外用剤を皮膚に適用する工程を有する、皮膚の赤外線防御方法を提供する。
 本発明の赤外線防御方法は、前記本発明の皮膚外用剤を皮膚に適用する工程を有していれば特に制限されない。皮膚外用剤の皮膚への適用方法は、塗布、噴霧等が挙げられる。
[Skin Infrared Protection Method]
The present invention also provides a method for protecting the skin from infrared rays, comprising the step of applying the external preparation for skin of the present invention to the skin.
The infrared protection method of the present invention is not particularly limited as long as it includes the step of applying the external preparation for skin of the present invention to the skin. Examples of the method of applying the skin external preparation to the skin include coating, spraying, and the like.
 本発明の赤外線防御方法においては、波長825nmの赤外線防御率が、好ましくは35%以上であり、より好ましくは45%以上であり、更に好ましくは55%以上である。また、波長825nmの赤外線防御率が65%以上であると皮膚の遮熱実感が特に良好になる。赤外線防御率(%)は、具体的には実施例に記載の方法により測定できる。 In the infrared protection method of the present invention, the infrared protection rate at a wavelength of 825 nm is preferably 35% or higher, more preferably 45% or higher, and even more preferably 55% or higher. Moreover, when the infrared protection rate at a wavelength of 825 nm is 65% or more, the feeling of heat shielding on the skin becomes particularly good. The infrared protection rate (%) can be specifically measured by the method described in Examples.
 上述した実施形態に関し、本発明は更に以下の皮膚外用剤等を開示する。
 <1>
 成分(A):平均粒径が、350nm以上、好ましくは400nm以上、より好ましくは700nm以上、更に好ましくは800nm以上であり、また、2,500nm以下、好ましくは2,000nm以下、より好ましくは1,800nm以下、更に好ましくは1,500nm以下、より更に好ましくは1,200nm以下である球状金属酸化物(A1)及び板状金属酸化物(A2)からなる群から選ばれる1種以上の金属酸化物、並びに成分(B):不揮発性油、を含有する皮膚外用剤であって、該皮膚外用剤中の成分(A)の含有量が、2質量%以上、好ましくは3質量%以上、より好ましくは5質量%以上であり、50質量%以下であり、25℃における粘度が2,500mPa・s以上である、皮膚外用剤。
 <2>
 成分(A1)及び成分(A2)における金属酸化物が、好ましくは、酸化チタン、酸化亜鉛、酸化ジルコニウム、酸化鉄、酸化アルミニウム、及び酸化セリウムからなる群から選ばれる1種以上である、<1>に記載の皮膚外用剤。
 <3>
 25℃における粘度が、好ましくは2,500mPa・s以上150,000mPa・s以下、より好ましくは2,500mPa・s以上100,000mPa・s以下、更に好ましくは2,500mPa・s以上50,000mPa・s以下、より更に好ましくは2,500mPa・s以上30,000mPa・s以下、より更に好ましくは2,500mPa・s以上20,000mPa・s以下である、<1>又は<2>に記載の皮膚外用剤。
 <4>
 前記皮膚外用剤中の前記成分(A)の含有量(質量%)に対する前記皮膚外用剤の粘度(mPa・s)が、好ましくは100以上、より好ましくは250以上、更に好ましくは300以上、より更に好ましくは350以上であり、また、好ましくは25,000以下、より好ましくは20,000以下、更に好ましくは15,000以下、より更に好ましくは10,000以下、より更に好ましくは5,000以下、より更に好ましくは3,000以下である、<1>~<3>のいずれかに記載の皮膚外用剤。
 <5>
 前記皮膚外用剤中の前記成分(A)の含有量(質量%)に対する前記皮膚外用剤の粘度(mPa・s)が、好ましくは100以上25,000以下、より好ましくは250以上20,000以下、更に好ましくは300以上15,000以下、より更に好ましくは350以上10,000以下、より更に好ましくは350以上5,000以下、より更に好ましくは350以上3,000以下である、<1>~<4>のいずれかに記載の皮膚外用剤。
 <6>
 前記皮膚外用剤の不揮発性成分中の前記成分(A)の含有量が、好ましくは3質量%以上、より好ましくは5質量%以上、更に好ましくは10質量%以上であり、また好ましくは50質量%以下、より好ましくは40質量%以下、更に好ましくは30質量%以下、より更に好ましくは20質量%以下である、<1>~<5>のいずれかに記載の皮膚外用剤。
 <7>
 皮膚外用剤の不揮発性成分中の成分(A)の含有量が、好ましくは3質量%以上50質量%以下、より好ましくは5質量%以上40質量%以下、更に好ましくは10質量%以上30質量%以下、より更に好ましくは10質量%以上20質量%以下である、<1>~<6>のいずれかに記載の皮膚外用剤。
 <8>
 成分(A1)の平均粒径が、好ましくは400nm以上2,000nm以下、より好ましくは700nm以上2,000nm以下、更に好ましくは700nm以上1,800nm以下、より更に好ましくは700nm以上1,500nm以下、より更に好ましくは800nm以上1,200nm以下である、<1>~<7>のいずれかに記載の皮膚外用剤。
 <9>
 前記成分(A)が成分(A1)として好ましくは平均粒径700nm以上2,500nm以下の球状金属酸化物を含み、好ましくは25℃における粘度が2,500mPa・s以上20,000mPa・s以下である、<1>~<8>のいずれかに記載の皮膚外用剤。
 <10>
 前記成分(A)が成分(A2)として、好ましくは板状酸化チタン及び板状酸化亜鉛からなる群から選ばれる1種以上を含む、<1>~<9>のいずれかに記載の皮膚外用剤。
 <11>
 前記成分(A2)の厚さが、好ましくは30nm以上、より好ましくは50nm以上、更に好ましくは60nm以上、より更に好ましくは75nm以上、より更に好ましくは90nm以上、より更に好ましくは100nm以上であり、また、好ましくは360nm以下、より好ましくは330nm以下、更に好ましくは310nm以下、更に好ましくは280nm以下、より更に好ましくは270nm以下、より更に好ましくは230nm以下、より更に好ましくは200nm以下、より更に好ましくは180nm以下である、<1>~<10>のいずれかに記載の皮膚外用剤。
 <12>
 成分(A2)の厚さが、好ましくは30nm以上360nm以下、より好ましくは50nm以上330nm以下、更に好ましくは60nm以上310nm以下、より更に好ましくは75nm以上280nm以下、より更に好ましくは90nm以上270nm以下、より更に好ましくは100nm以上230nm以下、より更に好ましくは100nm以上200nm以下、より更に好ましくは100nm以上180nm以下である、<1>~<11>のいずれかに記載の皮膚外用剤。
 <13>
 前記成分(A2)のアスペクト比が、好ましくは3以上、より好ましくは5以上、更に好ましくは10以上、より更に好ましくは30以上、より更に好ましくは50以上、より更に好ましくは55以上であり、また、好ましくは300以下、より好ましくは230以下、更に好ましくは200以下、より更に好ましくは140以下、より更に好ましくは125以下、より更に好ましくは120以下である、<1>~<12>のいずれかに記載の皮膚外用剤。
 <14>
 前記成分(A2)のアスペクト比が、好ましくは3以上300以下、より好ましくは3以上230以下、更に好ましくは10以上230以下、より更に好ましくは30以上230以下、より更に好ましくは50以上200以下、より更に好ましくは55以上140以下、より更に好ましくは55以上125以下、より更に好ましくは55以上120以下である、<1>~<13>のいずれかに記載の皮膚外用剤。
 <15>
 成分(A)中の成分(A2)の含有量が、好ましくは50質量%以上、より好ましくは60質量%以上、更に好ましくは70質量%以上、より更に好ましくは80質量%以上、より更に好ましくは90質量%以上であり、100質量%以下である、<1>~<14>のいずれかに記載の皮膚外用剤。
 <16>
 皮膚外用剤中の平均粒径350nm以上800nm未満の球状酸化チタンの含有量が、好ましくは5質量%以上30質量%以下、より好ましくは5質量%以上25質量%以下である、<1>~<15>のいずれかに記載の皮膚外用剤。
 <17>
 皮膚外用剤中の平均粒径800nm以上2,500nm以下の球状酸化チタンの含有量が、好ましくは5質量%以上40質量%以下、より好ましくは5質量%以上30質量%以下である、<1>~<16>のいずれかに記載の皮膚外用剤。
 <18>
 前記皮膚外用剤中の前記板状酸化チタンの含有量が、好ましくは5質量%以上30質量%以下である、<1>~<17>のいずれかに記載の皮膚外用剤。
 <19>
 皮膚外用剤中の平均粒径350nm以上2,500nm以下の球状酸化亜鉛、又は板状酸化亜鉛の含有量が、好ましくは7質量%以上50質量%以下、より好ましくは10質量%以上50質量%以下である、<1>~<18>のいずれかに記載の皮膚外用剤。
 <20>
 成分(B)の25℃における粘度が、好ましくは500mPa・s以下、より好ましくは300mPa・s以下、更に好ましくは100mPa・s以下、より更に好ましくは50mPa・s以下であり、また、好ましくは5mPa・s以上である、<1>~<19>のいずれかに記載の皮膚外用剤。
 <21>
 前記成分(B)が、好ましくは25℃で液状であり、より好ましくはエステル油、シリコーン油、炭化水素油、高級脂肪酸、及び高級アルコールからなる群から選ばれる1種以上である、<1>~<20>のいずれかに記載の皮膚外用剤。
 <22>
 皮膚外用剤中の成分(B)の含有量が、好ましくは1質量%以上、より好ましくは5質量%以上であり、また、好ましくは90質量%以下、より好ましくは80質量%以下、更に好ましくは70質量%以下、より更に好ましくは65質量%以下である、<1>~<21>のいずれかに記載の皮膚外用剤。
 <23>
 皮膚外用剤が油中水型乳化組成物であり、皮膚外用剤中の成分(B)の含有量が、好ましくは15質量%以上、より好ましくは20質量%以上、更に好ましくは25質量%以上、より更に好ましくは30質量%以上、より更に好ましくは35質量%以上である<1>~<22>のいずれかに記載の皮膚外用剤。
 <24>
 皮膚外用剤が水中油型乳化組成物であり、皮膚外用剤中の成分(B)の含有量が、好ましくは30質量%以下、より好ましくは20質量%以下、より更に好ましくは10質量%以下である<1>~<23>のいずれかに記載の皮膚外用剤。
 <25>
 成分(A)の含有量に対する成分(B)の含有量の質量比[(B)/(A)]が、好ましくは0.05以上、より好ましくは0.1以上、更に好ましくは0.2以上、より更に好ましくは0.5以上、より更に好ましくは1以上、より更に好ましくは2以上、より更に好ましくは3以上、より更に好ましくは3.6以上であり、また、好ましくは60以下、より好ましくは50以下、更に好ましくは30以下、より更に好ましくは20以下、より更に好ましくは10以下、より更に好ましくは8以下である、<1>~<24>のいずれかに記載の皮膚外用剤。
 <26>
 成分(A)の含有量に対する成分(B)の含有量の質量比[(B)/(A)]が、好ましくは0.05以上60以下、より好ましくは0.1以上50以下、更に好ましくは0.2以上30以下、より更に好ましくは0.5以上20以下、より更に好ましくは1以上10以下、より更に好ましくは2以上10以下、より更に好ましくは3以上10以下、より更に好ましくは3.6以上8以下である、<1>~<25>のいずれかに記載の皮膚外用剤。
 <27>
 皮膚外用剤中の成分(A)及び成分(B)の合計含有量が、好ましくは2質量%以上、より好ましくは10質量%以上、更に好ましくは20質量%以上、より更に好ましくは30質量%以上、より更に好ましくは40質量%以上、より更に好ましくは45質量%以上、より更に好ましくは47質量%以上、より更に好ましくは50質量%以上であり、また、100質量%以下である、<1>~<26>のいずれかに記載の皮膚外用剤。
 <28>
 前記皮膚外用剤が、好ましくはさらに増粘剤を含有する、<1>~<27>のいずれかに記載の皮膚外用剤。
 <29>
 前記増粘剤が好ましくは油増粘剤である、<28>に記載の皮膚外用剤。
 <30>
 前記増粘剤が、好ましくは固形のワックス、有機変性粘土鉱物、デキストリン脂肪酸エステル、及びアミノ酸系ゲル化剤からなる群から選ばれる1種以上である、<28>又は<29>に記載の皮膚外用剤。
 <31>
 前記皮膚外用剤中の前記増粘剤の含有量が、好ましくは0.5質量%以上、より好ましくは1質量%以上、更に好ましくは2質量%以上、より更に好ましくは3質量%以上であり、また、好ましくは50質量%以下、より好ましくは30質量%以下、更に好ましくは25質量%以下、より更に好ましくは20質量%以下、より更に好ましくは15質量%以下である、<28>~<30>のいずれかに記載の皮膚外用剤。
<32>
 皮膚外用剤中の前記増粘剤の含有量が、好ましくは0.5質量%以上50質量%以下、より好ましくは0.5質量%以上30質量%以下、更に好ましくは1質量%以上25質量%以下、より更に好ましくは2質量%以上20質量%以下、より更に好ましくは3質量%以上15質量%以下である、<28>~<31>のいずれかに記載の皮膚外用剤。
 <33>
 前記皮膚外用剤が好ましくはさらに水を含有し、皮膚外用剤中の水の含有量が、好ましくは1質量%以上、より好ましくは5質量%以上、更に好ましくは8質量%以上、より更に好ましくは10質量%以上であり、好ましくは50質量%以下、より好ましくは30質量%以下、更に好ましくは25質量%以下である、<1>~<32>のいずれかに記載の皮膚外用剤。
<34>
 前記皮膚外用剤が、好ましくは液状、ゲル状、クリーム状、又は固形状である、<1>~<33>のいずれかに記載の皮膚外用剤。
 <35>
 紫外線又は赤外線防御用、皮膚温度上昇抑制用、又は疲労抑制用の皮膚外用剤である、<1>~<34>のいずれかに記載の皮膚外用剤。
 <36>
 <1>~<35>のいずれかに記載の皮膚外用剤を皮膚に適用する工程を有し、好ましくは前記適用方法が、塗布又は噴霧である、皮膚の赤外線防御方法。
 <37>
 波長825nmの赤外線防御率が、好ましくは35%以上、より好ましくは45%以上、更に好ましくは55%以上、より更に好ましくは65%以上である、<36>に記載の皮膚の赤外線防御方法。
 <38>
 <1>~<34>のいずれかに記載の皮膚外用剤の、紫外線防御用剤、赤外線防御用剤、皮膚温度上昇抑制用剤、又は疲労抑制用剤としての使用。
Regarding the above-described embodiments, the present invention further discloses the following external preparations for skin.
<1>
Component (A): The average particle size is 350 nm or more, preferably 400 nm or more, more preferably 700 nm or more, still more preferably 800 nm or more, and is 2,500 nm or less, preferably 2,000 nm or less, more preferably 1 , 800 nm or less, more preferably 1,500 nm or less, and even more preferably 1,200 nm or less, one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-shaped metal oxides (A2) and component (B): non-volatile oil, wherein the content of component (A) in the skin external preparation is 2% by mass or more, preferably 3% by mass or more, and more An external preparation for skin, which preferably contains 5% by mass or more and 50% by mass or less, and has a viscosity of 2,500 mPa·s or more at 25°C.
<2>
The metal oxide in component (A1) and component (A2) is preferably one or more selected from the group consisting of titanium oxide, zinc oxide, zirconium oxide, iron oxide, aluminum oxide, and cerium oxide, <1 >.
<3>
Viscosity at 25°C is preferably 2,500 mPa s or more and 150,000 mPa s or less, more preferably 2,500 mPa s or more and 100,000 mPa s or less, still more preferably 2,500 mPa s or more and 50,000 mPa s. s or less, more preferably 2,500 mPa s or more and 30,000 mPa s or less, still more preferably 2,500 mPa s or more and 20,000 mPa s or less, the skin according to <1> or <2> External agent.
<4>
The viscosity (mPa s) of the external skin preparation relative to the content (% by mass) of the component (A) in the external skin preparation is preferably 100 or more, more preferably 250 or more, still more preferably 300 or more, and more more preferably 350 or more, preferably 25,000 or less, more preferably 20,000 or less, even more preferably 15,000 or less, even more preferably 10,000 or less, still more preferably 5,000 or less , and more preferably 3,000 or less, the external preparation for skin according to any one of <1> to <3>.
<5>
The viscosity (mPa s) of the external skin preparation relative to the content (% by mass) of the component (A) in the external skin preparation is preferably 100 or more and 25,000 or less, more preferably 250 or more and 20,000 or less. , More preferably 300 or more and 15,000 or less, still more preferably 350 or more and 10,000 or less, still more preferably 350 or more and 5,000 or less, still more preferably 350 or more and 3,000 or less, <1> ~ The skin external preparation according to any one of <4>.
<6>
The content of the component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more, more preferably 5% by mass or more, still more preferably 10% by mass or more, and preferably 50% by mass. % or less, more preferably 40% by mass or less, still more preferably 30% by mass or less, still more preferably 20% by mass or less, the external preparation for skin according to any one of <1> to <5>.
<7>
The content of component (A) in the non-volatile components of the external preparation for skin is preferably 3% by mass or more and 50% by mass or less, more preferably 5% by mass or more and 40% by mass or less, and still more preferably 10% by mass or more and 30% by mass. % or less, more preferably 10% by mass or more and 20% by mass or less.
<8>
Component (A1) preferably has an average particle size of 400 nm or more and 2,000 nm or less, more preferably 700 nm or more and 2,000 nm or less, still more preferably 700 nm or more and 1,800 nm or less, still more preferably 700 nm or more and 1,500 nm or less, The external preparation for skin according to any one of <1> to <7>, which is more preferably 800 nm or more and 1,200 nm or less.
<9>
The component (A) preferably contains a spherical metal oxide having an average particle size of 700 nm or more and 2,500 nm or less as the component (A1), and preferably has a viscosity of 2,500 mPa s or more and 20,000 mPa s or less at 25°C. The skin external preparation according to any one of <1> to <8>.
<10>
The skin external application according to any one of <1> to <9>, wherein the component (A) contains, as component (A2), preferably one or more selected from the group consisting of plate-like titanium oxide and plate-like zinc oxide. agent.
<11>
The thickness of the component (A2) is preferably 30 nm or more, more preferably 50 nm or more, still more preferably 60 nm or more, still more preferably 75 nm or more, still more preferably 90 nm or more, still more preferably 100 nm or more, Also, preferably 360 nm or less, more preferably 330 nm or less, still more preferably 310 nm or less, still more preferably 280 nm or less, even more preferably 270 nm or less, even more preferably 230 nm or less, still more preferably 200 nm or less, still more preferably 200 nm or less. The skin external preparation according to any one of <1> to <10>, which is 180 nm or less.
<12>
The thickness of component (A2) is preferably 30 nm or more and 360 nm or less, more preferably 50 nm or more and 330 nm or less, still more preferably 60 nm or more and 310 nm or less, still more preferably 75 nm or more and 280 nm or less, still more preferably 90 nm or more and 270 nm or less, The external preparation for skin according to any one of <1> to <11>, which is more preferably 100 nm or more and 230 nm or less, still more preferably 100 nm or more and 200 nm or less, still more preferably 100 nm or more and 180 nm or less.
<13>
The aspect ratio of the component (A2) is preferably 3 or more, more preferably 5 or more, still more preferably 10 or more, still more preferably 30 or more, still more preferably 50 or more, still more preferably 55 or more, Also, preferably 300 or less, more preferably 230 or less, still more preferably 200 or less, still more preferably 140 or less, still more preferably 125 or less, still more preferably 120 or less, <1> to <12> The skin external preparation according to any one of the above.
<14>
The aspect ratio of the component (A2) is preferably 3 or more and 300 or less, more preferably 3 or more and 230 or less, still more preferably 10 or more and 230 or less, still more preferably 30 or more and 230 or less, still more preferably 50 or more and 200 or less. , More preferably 55 or more and 140 or less, still more preferably 55 or more and 125 or less, still more preferably 55 or more and 120 or less, <1> to <13>.
<15>
The content of component (A2) in component (A) is preferably 50% by mass or more, more preferably 60% by mass or more, still more preferably 70% by mass or more, still more preferably 80% by mass or more, and even more preferably is 90% by mass or more and 100% by mass or less, the skin external preparation according to any one of <1> to <14>.
<16>
The content of spherical titanium oxide having an average particle size of 350 nm or more and less than 800 nm in the skin external preparation is preferably 5% by mass or more and 30% by mass or less, more preferably 5% by mass or more and 25% by mass or less. The skin external preparation according to any one of <15>.
<17>
The content of spherical titanium oxide having an average particle size of 800 nm or more and 2,500 nm or less in the external preparation for skin is preferably 5% by mass or more and 40% by mass or less, more preferably 5% by mass or more and 30% by mass or less, <1 The skin external preparation according to any one of > to <16>.
<18>
The external preparation for skin according to any one of <1> to <17>, wherein the content of the plate-like titanium oxide in the external preparation for skin is preferably 5% by mass or more and 30% by mass or less.
<19>
The content of spherical zinc oxide or plate-shaped zinc oxide having an average particle size of 350 nm or more and 2,500 nm or less in the skin external preparation is preferably 7% by mass or more and 50% by mass or less, more preferably 10% by mass or more and 50% by mass. The skin external preparation according to any one of <1> to <18> below.
<20>
The viscosity of component (B) at 25° C. is preferably 500 mPa·s or less, more preferably 300 mPa·s or less, still more preferably 100 mPa·s or less, still more preferably 50 mPa·s or less, and preferably 5 mPa. · The external preparation for skin according to any one of <1> to <19>, which is s or more.
<21>
The component (B) is preferably liquid at 25° C., more preferably one or more selected from the group consisting of ester oils, silicone oils, hydrocarbon oils, higher fatty acids, and higher alcohols, <1> The skin external preparation according to any one of <20>.
<22>
The content of component (B) in the external preparation for skin is preferably 1% by mass or more, more preferably 5% by mass or more, and is preferably 90% by mass or less, more preferably 80% by mass or less, and still more preferably. is 70% by mass or less, more preferably 65% by mass or less.
<23>
The topical skin preparation is a water-in-oil emulsion composition, and the content of component (B) in the topical skin preparation is preferably 15% by mass or more, more preferably 20% by mass or more, and still more preferably 25% by mass or more. , More preferably 30% by mass or more, still more preferably 35% by mass or more, <1> to <22>.
<24>
The topical skin preparation is an oil-in-water emulsified composition, and the content of component (B) in the topical skin preparation is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less. The skin external preparation according to any one of <1> to <23>.
<25>
The mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] is preferably 0.05 or more, more preferably 0.1 or more, and still more preferably 0.2 more preferably 0.5 or more, still more preferably 1 or more, still more preferably 2 or more, still more preferably 3 or more, still more preferably 3.6 or more, and preferably 60 or less, The external skin treatment according to any one of <1> to <24>, which is more preferably 50 or less, still more preferably 30 or less, still more preferably 20 or less, still more preferably 10 or less, and even more preferably 8 or less. agent.
<26>
The mass ratio of the content of component (B) to the content of component (A) [(B)/(A)] is preferably 0.05 or more and 60 or less, more preferably 0.1 or more and 50 or less, and still more preferably is 0.2 or more and 30 or less, more preferably 0.5 or more and 20 or less, still more preferably 1 or more and 10 or less, still more preferably 2 or more and 10 or less, still more preferably 3 or more and 10 or less, still more preferably The skin external preparation according to any one of <1> to <25>, which is 3.6 or more and 8 or less.
<27>
The total content of component (A) and component (B) in the external skin preparation is preferably 2% by mass or more, more preferably 10% by mass or more, still more preferably 20% by mass or more, and even more preferably 30% by mass. More preferably 40% by mass or more, still more preferably 45% by mass or more, still more preferably 47% by mass or more, still more preferably 50% by mass or more, and 100% by mass or less <1> to <26>, the external preparation for skin.
<28>
The external preparation for skin according to any one of <1> to <27>, which preferably further contains a thickening agent.
<29>
The external preparation for skin according to <28>, wherein the thickener is preferably an oil thickener.
<30>
The skin according to <28> or <29>, wherein the thickener is preferably one or more selected from the group consisting of solid waxes, organically modified clay minerals, dextrin fatty acid esters, and amino acid gelling agents. External agent.
<31>
The content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more, more preferably 1% by mass or more, still more preferably 2% by mass or more, and even more preferably 3% by mass or more. , Also preferably 50% by mass or less, more preferably 30% by mass or less, still more preferably 25% by mass or less, even more preferably 20% by mass or less, still more preferably 15% by mass or less <28> ~ The skin external preparation according to any one of <30>.
<32>
The content of the thickening agent in the external preparation for skin is preferably 0.5% by mass or more and 50% by mass or less, more preferably 0.5% by mass or more and 30% by mass or less, and still more preferably 1% by mass or more and 25% by mass. % or less, more preferably 2 to 20 mass %, still more preferably 3 to 15 mass %, the external preparation for skin according to any one of <28> to <31>.
<33>
The external skin preparation preferably further contains water, and the content of water in the external skin preparation is preferably 1% by mass or more, more preferably 5% by mass or more, still more preferably 8% by mass or more, and even more preferably. is 10% by mass or more, preferably 50% by mass or less, more preferably 30% by mass or less, and even more preferably 25% by mass or less.
<34>
The external preparation for skin according to any one of <1> to <33>, which is preferably liquid, gel, cream or solid.
<35>
The external preparation for skin according to any one of <1> to <34>, which is for protection against ultraviolet rays or infrared rays, suppression of skin temperature rise, or suppression of fatigue.
<36>
A method for protecting the skin from infrared rays, comprising the step of applying the external preparation for skin according to any one of <1> to <35> to the skin, preferably by coating or spraying.
<37>
The infrared protection method for skin according to <36>, wherein the infrared protection rate at a wavelength of 825 nm is preferably 35% or higher, more preferably 45% or higher, even more preferably 55% or higher, and even more preferably 65% or higher.
<38>
Use of the external preparation for skin according to any one of <1> to <34> as an ultraviolet protective agent, an infrared protective agent, an agent for suppressing skin temperature rise, or an agent for suppressing fatigue.
 以下、本発明を実施例により説明するが、本発明は実施例の範囲に限定されない。なお本実施例において、各種測定及び評価は以下の方法により行った。 The present invention will be described below with reference to examples, but the present invention is not limited to the scope of the examples. In addition, in the present Examples, various measurements and evaluations were performed by the following methods.
<粘度>
 各例の皮膚外用剤の25℃における粘度は、B型粘度計(東機産業(株)製「TOKI SANGYO VISCOMETER TVB-10M」)を用いて、ローター回転数6.0rpm、回転時間60秒の条件にて、皮膚外用剤の調製翌日に測定した。ローターは粘度に応じてNo.2-No.4を使用した。[No.2:粘度500-5000mPa・s、No.3:粘度5000mPa・s超20000mPa・s以下、No.4:粘度20000mPa・s超]
<Viscosity>
The viscosity at 25° C. of each example of the external preparation for skin was measured using a Brookfield viscometer ("TOKI SANGYO VISCOMETER TVB-10M" manufactured by Toki Sangyo Co., Ltd.) at a rotor speed of 6.0 rpm and a rotation time of 60 seconds. Under these conditions, measurements were made on the next day after preparation of the external preparation for skin. The rotor is No. 1 depending on the viscosity. 2-No. 4 was used. [No. 2: Viscosity 500-5000 mPa·s, No. 3: Viscosity more than 5000 mPa·s and 20000 mPa·s or less, No. 4: Viscosity over 20000 mPa s]
<近赤外線防御率>
 各例の皮膚外用剤50.0mgを5cm×5cmのポリメタクリル酸メチル樹脂(PMMA)基板(不二化成(株)製「SPF Matser PA-1」)に塗布し、15分間乾燥させて測定用の試料とした。また、同様に未塗布のPMMA基板を対照用の試料とした。測定用試料、対照用試料それぞれについて、波長825nmにおける透過率を、近赤外線顕微鏡を用いて測定した。測定用試料の透過率を対照用試料の透過率で除した値を透過率X(%)とし、100-X(%)を近赤外線防御率とした。この値が大きいほど、皮膚外用剤自体の近赤外線防御効果が高いことを意味する。
<Near-infrared protection rate>
50.0 mg of the external skin preparation of each example is applied to a 5 cm × 5 cm polymethyl methacrylate (PMMA) substrate (“SPF Matser PA-1” manufactured by Fuji Kasei Co., Ltd.), dried for 15 minutes, and used for measurement. was used as a sample. Similarly, an uncoated PMMA substrate was used as a control sample. The transmittance at a wavelength of 825 nm was measured for each of the measurement sample and the control sample using a near-infrared microscope. The value obtained by dividing the transmittance of the measurement sample by the transmittance of the control sample was defined as the transmittance X (%), and 100-X (%) was defined as the near-infrared protection rate. A larger value means that the external preparation for skin has a higher near-infrared protective effect.
 また近赤外線防御効果について、下記基準で5段階評価を行った。
(評価基準)
5:近赤外線防御率が65.0%以上
4:近赤外線防御率が55.0%以上65.0%未満
3:近赤外線防御率が45.0%以上55.0%未満
2:近赤外線防御率が35.0%以上45.0%未満
1:近赤外線防御率が35.0%未満
In addition, the near-infrared protective effect was evaluated in 5 stages according to the following criteria.
(Evaluation criteria)
5: Near-infrared protection rate is 65.0% or more 4: Near-infrared protection rate is 55.0% or more and less than 65.0% 3: Near-infrared protection rate is 45.0% or more and less than 55.0% 2: Near infrared rays Protection rate is 35.0% or more and less than 45.0% 1: Near infrared protection rate is less than 35.0%
<塗膜均一性>
 5cm×5cmのポリメチルメタクリレート(PMMA)基板上に、各例の皮膚外用剤を2mg/cmになるように均一に塗布し、25℃で15分乾燥させた。
 皮膚外用剤を塗布した基板について、近赤外線顕微鏡(IR顕微鏡)を用いて、波長825nmにおける透過率の分布を撮影した。この分布画像から、皮丘部分(PMMA板における凸の部分)と皮溝部分(PMMA板における凹の部分)の透過率分布を確認し、その均一性について、「皮溝部分しか防御されておらず、皮丘部分がほとんど防御されていない」場合を1点、「皮丘と皮溝どちらも均一に防御されている」場合を5点として5段階で評価した。
(評価基準)
1:皮溝部分しか防御されておらず、皮丘部分がほとんど防御されていない
2:皮溝部分が防御されており、皮丘部分は少し防御されている
3:皮溝部分が防御されており、皮丘部分はある程度防御されている
4:皮溝部分が防御されており、皮丘部分はしっかり防御されている
5:皮溝と皮丘どちらも均一に防御されている
<Coating film uniformity>
On a polymethyl methacrylate (PMMA) substrate of 5 cm x 5 cm, each external preparation for skin was uniformly applied to 2 mg/cm 2 and dried at 25°C for 15 minutes.
Using a near-infrared microscope (IR microscope), the transmittance distribution at a wavelength of 825 nm was photographed for the substrate on which the external preparation for skin was applied. From this distribution image, the transmittance distribution of the corniculus part (the convex part of the PMMA plate) and the transcutaneous part (the concave part of the PMMA plate) was confirmed, and the uniformity was evaluated as "only the sulcus cutis is protected." The evaluation was made on a 5-point scale, with 1 point for the case where the skin bumps were almost completely protected, and 5 points for the case where both the skin bumps and the skin folds were evenly protected.
(Evaluation criteria)
1: Only the sulcus cutis is protected, and the corniculus is hardly protected 2: The sulcus cutis is protected, and the sulcus cutis is slightly protected 3: The sulcus cutis is protected 4: sulcus cutis protected, and sulcus cutis well protected
<皮膚に塗布した際の白浮き>
 各例の皮膚外用剤約0.09gを、専門パネラーの前腕内側の約3cm×3cmの面積に塗布した直後の白さについて、とても白く、非常に不自然さを感じる場合を1点、自然な白さで違和感がない場合を5点として5段階で評価した。専門パネラー3名で評価を行い、その平均点を評価結果とした。
(評価基準)
1:とても白く、非常に不自然さを感じる
2:やや白く、不自然さを感じる
3:どちらでもない
4:自然な白さだが、やや違和感がある
5:自然な白さで違和感がない
<Whitening when applied to the skin>
Approximately 0.09 g of each topical skin preparation was applied to an area of approximately 3 cm x 3 cm on the inner side of the forearm of the expert panelist. Evaluation was made on a scale of 5, with 5 points indicating no discomfort in whiteness. Evaluation was performed by three expert panelists, and the average score was used as the evaluation result.
(Evaluation criteria)
1: Very white, feels very unnatural 2: Slightly white, feels unnatural 3: Neither 4: Natural whiteness, but slightly uncomfortable 5: Natural whiteness, no discomfort
<皮膚温度上昇抑制効果>
 実施例6及び比較例5の皮膚外用剤約3.2gを、専門パネラーの前腕内側の約4cm×4cmの面積に均一に塗布し、25℃、40%RH環境下で15分乾燥させた。その後、ソーラーシュミレーター(朝日分光(株)製「HAL-320W」)を用いて、24cmの距離から、疑似太陽光を5分間塗布部位に照射した。
 サーモカメラ(FLIR社製「T-420」)を用いて、照射中の皮膚温度変化を測定した。同様の方法で、皮膚外用剤未塗布の際の温度上昇も測定し、(皮膚外用剤未塗布の際の上昇温度(℃))-(皮膚外用剤を塗布した際の上昇温度(℃))を表に示した。この値が大きいほど、皮膚温度上昇抑制効果が高いことを意味する。
<Skin temperature rise suppression effect>
About 3.2 g of the external skin preparations of Example 6 and Comparative Example 5 were evenly applied to an area of about 4 cm x 4 cm on the inside of the forearm of a professional panelist, and dried for 15 minutes at 25°C and 40% RH. After that, using a solar simulator (“HAL-320W” manufactured by Asahi Spectrosco Co., Ltd.), the application site was irradiated with simulated sunlight for 5 minutes from a distance of 24 cm.
A thermocamera (“T-420” manufactured by FLIR) was used to measure changes in skin temperature during irradiation. By the same method, the temperature rise when the topical skin preparation was not applied was also measured, and (Temperature rise when the topical skin preparation was not applied (°C)) - (Temperature rise when the topical skin preparation was applied (°C)). are shown in the table. A larger value means that the effect of suppressing a rise in skin temperature is higher.
実施例1~23、比較例1~6(皮膚外用剤の製造及び評価)
 表1~4に示す成分のうち、水を除く全成分を配合してディスパーで均一に混合した。次いで得られた混合液に水を添加し、ホモジナイザーを用いて均一に混合し、表1~4に示す組成の、油中水型の皮膚外用剤を製造した。得られた皮膚外用剤について、前記方法で評価を実施した。結果を表1~4に示す。なお、各表に記載した配合量は、「BENTONE GEL PTM V」を除き、各成分の有効成分量(質量%)である。「BENTONE GEL PTM V」の配合量は有姿での質量%である。また表中、成分(A)に該当しない金属酸化物を「成分(A1’)」と表記した。
Examples 1 to 23, Comparative Examples 1 to 6 (manufacture and evaluation of external preparations for skin)
Of the components shown in Tables 1 to 4, all components except water were blended and uniformly mixed with a disper. Then, water was added to the resulting mixed solution and mixed uniformly using a homogenizer to produce a water-in-oil type external preparation for skin having the composition shown in Tables 1 to 4. The resulting external preparation for skin was evaluated by the method described above. The results are shown in Tables 1-4. In addition, the compounding quantity described in each table|surface is the amount of active ingredients (mass %) of each component except "BENTONE GEL PTM V." The blending amount of "BENTONE GEL PTM V" is mass % in the actual state. In the table, a metal oxide that does not correspond to component (A) is indicated as "component (A1')".
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
実施例24~27(皮膚外用剤の製造)
 実施例24及び25については、表5に示す成分のうち、水を除く全成分を配合してディスパーで均一に混合した。次いで得られた混合液に水を添加し、ホモジナイザーを用いて均一に混合し、表5に示す組成の、油中水型の固形状の皮膚外用剤を製造した。実施例26及び27については、表5に示す全成分を配合してディスパーで均一に混合し、固形状の皮膚外用剤を製造した。なお、表に記載した配合量は、各成分の有効成分量(質量%)である。
Examples 24 to 27 (manufacture of external preparation for skin)
For Examples 24 and 25, among the components shown in Table 5, all components except water were blended and uniformly mixed with a disper. Next, water was added to the resulting mixed solution and mixed uniformly using a homogenizer to produce a water-in-oil type solid skin preparation for external use having the composition shown in Table 5. For Examples 26 and 27, all the components shown in Table 5 were blended and uniformly mixed with a disper to produce a solid external preparation for skin. In addition, the compounding quantity described in the table|surface is the active-ingredient amount (mass %) of each component.
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000005
 表中の配合成分は下記のとおりである。
*1:堺化学工業(株)製「R-38L」、ZrO-Al被覆処理球状酸化チタン、平均粒径400nm
*2:チタン工業(株)製「ST-750EC」、水酸化アルミニウム-ハイドロゲンジメチコン被覆処理球状酸化チタン、平均粒径1,000nm
*3:堺化学工業(株)製「LP-ZINC-2KS」、ハイドロゲンジメチコン被覆処理球状酸化亜鉛、平均粒径2,000nm
*4:テイカ(株)製「JR800s」、ハイドロゲンジメチコン被覆処理球状酸化チタン、平均粒径270nm
*5:大東化成工業(株)製、板状酸化チタン(CQV社製「Featheleve PT-7801K」)の表面ASC処理品、厚さ134nm、アスペクト比95
*6:大東化成工業(株)製、板状酸化チタン(CQV社製「Featheleve PT-7401K」)の表面ASC処理品、厚さ112nm、アスペクト比126
*7:大東化成工業(株)製、板状酸化チタン(CQV社製「Featheleve PT-7901K」)の表面ASC処理品、厚さ191nm、アスペクト比58
*8:堺化学工業(株)製「XZ-1000F-LP」、ハイドロゲンジメチコン被覆処理板状酸化亜鉛、厚さ290nm、アスペクト比3.4
*9:花王(株)製「エキセパール IPP」、パルミチン酸イソプロピル
*10:信越化学工業(株)製「KF-96L-10cs」、ジメチコン、粘度10mPa・s
*11:エレメンティス社製「BENTONE GEL PTM V」、カプリル酸/カプリン酸トリグリセリド、ステアラルコニウムヘクトライト及びプロピレンカーボネート、不揮発性成分96.8質量%(実測値)
*12:千葉製粉(株)製「レオパール KL2」、パルミチン酸デキストリン
*13:ダウ・東レ(株)製「DOWSIL AMS-C30 COSMETIC WAX」、アルキル(C30-45)メチコン
*14:信越化学工業(株)製「シリコーン KF-6028」、PEG-9ポリジメチルシロキシエチルジメチコン
*15:花王(株)製「OS-88E-TV-E」、N-プロピオニルポリエチレンイミン・メチルポリシロキサン共重合体(30質量%-エタノール溶液)
*16:味の素(株)製「EB-21」、ジブチルエチルヘキサノイルグルタミド
*17:日本精蝋(株)製「HNP-9」、パラフィンワックス、融点:80℃
*18:日興リカ(株)製「セレシン#810K」、セレシン、融点:74℃
The ingredients in the table are as follows.
*1: “R-38L” manufactured by Sakai Chemical Industry Co., Ltd., ZrO 2 —Al 2 O 3 coated spherical titanium oxide, average particle size 400 nm
*2: "ST-750EC" manufactured by Titan Kogyo Co., Ltd. Aluminum hydroxide-hydrogen dimethicone coated spherical titanium oxide, average particle size 1,000 nm
*3: “LP-ZINC-2KS” manufactured by Sakai Chemical Industry Co., Ltd. Hydrogen dimethicone-coated spherical zinc oxide, average particle size 2,000 nm
*4: “JR800s” manufactured by Tayka Co., Ltd. Hydrogen dimethicone-coated spherical titanium oxide, average particle size 270 nm
* 5: Made by Daito Kasei Kogyo Co., Ltd., plate-shaped titanium oxide ("Featheleve PT-7801K" made by CQV) surface ASC-treated product, thickness 134 nm, aspect ratio 95
* 6: Made by Daito Kasei Kogyo Co., Ltd., plate-shaped titanium oxide ("Featheleve PT-7401K" made by CQV) surface ASC-treated product, thickness 112 nm, aspect ratio 126
* 7: Made by Daito Kasei Kogyo Co., Ltd., plate-shaped titanium oxide ("Featheleve PT-7901K" made by CQV) surface ASC-treated product, thickness 191 nm, aspect ratio 58
*8: “XZ-1000F-LP” manufactured by Sakai Chemical Industry Co., Ltd., plate-shaped zinc oxide coated with hydrogen dimethicone, thickness 290 nm, aspect ratio 3.4
* 9: "Exepar IPP" manufactured by Kao Corporation, isopropyl palmitate * 10: "KF-96L-10cs" manufactured by Shin-Etsu Chemical Co., Ltd., dimethicone, viscosity 10 mPa s
*11: "BENTONE GEL PTM V" manufactured by Elementis, caprylic acid/capric acid triglyceride, stearalkonium hectorite and propylene carbonate, non-volatile component 96.8% by mass (measured value)
*12: "Leopearl KL2" manufactured by Chiba Flour Milling Co., Ltd., dextrin palmitate *13: "DOWSIL AMS-C30 COSMETIC WAX" manufactured by Dow Toray Industries, Inc., alkyl (C30-45) methicone *14: Shin-Etsu Chemical Co., Ltd. ( "Silicone KF-6028" manufactured by Kao Corporation, "Silicone KF-6028", PEG-9 polydimethylsiloxyethyl dimethicone *15: "OS-88E-TV-E" manufactured by Kao Corporation, N-propionylpolyethyleneimine-methylpolysiloxane copolymer (30 % by mass-ethanol solution)
*16: “EB-21” manufactured by Ajinomoto Co., Inc., dibutylethylhexanoyl glutamide *17: “HNP-9” manufactured by Nippon Seiro Co., Ltd., paraffin wax, melting point: 80 ° C.
*18: "Ceresin #810K" manufactured by Nikko Rica Co., Ltd., ceresin, melting point: 74°C
 表1~4より、本実施例の皮膚外用剤は赤外線防御効果、塗膜均一性が高く、皮膚に塗布した際の白浮きが少ないことがわかる。また皮膚温度上昇抑制効果にも優れる。 From Tables 1 to 4, it can be seen that the external preparation for skin of this example has a high infrared protection effect and a high coating uniformity, and causes little whitening when applied to the skin. In addition, it is also excellent in skin temperature rise suppressing effect.
 なお、図1には実施例9の皮膚外用剤の塗膜均一性評価における、IR顕微鏡による観察写真(スコア5)、図2には比較例2の皮膚外用剤の塗膜均一性評価における、IR顕微鏡による観察写真(スコア1)を示した。図1及び図2において、白い部分は成分(A)が存在する箇所、黒い部分は存在しない箇所を示す。実施例9の皮膚外用剤を塗布した場合、皮溝だけでなく、皮丘にも成分(A)が多く存在しているのに対し(図1)、比較例2の皮膚外用剤を塗布した場合には、ほとんどの成分(A)が皮溝に落ちており、塗膜均一性が低いことがわかる(図2)。 In addition, FIG. 1 shows an IR microscope observation photograph (score 5) in the coating film uniformity evaluation of the external skin preparation of Example 9, and FIG. An observation photograph (score 1) by an IR microscope is shown. In FIGS. 1 and 2, white portions indicate locations where component (A) is present, and black portions indicate locations where component (A) is not present. When the topical skin preparation of Example 9 was applied, a large amount of component (A) was present not only in the sulcus cutis but also in the carpus (Fig. 1), whereas the topical skin preparation of Comparative Example 2 was applied. In this case, most of the component (A) fell into the sulci, indicating that the uniformity of the coating film was low (Fig. 2).
 本発明によれば、紫外線、赤外線等の防御効果に優れ、且つ、皮膚に塗布した際の白浮きが少ない皮膚外用剤を提供できる。該皮膚外用剤を皮膚に適用すると、紫外線、赤外線等から皮膚を防御することができ、更に、太陽光照射による皮膚温度上昇抑制効果及び疲労抑制効果も得ることができる。 According to the present invention, it is possible to provide an external preparation for skin that has excellent protective effects against ultraviolet rays, infrared rays, etc., and that leaves little whitening when applied to the skin. When the external preparation for skin is applied to the skin, it can protect the skin from ultraviolet rays, infrared rays, and the like, and can also provide an effect of suppressing an increase in skin temperature and an effect of suppressing fatigue due to sunlight irradiation.

Claims (17)

  1.  成分(A):平均粒径350nm以上2,500nm以下の球状金属酸化物(A1)及び板状金属酸化物(A2)からなる群から選ばれる1種以上の金属酸化物、並びに
     成分(B):不揮発性油、
    を含有する皮膚外用剤であって、
    該皮膚外用剤中の成分(A)の含有量が2質量%以上50質量%以下であり、
    25℃における粘度が2,500mPa・s以上である、皮膚外用剤。
    Component (A): one or more metal oxides selected from the group consisting of spherical metal oxides (A1) and plate-like metal oxides (A2) having an average particle size of 350 nm or more and 2,500 nm or less, and component (B) : non-volatile oil,
    A skin external preparation containing
    The content of component (A) in the external preparation for skin is 2% by mass or more and 50% by mass or less,
    An external skin preparation having a viscosity of 2,500 mPa·s or more at 25°C.
  2.  前記皮膚外用剤中の前記成分(A)の含有量(質量%)に対する前記皮膚外用剤の粘度(mPa・s)が100以上である、請求項1に記載の皮膚外用剤。 The external preparation for skin according to claim 1, wherein the viscosity (mPa·s) of the external preparation for skin relative to the content (% by mass) of the component (A) in the preparation for external use for skin is 100 or more.
  3.  前記皮膚外用剤の不揮発性成分中の前記成分(A)の含有量が50質量%以下である、請求項1又は2に記載の皮膚外用剤。 The external preparation for skin according to claim 1 or 2, wherein the content of said component (A) in the non-volatile components of said external preparation for skin is 50% by mass or less.
  4.  前記成分(A)が成分(A2)として板状酸化チタンを含む、請求項1~3のいずれか1項に記載の皮膚外用剤。 The skin external preparation according to any one of claims 1 to 3, wherein the component (A) contains plate-like titanium oxide as the component (A2).
  5.  前記皮膚外用剤中の前記板状酸化チタンの含有量が5質量%以上30質量%以下である、請求項4に記載の皮膚外用剤。 The external preparation for skin according to claim 4, wherein the content of the plate-like titanium oxide in the external preparation for skin is 5% by mass or more and 30% by mass or less.
  6.  前記成分(A2)の厚さが30nm以上360nm以下である、請求項1~5のいずれか1項に記載の皮膚外用剤。 The skin external preparation according to any one of claims 1 to 5, wherein the component (A2) has a thickness of 30 nm or more and 360 nm or less.
  7.  前記成分(A2)のアスペクト比が3以上300以下である、請求項1~6のいずれか1項に記載の皮膚外用剤。 The skin external preparation according to any one of claims 1 to 6, wherein the component (A2) has an aspect ratio of 3 or more and 300 or less.
  8.  前記成分(A)が成分(A1)として平均粒径700nm以上2,500nm以下の球状金属酸化物を含み、25℃における粘度が2,500mPa・s以上20,000mPa・s以下である、請求項1~7のいずれか1項に記載の皮膚外用剤。 The component (A) contains a spherical metal oxide having an average particle size of 700 nm or more and 2,500 nm or less as the component (A1), and has a viscosity of 2,500 mPa·s or more and 20,000 mPa·s or less at 25°C. The skin external preparation according to any one of 1 to 7.
  9.  前記成分(B)がエステル油、シリコーン油、炭化水素油、高級脂肪酸、及び高級アルコールからなる群から選ばれる1種以上である、請求項1~8のいずれか1項に記載の皮膚外用剤。 The external preparation for skin according to any one of claims 1 to 8, wherein the component (B) is one or more selected from the group consisting of ester oils, silicone oils, hydrocarbon oils, higher fatty acids, and higher alcohols. .
  10.  前記皮膚外用剤がさらに増粘剤を含有する、請求項1~9のいずれか1項に記載の皮膚外用剤。 The external preparation for skin according to any one of claims 1 to 9, further comprising a thickening agent.
  11.  前記増粘剤が油増粘剤である、請求項10に記載の皮膚外用剤。 The skin external preparation according to claim 10, wherein the thickener is an oil thickener.
  12.  前記油増粘剤が固形のワックス、有機変性粘土鉱物、デキストリン脂肪酸エステル、及びアミノ酸系ゲル化剤からなる群から選ばれる1種以上である、請求項11に記載の皮膚外用剤。 The skin external preparation according to claim 11, wherein the oil thickener is one or more selected from the group consisting of solid waxes, organically modified clay minerals, dextrin fatty acid esters, and amino acid-based gelling agents.
  13.  前記皮膚外用剤中の前記増粘剤の含有量が0.5質量%以上50質量%以下である、請求項10~12のいずれか1項に記載の皮膚外用剤。 The external preparation for skin according to any one of claims 10 to 12, wherein the content of said thickening agent in said external preparation for skin is 0.5% by mass or more and 50% by mass or less.
  14.  前記皮膚外用剤がさらに水を含有する、請求項1~13のいずれか1項に記載の皮膚外用剤。 The external preparation for skin according to any one of claims 1 to 13, which further contains water.
  15.  前記皮膚外用剤が固形状である、請求項1~14のいずれか1項に記載の皮膚外用剤。 The external skin preparation according to any one of claims 1 to 14, wherein the skin external preparation is solid.
  16.  紫外線又は赤外線防御用、皮膚温度上昇抑制用、又は疲労抑制用の皮膚外用剤である、請求項1~15のいずれか1項に記載の皮膚外用剤。 The external preparation for skin according to any one of claims 1 to 15, which is for protecting against ultraviolet rays or infrared rays, for suppressing skin temperature rise, or for suppressing fatigue.
  17.  請求項1~16のいずれか1項に記載の皮膚外用剤を皮膚に適用する工程を有する、皮膚の赤外線防御方法。
     
    A method for protecting the skin from infrared rays, comprising applying the external preparation for skin according to any one of claims 1 to 16 to the skin.
PCT/JP2022/020110 2021-05-14 2022-05-12 Skin external agent WO2022239842A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280020822.9A CN117042746A (en) 2021-05-14 2022-05-12 External preparation for skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-082670 2021-05-14
JP2021082670 2021-05-14

Publications (1)

Publication Number Publication Date
WO2022239842A1 true WO2022239842A1 (en) 2022-11-17

Family

ID=84028341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/020110 WO2022239842A1 (en) 2021-05-14 2022-05-12 Skin external agent

Country Status (4)

Country Link
JP (1) JP2022176168A (en)
CN (1) CN117042746A (en)
TW (1) TW202310823A (en)
WO (1) WO2022239842A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09301828A (en) * 1996-05-16 1997-11-25 Miyoshi Kasei:Kk Composition for cosmetic and cosmetic
JP2004210730A (en) * 2003-01-06 2004-07-29 Pola Chem Ind Inc Oily liquid cosmetic
JP2017095361A (en) * 2015-11-18 2017-06-01 花王株式会社 Near-infrared ray shielding cosmetic composition
JP2018024577A (en) * 2017-09-11 2018-02-15 住友大阪セメント株式会社 Zinc oxide powder, dispersion liquid, paint, and cosmetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09301828A (en) * 1996-05-16 1997-11-25 Miyoshi Kasei:Kk Composition for cosmetic and cosmetic
JP2004210730A (en) * 2003-01-06 2004-07-29 Pola Chem Ind Inc Oily liquid cosmetic
JP2017095361A (en) * 2015-11-18 2017-06-01 花王株式会社 Near-infrared ray shielding cosmetic composition
JP2018024577A (en) * 2017-09-11 2018-02-15 住友大阪セメント株式会社 Zinc oxide powder, dispersion liquid, paint, and cosmetics

Also Published As

Publication number Publication date
JP2022176168A (en) 2022-11-25
TW202310823A (en) 2023-03-16
CN117042746A (en) 2023-11-10

Similar Documents

Publication Publication Date Title
JP6689608B2 (en) Oil-in-water skin cosmetics
KR100621383B1 (en) Sunscreen composition
JP4560122B2 (en) Titanium oxide dispersion and cosmetics containing the same
JP2013136569A (en) Oil-in-water-type emulsion cosmetic
JP6690947B2 (en) Water-in-oil skin cosmetics
WO2018225768A1 (en) Water-in-oil emulsified cosmetic preparation
JP7043803B2 (en) Underwater oil type emulsified cosmetic
US20230165763A1 (en) Water-in-oil-type emulsified sunscreen cosmetic
JP2017137300A (en) Oil-in-water type emulsion cosmetic
WO2022239842A1 (en) Skin external agent
JP6865522B2 (en) Underwater oil type UV protection cosmetics
WO2021100676A1 (en) External preparation for skin
TWI828835B (en) Skin external preparations
WO2020138431A1 (en) External preparation
WO2018225765A1 (en) Water-in-oil emulsified cosmetic preparation
JP2020105175A (en) External preparation for skin
JP2020105177A (en) External preparation for skin
JP2020105176A (en) External preparation for skin
TW202406530A (en) Water-in-oil emulsion cosmetic
US20220362111A1 (en) Oil powder foundation
JP2022159111A (en) Cosmetic
JP2023145234A (en) Sunscreen cosmetic
JP2020128344A (en) Oil-in-water emulsion cosmetic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22807541

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280020822.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE